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Abstract		
	
Escherichia	coli	 is	a	common	commensal	organism	that	is	present	in	all	humans	digestive	 tracts.	 When	 E.	 coli	 is	 infected	 by	 a	 bacteriophage	 containing	 Shiga	toxin	 genes	 (Stx	 phage),	 the	 E.	 coli	 cell	 is	 converted	 into	 a	 pathogen	 that	 can	cause	 serious	 harm	 to	 humans	 in	 the	 form	 of	 Haemolytic	 Uraemic	 Syndrome	(HUS)	 or	 Thrombotic,	 Thrombocytopaenic	 Purpura	 (TTP).	 It	 has	 been	 shown	that	 ~70%	 of	 environmental	 Stx	 phages	 possess	 a	 tail	 that	 recognises	 an	essential	protein	in	the	outer	membrane	of	E.	coli,	BamA.	This	 study	 presents	 the	 final	 proof	 required	 to	 demonstrate	 that	 BamA	 is	 the	target	of	 these	short-tailed	Stx	phages	and	 intends	to	dissect	which	epitopes	of	extracellular	surface	of	BamA	support	phage	adsorption	by	comparing	E.	coli	to	a	phage	resistant	species,	Pectobacterium	atrosepticum.		This	resulted	in	the	production	of	a	library	of	32	BamA	mutants,	which	could	be	compared	in	an	adsorption	assay.	The	physiological	effects	of	these	mutants	on	the	adsorption	process	were	then	examined	in	a	fluorescence	microscopy-based	adsorption	 assay	 that	 allows	 the	 visualisation	 of	 temporal	 resolution	 of	 these	processes.	Given	 that	BamA	 is	 conserved	 across	 all	Enterobacteriaceae.	 There	 is	 potential	for	 host	 range	 expansion,	 thereby	 converting	 more	 species	 that	 are	 currently	harmless	 into	 potential	 human	 pathogens.	 The	 information	 obtained	 from	 this	study	may	help	in	predicting	which	species	is	the	next	likely	to	become	Stx	phage	susceptible.			
15	
CHAPTER	1:	Introduction	
	
1.1	Escherichia	coli		
Escherichia	 coli	 is	 one	 of	 the	 most	 thoroughly	 studied	 organisms	 on	 Earth,	leading	to	its	current	status	of	“biological	rock	star”	(Blount,	2015).	E.	coli	is	used	in	a	multitude	of	applications	from	being	a	model	organism	through	to	molecular	biology,	 genetic	 engineering,	 and	 being	 a	 host	 for	 protein	 overexpression	(Blount,	2015).			There	are	an	estimated	total	of	1021	E.	coli	cells	in	the	collective	gut	of	the	human	population	(Conway	&	Cohen,	2015),	the	majority	of	which	are	harmless	and	are	a	lifelong	member	of	the	normal	human	gut	flora	from	just	after	birth	(Palmer	et	
al.,	 2007).	 However,	 there	 are	 strains	 of	 E.	 coli	 that	 have	 potential	 to	 cause	disease	in	humans	(Kaper	et	al.,	2004).			
1.2 	Pathogenic	Escherichia	coli		Every	 year	 there	 are	 both	 isolated	 cases	 and	 outbreaks	 of	 E.	 coli	 mediated	disease	 across	 the	 globe	 (Majowicz	 et	 al.,	 2014).	 E.	 coli	 can	 cause	 a	 range	 of	symptoms	from	mild	diarrhoea	to	urinary	tract	 infections	(Flores-Mireles	et	al.,	2015)	and	sepsis	or	meningitis	(Croxen	&	Finlay,	2009).	The	array	of	infections	and	 syndromes	 caused	 by	 all	 the	 forms	 of	E.	 coli	 are	 beyond	 the	 scope	 of	 this	thesis,	 which	 will	 focus	 on	 diarrhoegenic	 E.	 coli	 strains.	 The	 general	 infection	
16	
strategy	 for	 these	 pathogenic	 E.	 coli	 is	 to	 colonise	 a	 mucosal	 site	 somewhere	along	 the	 gastrointestinal	 tract,	 where	 it	 evades	 host	 defences	 and	 multiplies	before	ultimately	distressing	the	host	(Nataro	&	Kaper,	1998).	Among	the	subset	of	 diarrhoegenic	 E.	 coli,	 symptoms	 can	 range	 from	 mild	 to	 potentially	 life	threatening,	depending	on	which	strain	has	caused	the	infection.		
	
E.	coli	has	been	 linked	with	clinical	cases	of	diarrhoea	since	 the	1940s	(Bray	&	Beavan,	 1948),	 but	 the	 first	 confirmed	 association	 between	 E.	 coli	 and	 life-threatening	 symptoms	 was	 not	 made	 for	 another	 4	 decades	 (Karmali	 et	 al.,	1983).	E.	coli	strains	associated	with	disease	have	been	classified	into	serotypes.	Serotypes	are	assigned	to	strains	of	E.	coli	based	on	the	variety	and	combination	of	O	(somatic),	H	(flagellar),	and	K	(capsular)	surface	antigens	that	are	presented	on	the	cell	surface	(Lior,	1996).	Historically,	the	serotyping	of	E.	coli	strains	was	critical	 to	 understanding	 their	 virulence,	 and	 this	 classification	 system	 is	 still	used	 today.	 Although	 these	 surface	 antigens	 do	 not	 confer	 virulence	 to	 strains	directly,	they	reliably	correlate	with	strains	that	cause	specific	clinical	symptoms	(Whittam	et	al.,	1993).	There	are	currently	over	500	different	serotypes	of	E.	coli	identified	(Allison,	2007)	 from	all	 the	possible	combinations	of	173	O	antigens,	80	K	antigens,	and	56	H	antigens	(Orskov	&	Orskov,	1992;	Tenaillon	et	al.,	2010).		Within	 the	 umbrella	 term	 of	 diarrhoegenic	 E.	 coli,	 there	 are	 different	classifications	based	on	the	mechanism	of	pathogenicity.	For	the	purpose	of	this	thesis,	 these	 subtypes	 have	 been	 separated	 into	 those	 that	 produce	 the	potentially	 life-threatening	 Shiga	 toxin	 and	 those	 that	 do	 not.	 The	 Shiga	 toxin	producing	E.	 coli	 (STEC)	 are	 the	 two	 supervirulent,	 human-adapted	 subgroups	
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the	Enterohaemorrhagic	E.	coli	 (EHEC)	 and	Enteroaggregative	haemorrhagic	E.	
coli	 (EAHEC).	 The	 subtypes	 that	 do	 not	 produce	 Shiga	 toxin	 are	Enteropathogenic	E.	coli	 (EPEC),	 Enterotoxigenic	E.	coli	 (ETEC),	 Enteroinvasive	
E.	coli	(EIEC),	and	Enteroaggregative	E.	coli	(EAEC).		
1.2.1	Non-shigatoxigenic	diarrheogenic	E.	coli		
1.2.1.1	Enteropathogenic	E.	coli	(EPEC)	EPEC	 have	 been	 a	 known	 causative	 agent	 of	 diarrhoea	 since	 the	 1940s	 and	remains	one	in	present	day	developing	countries	(Frankel	et	al.,	1998;	Kotloff	et	
al.,	2013;	Levine,	1987).	EPEC	strains	are	defined	by	pathogenic	mechanics	that	involve	 intimate	binding	with	 the	host	 intestinal	mucosa.	EPEC	cells	do	 this	by	forming	“attaching	and	effacing”	(A/E)	lesions,	which	are	pedestal	structures	on	the	surface	of	 the	cell	 caused	by	remodelling	of	 the	cytoskeleton	of	 cells	 in	 the	intestinal	wall,	 destroying	 the	microvilli	 structures	 in	 the	process	 (Moon	et	al.,	1983)	(Polotsky	et	al.,	1977;	Wong	et	al.,	2011).	Genes	that	confer	this	ability	on	EPEC	strains	are	encoded	on	a	pathogenicity	island	called	the	locus	of	enterocyte	
effacement	 (LEE),	 which	 encodes	 a	 type	 III	 secretion	 system	 (TTSS),	 secreted	proteins,	 and	 an	 adhesin	 called	 intimin	 (Hartland	 et	 al.,	 1999).	 Translocated	intimin	receptor,	 tir,	 is	a	secreted	protein	encoded	by	espE	 in	the	LEE,	which	is	translocated	into	the	eukaryotic	cell	using	the	TTSS,	which	is	then	recognised	by	intimin	on	the	bacterial	surface	(Batchelor	et	al.,	2000).	Once	these	proteins	bind,	the	bacterial	cell	is	intimately	attached	to	the	intestinal	mucosa	where	it	is	able	to	 evade	 phagocytosis	 (Celli	 et	 al.,	 2001),	 and	 cause	 diarrhoea	 and	 localised	
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inflammation	 (Ruchaud-Sparagano	 et	 al.,	 2007).	 Most	 cases	 of	 EPEC	 are	 self-limiting	and	can	be	successfully	treated	by	drinking	lots	of	fluids.		
1.2.1.2	Enterotoxigenic	E.	coli	(ETEC)	ETEC	 are	 a	 major	 cause	 of	 infant	 and	 traveller’s	 diarrhoea	 in	 the	 developing	world	(Black	et	al.,	1981;	Sack	et	al.,	1978).	ETEC	are,	unsurprisingly,	defined	by	their	 secretion	 of	 toxins.	 After	 colonisation	 of	 the	 small-bowel,	 ETEC	 secrete	either	a	heat	liable	(LT)	toxin,	a	heat	stable	(ST)	toxin,	or	both	(Jobling	&	Holmes,	2012).	These	toxins	are	usually	plasmid-encoded	(Shepard	et	al.,	2012),	but	act	in	different	ways.	LT	is	an	86	kDa	AB5	toxin,	highly	similar	to	the	cholera	toxin	(Dickinson	&	Clements,	1995),	which	enhances	adherence	of	bacterial	cells	to	the	mammalian	 intestinal	 wall	 and	 disrupts	 regulation	 of	 adenylate	 cyclase	 in	 the	host	enterocytes.	ST	is	a	small	2	kDa	peptide	that	activates	guanylyl	cyclase	C	in	the	 host	 enterocytes	 to	 increase	 the	 intracellular	 concentration	 of	 cGMP.	 This	leads	to	chloride	and	carbonate	ion	secretion,	which	draws	water	into	the	lumen	of	the	intestines	by	osmosis,	leading	to	watery	diarrhoea	(Taxt	et	al.,	2010).			
1.2.1.3	Enteroinvasive	E.	coli	(EIEC)	First	 characterised	 in	 1971,	 EIEC	 have	 a	 similar	 pathogenicity	 mechanism	 to	
Shigella	spp.,	whereby	the	cell	enters	the	colonic	epithelial	cell	where	it	is	able	to	replicate	 and	 eventually	 kill	 that	 host	 cell	 (DuPont	 et	 al.,	 1971).	 EIEC	 strains	harbour	a	huge	140	MDa	plasmid	 that	encodes	 factors	required	 for	 invasion	of	the	 host	 epithelium(Hale	 et	 al.,	 1983).	 EIEC	 strains	 impair	 water	 and	 nutrient	uptake	in	the	colon	to	cause	symptoms	ranging	from	watery	diarrhoea	to	severe	
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dysentery,	abdominal	cramps	and	stools	containing	blood	and	mucus	(Schroeder	&	Hilbi,	2008).	
	
1.2.1.4	Enteroaggregative	E.	coli	(EAEC)	EAEC	 cells	 adhere	 to	 both	Hep2	 cells	 and	 one	 another	 in	 the	 intestinal	 lumen	(Nataro	 et	 al.,	 1987).	 EAEC	 are	 not	 associated	with	 invasive	 characteristics	 or	intimate	attachment	(Mathewson	et	al.,	1985;	1986),	but	they	do	possess	a	110	kb	plasmid	 that	 encodes	 aggregative	 adherence	 fimbrae	 I-IV	 (AAF/I-IV),	 and	3	toxins:	 Pet,	 EAST1,	 and	 ShET2	 (Chaudhuri	 et	 al.,	 2010).	 The	 AAF/I-IV	 factors	allow	 the	 colonisation	 of	 the	 intestinal	 mucosa	 by	 EAEC	 where	 they	 form	 a	biofilm.	 The	 toxins	 are	 then	 released	 from	 EAEC	 causing	 an	 inflammatory	response	and	 intestinal	 fluid	secretion	 leading	to	diarrhoea	(Arenas-Hernández	
et	al.,	2012).			
1.2.2	Shigatoxigenic	E.	coli	(STEC)		Shigatoxigenic	 E.	 coli	 (STEC)	 are	 food-borne	 bacterial	 pathogens	 capable	 of	producing	 a	 toxin	 similar	 to	 the	 one	 produced	 by	 Shigella	 dysenteriae	 type	 I.	STEC	 are	 a	 significant	 ongoing	 health	 risk	 in	 both	 developed	 and	 developing	countries	(Abbasi	et	al.,	2014;	Jenkins	et	al.,	2015).	The	defining	characteristic	of	STEC	 is	 that	 they	 produce	 Shiga	 toxin,	 Stx.	 In	 humans,	 Stx	 causes	 adverse	symptoms	 including	vomiting	and	diarrhoea,	 and	 in	disease	 cases	where	Stx	 is	produced,	 5%-25%	 of	 the	 infected	 patients	 from	 outbreaks	 go	 on	 to	 develop	systemic	 conditions,	 such	 as	 Haemolytic	 Uraemic	 Syndrome	 (HUS)	 and	Thrombotic	Thrombocytopaenic	Purpura	(TTP),	which	lead	to	lifelong	morbidity	
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including	hypertension	and	renal	 insufficiency	(Ethelberg	et	al.,	2004;	Griffin	et	
al.,	1988;	Nataro	&	Kaper,	1998;	Steele	et	al.,	1982).	The	serotype	O157:H7	has	the	strongest	correlation	with	incidents	of	HUS	worldwide	(Tarr	et	al.,	2005).		The	 genes	 encoding	 Shiga	 toxins,	 stx,	 are	 disseminated	 between	 host	 cells	 by	horizontal	gene	transfer	(HGT)	via	bacterial	viruses	(bacteriophages)		(Khalil	et	
al.,	 2016).	 There	 are	 examples	 of	 stx	 genes	 in	 bacterial	 genome	 that	 are	transferred	vertically,	but	 they	 form	part	of	phage	genomes	 integrated	 into	 the	STEC	genome	(Zhou	et	al.,	2015).	When	this	occurs	that	phage	genome	is	known	as	a	“prophage”	and	the	host	cell	has	become	a	“lysogen”.	The	collective	term	for	bacteriophages	containing	stx	gene	is	Stx	phages.			STEC	have	also	historically	been	referred	to	as	VTEC	(verocytotoxic	E.	coli)	due	to	the	 lethal	effect	the	toxin	has	on	cultured	Vero	cells	 -	a	kidney	cell	 line	from	the	African	 green	monkey	 (Konowalchuk	et	al.,	 1977).	 It	was	 later	 determined	this	cytotoxin	was	identical	to	the	Shiga	toxin	produced	by	E.	coli.	After	a	phase	where	 both	 were	 being	 used	 in	 the	 literature,	 STEC	 is	 now	 the	 favoured	terminology.		
1.2.2.1	Enterohaemorrhagic	E.	coli	(EHEC)	EHEC	are	a	subset	of	STEC	that	share	some	of	the	pathogenicity	mechanisms	of	EPEC	in	their	ability	to	intimately	attach	to	the	intestine	epithelium	via	intimin-tir	 binding	 and	 generate	 A/E	 lesions.	 Despite	 this	 similarity,	 there	 are	 2	 key	differences	that	define	them:	EHEC	cells	colonise	further	down	the	GI	tract	than	EPEC;	in	the	distal	ileum	or	the	colon,	rather	than	the	small	intestine	(Griffin	et	
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al.,	1988;	Kelly	et	al.,	1987).	EHEC	strains	also	produce	Shiga	toxin	(Stx)	which	at	various	times	as	also	known	as	Shiga-like	toxin	(SLT)	or	verocytotoxin	(VT).			The	 first	 EHEC	 strain	 identified	 was	 part	 of	 an	 outbreak	 in	 the	 USA	 that	originated	from	undercooked	beef	in	hamburgers	(Riley	et	al.,	1983).	It	was	soon	identified	that	this	was	due	to	an	O157:H7	strain	that	had	been	infected	by	a	Stx	phage	 (O'Brien	 et	 al.,	 1984).	 Stx	 genes	 have	 also	 spread,	 via	 phages,	 to	 other	members	of	the	Enterobacteriaceae	 family,	(Paton	&	Paton,	1996;	Strauch	et	al.,	2001)	 and	 even	 as	 far	 as	 Acinetobacter	 haemolyticus	 (Grotiuz	 et	 al.,	 2006),	crossing	into	another	order	–	an	astonishingly	large	phylogenetic	distance	given	that	phage	host	ranges	are	usually	limited	to	a	specific	species,	occasionally	even	strains	 of	 a	 particular	 species	 (Koskella	 &	 Meaden,	 2013).	 The	 continued	occurrences	of	STEC	outbreaks	up	to	the	present	day	and	emergence	of	new	host	species	 indicates	 the	 rapid	dissemination	of	stx	by	phages	 is	being	observed	 in	real	time,	and	the	next	severe	outbreak	is	probably	inevitable.		All	EHEC	strains	are	STEC	and	so	 recently,	 the	acronyms	EHEC	and	STEC	have	been	used	interchangeably	in	the	literature	e.g.	(Yang	et	al.,	2017).	However,	this	is	incorrect	as	not	all	STEC	strains	are	EHEC	(Nataro	&	Kaper,	1998).	Some	STEC	isolates	 e.g.	 from	 cattle	 (Callaway	 et	 al.,	 2013),	 may	 not	 be	 associated	 with	human	disease	and	others	are	enteroaggregative	haemorrhagic	E.	coli.		
1.2.2.2	Enteroaggregative	haemorrhagic	E.	coli	(EAHEC)	The	 largest	 outbreak	 of	 Shiga	 toxin-producing	 E.	 coli	 in	 recent	 history	 was	 in	Germany	 over	 the	 summer	 of	 2011.	 This	 was	 caused	 by	 a	 strain	 of	
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enteroaggregative	haemorrhagic	E.	coli	(EAHEC)	evolved	from	EAEC	after	being	infected	by	an	Stx	phage	(Beutin	&	Martin,	2012).	This	EAHEC	strain	combined	the	shigatoxigenic	potential	of	EHEC	with	the	self-aggregative	characteristics	of	EAEC.	This	 combination	of	 virulence	 factors	 leads	 to	 a	 larger	number	of	E.	coli	cells	per	colony	than	that	associated	with	EHEC	infections,	and	when	combined	with	 Stx	 phage	 carriage,	 more	 cells	 expressing	 Shiga	 toxin	 will	 potentially	increase	 the	 overall	 amount	 of	 Shiga	 toxin	 release.	 Increasing	 numbers	 of	colonising	 cell	 and	 increased	 Stx	 production	may	 explain	why	 the	 outbreak	 of	EAHEC	in	Germany	resulted	in	such	a	high	fatality	rate.	Recorded	numbers	vary	by	source	but	from	3816-4075	cases	of	food	poisoning	were	recorded,	and	there	were	around	810	–	908	cases	of	HUS	(21%	of	cases)	and	46	–	54	deaths	(1.1%	–	1.3%	 of	 cases)	 (Bielaszewska	 et	 al.,	 2011;	 Blaser,	 2011;	 Frank	 et	 al.,	 2011;	Mellmann	et	al.,	2011;	WHO,	2011).	Throughout	 the	outbreak,	vegetables	were	blamed	 for	 spreading	 the	 infection	 across	 Europe	 (Buchholz	 et	al.,	 2011)	with	cucumbers	 and	 then	 beansprouts	 receiving	 most	 of	 the	 media	 attention.	Eventually,	the	infection	was	traced	back	to	the	storage	of	fenugreek	seeds,	and	could	have	spread	further	via	mishandling	this	stock	at	any	stage	of	crop	growth,	harvest,	or	handling	(Aldabe	et	al.,	2011;	King	et	al.,	2012).			
1.3 	Shiga	toxin		The	 Shiga	 toxin	 (Stx)	 protein	 complex	 was	 first	 characterised	 from	 Shigella	
dysenteriae	serotype	1	after	it	was	identified	in	1896	as	the	cause	of	a	dysentery	outbreak	 in	 Japan	 (Shiga,	 1898)	 .	 The	 illness	 causing	 bacteria	 was	 originally	
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named	Bacillus	dysenteryie,	which	was	associated	with	a	mortality	rate	reaching	>20%	in	infants	(Shiga,	1906;	1936).			During	the	early-	and	mid-20th	century,	repeated	efforts	were	made	to	isolate	the	Shiga	 toxin	protein	 (Stx),	 as	well	 as	 to	 define	 its	 role	 in	 disease	 (Keusch	et	al.,	1981).	 Stx	expression	 is	not	essential	 for	S.	dysenteriae	to	 cause	dysentery,	but	loss	of	Stx	expression	in	naturally-occurring	S.	dysenteriae	strains	or	Stx	knock-out	 mutants	 has	 been	 associated	 with	 decreased	 severity	 of	 symptoms	 of	dysentery	 in	 human	 or	 rhesus	 monkey	 subjects,	 respectively	 (Fontaine	 et	 al.,	1988;	 Levine,	 1987).	 Homogeneous	 purification	 of	 Stx	 was	 finally	 achieved	 in	1980	(O'Brien	et	al.,	1980),	and	the	purified	toxin	was	confirmed	to	cause	HUS	or	HUS-like	 symptoms	 in	 mice	 (Lindgren	 et	 al.,	 1994),	 rabbits	 (Eiklid	 &	 Olsnes,	1983),	dogs	(Raife	et	al.,	2004),	and	baboons	(Siegler	et	al.,	2003).	Shiga	toxin	can	also	 be	 the	 aetiological	 agent	 in	 infection-associated	 cases	 of	 bloody	diarrhoea	due	to	its	ability	to	bind	to	human	intestinal	mucosa	despite	the	absence	of	Gb3	(Hodges	&	Gill,	2010;	Schüller	et	al.,	2007).		Evidence	 for	 the	 production	 of	 Stx	 by	 certain	 diarrhoegenic	 strains	 of	 E.	 coli	developed	 from	 observations	 that	 protein	 extracts	 of	 these	 strains	 and	 S.	
dysenteriae	had	similar	biological	and	antigenic	properties	(O'Brien	et	al.,	1982)	and	 from	 the	 structural	 similarity	 of	 their	 purified	 toxins	 (O'Brien	 &	 LaVeck,	1983).	 Two	 antigenically-distinct	 Shiga-like	 toxins	 were	 identified	 in	 different	strains	of	E.	coli	EDL933	of	serotype	O157:H7,	and	were	designated	as	Stx1	and	Stx2	 (O'Brien	 et	 al.,	 1984;	 Strockbine	 et	 al.,	 1986).	 Stx1	 was	 found	 to	 be	neutralised	by	antiserum	to	Stx	produced	by	S.	dysenteriae,	whereas	Stx2	was	not	
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(Strockbine	et	al.,	1986).	The	primary	structure	of	Stx1	was	identical	to	Stx	of	S.	
dysenteriae,	 except	 for	a	 single	amino	acid	substitution,	whereas	Stx2	was	only	~55%	identical	at	the	amino	acid	level	(Jackson	et	al.,	1987;	Johannes	&	Römer,	2010;	Strockbine	et	al.,	1988).	Stx1	and	Stx2	toxins	have	both	been	sub-divided	into	more	than	one	subtype	(described	in	section	1.3.1).	Irrespective	of	sub-type,	Shiga	 toxin	 production	 occurs	 post-induction	 of	 the	 prophage	 (Wagner	 et	 al.,	2001)	and	is	released	upon	cell	lysis	(Wagner	et	al.,	2002).		Stx	toxins	have	an	‘AB5’	quaternary	structure	(Fig.	1.3.1),	similar	to	other	toxins,	such	as	Cholera	(Ctx)	and	Pertussis	(Pt)	toxins,	which	are	also	carried	by	phages	(Beddoe	 et	 al.,	 2010).	 Subunit	 A	 of	 Stx	 possesses	 N-glycosidase	 activity	responsible	 for	 their	 toxicity	 (Endo	 et	 al.,	 1988),	 while	 the	 five	 B	 subunits	mediate	host-cell	surface	binding	and	initiate	endocytosis	(Donohue-Rolfe	et	al.,	1989;	 Ling	 et	 al.,	 1998).	 With	 the	 exception	 of	 Stx2e,	 Stx	 toxins	 bind	 the	glycolipid	globotriaosylceramide	(Gb3)	as	their	receptor	on	the	surface	of	target	cells	 (Jacewicz	 et	 al.,	 1986).	 The	 presence	 and	 prevalence	 of	 Gb3	 within	 the	tissues	of	the	host	organism	is	directly	correlated	to	severity	of	the	disease,	with	Gb3	 deficient	 cell	 lines	 and	 Gb3	 deficient	 animals	 e.g.	 deer	 and	 cattle,	 being	insensitive	to	Shiga	toxin	(Acheson	et	al.,	1996;	Okuda	et	al.,	2006).	Treatments	that	 protect	 against	 development	 of	 HUS	 and	 TPP	 include	 chloroquine	 and	glucose	analogues,	which	competitively	inhibit	the	interaction	between	Gb3	the	B	subunits	of	Shiga	toxin	(Kavaliauskiene	et	al.,	2017).				
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Figure	1.3.1:	A	schematic	of	the	AB5	structure	of	Shiga	toxin	(PDB	1R4P).		This	representation	of	Stx2	was	generated	from	data	published	by	(Fraser	et	al.,	2004).	The	subunits	of	the	toxin	are	coloured	by	chain	–	StxA,	the	toxic	subunit,	is	blue	with	the	5	identical,	non-toxic	StxB	subunits	coloured	yellow,	green,	pink,	grey	and	orange.	The	underside	view	(left)	shows	the	5	fold	rotational	symmetry	of	the	StxB	pentamer	that	encapsulates	an	α-helix	at	the	C-terminal	end	of	StxA.	The	 profile	 view	 (right)	 shows	 that	 the	 pentamer	 only	 needs	 to	 bind	 a	 small	region	of	StxA	in	order	to	protect	the	A	subunit	from	premature	activation.			
90˚	
From	below	 Profile	view	
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Gb3	 is	 comprised	 of	 a	 ceramide	 and	 a	 trisaccharide	 moiety,	 i.e.	 Galα1-4Galβ1-4Glc-ceramide	 (Bergan	 et	 al.,	 2012).	 The	 ceramide	 moiety	 anchors	 Gb3	 to	 the	outer	leaflet	of	the	plasma	membrane	through	hydrophobic	interactions	with	its	pair	 of	 hydrocarbon	 chains.	 The	 Gb3	 trisaccharide	 moiety	 is	 exposed	 on	 the	exterior	surface	of	the	plasma	membrane	for	Stx	to	bind	(Chan	&	Ng,	2016;	Ling	
et	 al.,	 1998).	 During	 HUS	 development,	 the	 presence	 of	 Gb3	 on	 the	 plasma	membrane	external	leaflet	of	certain	cell	types	in	the	kidney	and	central	nervous	system	 (CNS)	 is	 thought	 to	 result	 in	 Stx-mediated	 cytotoxicity	 and	 damage	 to	these	tissues	(Trachtman	et	al.,	2012).		X-ray	 crystallography	 of	 Stx	 has	 shown	 that	 the	 B	 subunits	 form	 a	homopentameric	 ring	with	 five-fold	rotational	 symmetry	 (Figure	1.3.1).	Each	B	subunit	contributes	a	single	α-helix	to	the	inner	surface	of	the	ring,	and	an	anti-parallel	β-sheet	to	its	outer	surface	(Fraser	et	al.,	1994;	2004).	Stx	has	three	Gb3	binding	sites	for	each	B	subunit	-	15	in	total	-	in	contrast	to	other	AB5	toxins	such	as	Ctx,	which	has	five	host	binding	sites	in	total	(Beddoe	et	al.,	2010;	Ling	et	al.,	1998).	A	mutagenesis	study	of	Stx1	suggested	that	its	three	quintets	of	identical	Gb3	binding	sites	had	different	affinities	for	Gb3,	and	found	that	the	lower	affinity	of	 mutated	 individual	 binding	 sites	 was	 correlated	 with	 the	 impairment	 of	cytotoxicity	to	Vero	cells	(Bast	et	al.,	1999).		The	 A	 subunit	 of	 Shiga	 toxins	 is	 divided	 into	 two	 domains.	 The	 N-terminal	 A1	domain,	 containing	 its	N-glycosidase	 active	 site,	 and	 the	 C-terminal	 A2	 domain	that	 is	 inserted	 into	 the	centre	of	 the	B	 subunit	 ring	 to	 form	 the	AB5	structure.	The	 A	 subunit	 contains	 a	 single	 disulphide	 bond	 that	 bridges	 the	 A1	 and	 A2	
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domains	 (Fraser	 et	 al.,	 1994;	 2004)	 and	 defines	 the	 polypeptide	 loop	 that	 is	cleaved	 by	 the	 host	 cell	 enzyme	 furin	 to	 activate	 the	 enzymatic	 activity	 of	 the	toxin	(described	in	1.3.2).			
1.3.1	Stx	variants		Following	the	discovery	of	Stx1	and	Stx2,	additional	subtypes	of	both	Stx	forms	were	 discovered	 that	 had	 divergent	 sequences	 from	 their	 “parent”	 Stx	 toxins.		Nomenclature	 for	 the	 Stx	 subtypes	was	 eventually	 formalised	by	 Scheutz	et	al.	(Scheutz	et	al.,	 2012)	 in	order	 to	develop	a	protocol	 for	assigning	a	 subtype	 to	each	newly-isolated	STEC	strain.	 Stx1	 toxins	were	divided	 into	 subtypes	Stx1a,	and	Stx1c-e.	Stx2	toxins	were	divided	into	subtypes	Stx2a-g	(Johannes	&	Römer,	2010;	Scheutz	et	al.,	2012).			In	 comparison	 to	 Stx2-producing	 STEC	 strains,	 Stx1-producing	 isolates	 have	been	 associated	with	 uncomplicated	 diarrhoea	without	 HUS,	 or	 with	 a	 lack	 of	symptoms	 altogether	 (Boerlin	 et	al.,	 1999;	 Chui	et	al.,	 2015).	S.	dysenteriae	Stx	(Strockbine	et	al.,	1988)	and	the	prototypical	Stx1	toxin	of	E.	coli	strain	O157:H7	EDL933	 (Jackson	 et	 al.,	 1987)	 were	 placed	 in	 the	 Stx1a	 subtype,	 and	 the	prototypical	 Stx2	 toxin	 from	 O157:H7	 strain	 933	 (Jackson	 et	 al.,	 1987)	 was	placed	in	the	Stx2a	subtype	(Scheutz	et	al.,	2012).			Stx1c	toxins	were	discovered	in	an	STEC	strain	isolated	from	sheep	(Paton	et	al.,	1995)	 and,	 independently,	 from	 a	 longitudinal	 study	 of	 STEC	 isolates	 from	human	patients	(Zhang	et	al.,	2002).	Stx1c	has	been	found	to	be	associated	with	
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less	 severe	 STEC	 infections,	 without	 complications	 from	 HUS	 (Friedrich	 et	 al.,	2003;	Orth	et	al.,	2007).			Stx1d	was	discovered	in	an	STEC	isolated	from	bovine	faeces	that	gave	a	positive	result	 from	an	ELISA	Stx	screen	but	a	negative	result	 from	a	PCR-based	screen	(Bürk	et	al.,	2003).	Stx1d-producing	STEC	have	subsequently	been	isolated	from	human	stool	samples,	but	this	toxin	subtype	is	not	thought	to	be	associated	with	a	severe	disease	course	(Kumar	et	al.,	2012;	Melton-Celsa,	2014).			Subsequently,	 an	 additional	 Stx1	 subtype,	 Stx1e,	 was	 discovered	 in	 a	 clinical	isolate	(Enterobacter	cloaceae)	from	a	human	patient	suffering	from	non-bloody	diarrhoea,	which	had	not	progressed	to	HUS	(Probert	et	al.,	2014).		Stx2c	 was	 originally	 isolated	 from	 the	 E32511	 strain	 of	 the	 O157:H7-	 ETEC	serotype,	 which	 was	 found	 to	 be	 associated	 with	 HUS	 in	 human	 patients	 and	produced	 Stx2a	 in	 addition	 to	 Stx2c	 (Schmitt	 et	 al.,	 1991).	 Stx2b	 was	 later	identified	 as	 a	 distinct	 subtype	 based	 on	 sequence	 divergence	 of	 its	members	from	 Stx2c	 (Persson	 et	 al.,	 2007).	 Stx2a	 and	 Stx2c	 are	 associated	 with	 more	severe	symptoms	of	gastrointestinal	infection	by	STEC,	in	particular	HUS	(Chui	et	
al.,	2015;	Friedrich	et	al.,	2002;	Orth	et	al.,	2007).			Stx2d	 was	 originally	 identified	 in	 a	 human	 patient	 whose	 STEC	 infection	 had	progressed	 to	 HUS	 (Ito	 et	 al.,	 1990).	 Cytotoxicity	 of	 Stx2d	 is	 activated	 upon	exposure	of	these	toxins	to	intestinal	mucus	(Melton-Celsa	et	al.,	1996;	Scheutz	et	
al.,	2012).	Elastase,	a	protease	that	is	a	component	of	intestinal	mucus,	activates	
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Stx2d	by	cleavage	of	a	glycine-glutamate	dipeptide	from	the	C-terminus	of	the	A	subunit	(Kokai-Kun	et	al.,	2000;	Melton-Celsa	et	al.,	2002).	Higher	cytotoxicity	of	Stx2d	 following	 elastase-catalysed	 activation	 has	 been	 attributed	 to	 higher	affinity	of	binding	to	the	Gb3	receptor	(Bunger	et	al.,	2013).	In	STEC	strains	that	lack	 the	 virulence	 gene	 eae,	which	 therefore	 do	 not	 intimately	 adhere	 or	 form	pedestals,	Stx2d	is	associated	with	severe	symptoms	including	bloody	diarrhoea	and	HUS	(Bielaszewska	et	al.,	2006).		Stx2e	 was	 originally	 identified	 in	 E.	 coli	 isolated	 from	 pigs	 affected	 by	 edema	disease	 (ED)	 (Weinstein	 et	al.,	 1988).	 Uniquely	 among	 the	 Stx	 subtypes,	 Stx2e	toxins	 preferentially	 bind	 globotetraosylceramide	 (Gb4)	 over	 Gb3	as	 their	 cell-surface	receptor	(DeGrandis	et	al.,	1989;	Samuel	et	al.,	1990).	Gb4	is	equivalent	to	Gb3	with	an	additional	N-acetylglucosamine	β1,3-linked	to	the	terminal	galactose	residue	 of	 its	 glucan	 chain;	 i.e.	 GalNAcβ1-3Galα1-4Galβ1-4Glc-ceramide	(DeGrandis	et	al.,	1989).	Stx2e-producing	STEC	have	been	isolated	from	human	patients	with	diarrhoea,	but	 this	subtype	has	been	 found	 to	be	associated	with	relatively	 mild	 progression	 of	 the	 symptoms,	 without	 HUS	 (Friedrich	 et	 al.,	2002).		Stx2f	was	initially	found	in	the	droppings	of	feral	pigeons	(Schmidt	et	al.,	2000),	while	 Stx2g	 was	 discovered	 in	 the	 faeces	 of	 cattle	 (Leung	 et	 al.,	 2003).	 Until	recently,	Stx2f	and	Stx2g	were	not	thought	to	be	associated	with	severe	disease	in	 humans	 (Melton-Celsa,	 2014).	 However,	 Stx2f-producing	 STEC	 strains	 have	been	 isolated	 from	 human	 patients	 suffering	 from	 HUS,	 and	 it	 has	 been	suggested	that	E.	coli	lysogens	of	Stx2f-encoding	prophages	can	be	transmitted	to	
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humans	and	cause	disease	when	they	have	acquired	additional	non-Stx	virulence	genes	 that	 have	 been	 functionally	 characterised	 in	 non-Stx2f-producing	 STEC	(Grande	et	al.,	2016).		
1.3.2	Mechanism	of	Action	of	Shiga	Toxin	(Stx)	on	Human	Cells		Stx	cytotoxicity	begins	with	the	binding	of	the	AB5	Stx	holotoxin	to	Gb3	on	the	cell	surface	 (Fig.	 1.3.2.1A).	 Correct	 targeting	 of	 Stx	 to	 the	 cytosol	 depends	 on	incorporation	of	Gb3	into	detergent-resistant	membranes	(DRMs),	also	known	as	lipid	 rafts	 or	 microdomains,	 which	 are	 heterogenous	 regions	 of	 the	 plasma	membrane	that	are	enriched	in	cholesterol.	In	Gb3-expressing	cells	without	Gb3-containing	DRMs,	 Stx	 is	 translocated	 to	 lysosomes	and	degraded	 (Falguières	et	
al.,	2001).	Following	binding	of	StxB	subunit	to	Gb3	in	a	DRM,	endocytosis	occurs	via	 the	 formation	 of	 self-contained	 vesicles	 with	 Gb3-Stx	 complexes	 on	 their	internal	 face	 (Bergan	et	al.,	 2012)	 (Fig.	1.3.2.1B).	Polymerisation	of	 the	protein	clathrin	on	the	inner	surface	of	the	plasma	membrane	can	deform	it	to	form	a	pit	in	the	membrane,	and	then	narrow	the	opening	of	the	pit	to	a	bottle-neck,	before	the	GTPase	dynamin	severs	the	neck	and	releases	a	clathrin-coated	vesicle	 into	the	 cell	 (Doherty	 &	 McMahon,	 2009).	 Clathrin-dependent	 endocytosis	 is	 an	important	 route	 for	 Stx	 entry	 into	 the	 cell,	 but	 loss-of-function	 mutations	 of	proteins	 involved	 in	 this	 pathway,	 including	 dynamin	 and	 clathrin,	 in	 cultured	cell	lines	have	shown	that	Stx	can	exploit	at	least	one	clathrin-independent	mode	of	endocytosis	(Bergan	et	al.,	2012;	Lauvrak	et	al.,	2004).		
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Figure	1.3.2.1:	The	journey	of	Shiga	toxin	from	binding	to	the	host	cell	to	
retrotranslocation.		(A)	 Shiga	 toxin	 recognises	 the	 cell	 via	 Gb3	 on	 the	 surface	 of	 the	 plasma	membrane.	(B)	Shiga	toxin	is	internalised	into	an	early	endosome	via	a	clathrin-coated	 vesicle.	 (C-D)	 Shiga	 toxin	 is	 trafficked	 to	 the	 Golgi	 body	 where	 it	undergoes	 retrograde	 transport	 into	 the	 ER	 where	 the	 toxin	 is	 cleaved	 by	 a	furinase	 to	 generate	 the	 activated	 Stx	 toxin	 (E-F).	 Activated	 Stx	 toxin	 is	retrotranslocated	 into	 the	 cytosol	 where	 it	 inhibits	 tRNA	 binding	 to	 the	ribosome,	 inducing	 the	 ribotoxic	 response	 and	 apoptosis.	 Figure	 adapted	 from	(Johannes	&	Römer,	2010)		
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Following	endocytosis,	Stx	is	transported	to	the	endoplasmic	reticulum	(ER)	(Fig.	1.3.2.1C-D)	 via	 the	 endosome	 and	 the	 Golgi	 apparatus	 (McKenzie	 et	 al.,	 2009;	Sandvig	et	al.,	1992;	Warnier	et	al.,	2006).	In	the	process	of	retrograde	transport,	the	 A1	 and	 A2	 domains	 of	 the	 A	 subunit	 become	 separated,	 with	 the	 former	becoming	 the	active	Stx,	or	activated	cytotoxin.	This	 is	achieved	by	cleavage	of	the	A	subunit	polypeptide	chain	at	an	Arg-Val-Ala-Arg	motif,	catalysed	by	furin,	a	membrane-bound	 endopeptidase	 principally	 localised	 to	 the	 trans-Golgi	network.	Reduction	of	the	disulfide	bond	is	also	required	to	allow	the	A1	and	A2	domains	to	separate	(Garred	et	al.,	1995;	1997;	Samuel	&	Gordon,	1994)			The	 holotoxin	 is	 retrotranslocated	 from	 the	 ER	 lumen	 to	 the	 cytosol	 (Fig.	1.3.2.1E-F).	 Stx	 exploits	 the	 ER-associated	 degradation	 (ERAD)	 mechanism,	which	 functions	 to	 translocate	 misfolded	 proteins	 from	 the	 ER	 lumen	 to	 the	cytosol	 so	 that	 they	 can	 be	 proteolytically	 degraded.	 Retrotranslocation	 of	activated	 StxA	 is	 dependent	 on	 the	 Sec61	 translocon,	 as	 revealed	 by	 siRNA-mediated	 knock-down	 of	 its	 subunits	 in	 HeLa	 cells	 (Moreau	 et	 al.,	 2011).	Cleavage	 of	 the	 A	 subunit	 exposes	 a	 C-terminal	 hydrophobic	 patch	 in	 the	 A1	domain	 that	 is	 thought	 to	 mimic	 the	 surface	 hydrophobicity	 of	 misfolded	proteins	 and	 trigger	 retrotranslocation	 (LaPointe	 et	al.,	 2005).	 Stx1	 can	 be	 co-immunoprecipitated	 with	 Sec61	 and	 the	 ER	 lumen	 chaperone	 HEDJ/ERdj3,	which	is	thought	to	indicate	that	HEDJ	recruits	the	A1	holotoxin	to	the	translocon	at	the	ER	membrane	(Yu	&	Haslam,	2005).		Stx	holotoxin	catalyses	the	removal	of	a	conserved	adenine	residue	from	the	28S	rRNA	of	eukaryotic	ribosomes	using	its	N-glycosidase	activity,	and	this	results	in	
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the	 inactivation	 of	 ribosomal	 binding	 of	 aminoacyl-tRNAs	 and	 thus	 of	 protein	synthesis	(Endo	et	al.,	1988).	Stx	intoxication	has	been	found	to	induce	apoptosis	in	multiple	cell	lines	(Tesh,	2012).	Inactivation	of	protein	synthesis	is	thought	to	induce	 apotosis	 via	 two	 endogenous	 signalling	 mechanisms:	 the	 ribotoxic	response,	 which	 is	 activated	 by	 inhibition	 of	 ribosomal	 tRNA	 binding	 and	peptidyl	 transferase	 activity,	 and	 the	 unfolded	 protein	 response,	 which	 is	activated	by	accumulation	of	improperly-folded	proteins	in	the	ER	lumen	(Tesh,	2012).			
1.4	Shiga	toxin	producing	E.	coli	infections		The	 disease	 characteristics	 of	 Shiga	 toxin-based	 illnesses	 result	 from	 E.	 coli	infections	where	 Shiga	 toxin	 is	 produced	 in	 the	 gut	 (Brigotti	 et	al.,	 2006).	 The	onset	 of	 symptoms	 can	 be	 caused	 by	 the	 ingestion	 of	 less	 than	 10	 organisms	(CFU	mL-1)	(Lindgren	et	al.,	1994).	This	makes	STEC	one	of	 the	most	notorious	causes	of	 foodborne	outbreaks;	 for	example,	 in	the	USA,	55%	(89	of	163)	of	all	reported	 foodborne	 outbreaks	 between	 2007-2012	 were	 associated	 with	shigatoxigenic	E.	coli	(Robertson	et	al.,	2016).	Case	numbers	are	comparable	but	the	rate	of	outbreaks	involving	E.	coli	in	England	and	Wales	from	2014	to	2018	is	much	lower	(12%	-	11	of	89).	This	may	be	due	to	the	lack	of	reporting	for	minor	food	 poisoning	 symptoms	 not	 providing	 enough	 cases	 to	 be	 classified	 as	outbreaks.	It	may	also	be	that	other	foodborne	pathogens	are	more	prevalent	in	the	 UK,	 with	 Salmonella	 (26%),	 Campylobacter	 (16%),	 and	 Clostridium	 (15%)	taking	a	significant	share	of	reported	outbreaks	(PHE,	2014-2018).		
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Responses	 to	 STEC	 epidemics	 using	 molecular	 biological	 and	 microbiological	approaches	 are	 thorough,	 but	 can	 be	 very	 laborious	 and	 take	 multiple	 days	(Bielaszewska	 et	al.,	 2011).	 The	 best	molecular	 biological	 approach	 involved	 a	complete	sequencing	and	assembly	of	a	draft	genome	of	the	outbreak	strain	that	was	 completed	 within	 62	 hours	 (Mellmann	 et	 al.,	 2011).	 The	 amount	 of	information	 generated	 from	 this	 approach	 was	 considerable	 and	 allowed	 the	identification	 of	 EAHEC,	 a	 new	 pathotype	 of	 diarrheogenic	E.	 coli.	 However,	 at	over	 2.5	 days,	 this	 method	 of	 pathogen	 detection	 is	 still	 extremely	 slow	 to	consider	 using	 it	 during	 an	 epidemic	 response	 time,	 as	 it	 would	 be	 unable	 to	inform	a	rapid	response	to	a	developing	situation.		
1.4.1	Detection	of	STEC		There	 used	 to	 be	 three	 methods	 of	 diagnosing	 an	 STEC	 infection:	 isolation	 of	viable	 STEC	 cells	 from	 stool	 samples,	 detection	 of	 Stx	 in	 stool	 sample,	 or	detection	of	 elevated	 levels	of	 antibodies	 to	STEC	antigens	 in	 serum	(Nataro	&	Kaper,	 1998).	 Patients	 presenting	 with	 bloody	 diarrhoea	 or	 HUS	 would	 have	stool	samples	analysed	on	sorbitol-MacConkey	(SMAC)	agar	plates	 to	select	 for	enteric	 Gram	 negative	 bacteria	 and	 the	 presence	 of	 EHEC	 strain	 O157:H7	 is	detected	 by	 its	 inability	 to	 ferment	 the	 sorbitol,	 producing	 colourless	 colonies	(Boyce	et	al.,	1995).	SMAC	agar	 is	only	able	 to	reliably	 identify	O157:H7;	other	culturing	methods	are	available	for	other	strains	(reviewed	by	Nataro	&	Kaper,	1998),	but	there	is	no	catch-all	culturing	solution	that	will	detect	all	known	EHEC	or	STEC	strains.			
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PCR	 based	methods	 can	 provide	 results	 in	 just	 hours	 as	 opposed	 to	 overnight	timescales	 for	bacterial	growth	on	agar	plates.	Gene	targets	 for	PCR	include	stx	(EHEC	and	EAHEC),	eae	(EHEC	and	EPEC),	or	the	pO157	plasmid	(O157:H7	only).	Both	Stx1	and	Stx2	can	be	detected	directly	from	stool	samples	by	PCR	(Ramotar	
et	al.,	1995).	Multiplexing	of	 targets	yields	a	more	reliable	method	of	diagnosis	with	 combinations	 of	 type	 III	 effector	 genes	 producing	 the	 highest	 level	 of	reliability	for	detecting	EHEC	(Delannoy	et	al.,	2013).			Looking	beyond	standardised	detection	methods,	STEC	can	also	be	identified	by	fluorescent-tagged	phages	or	endolysins	that	bind	specifically	to	pathogens	(Bai	
et	al.,	2016),	but	an	effective,	scalable	assay	for	this	would	need	to	be	developed	for	it	to	be	a	seful	diagnostic	tool.			
1.4.2	Medical	treatments/Preventative	measures		
1.4.2.1	Antibiotics:	Antibiotics	are	routinely	used	to	treat	non-STEC	E.	coli	infections.	However,	STEC	strains	present	a	dilemma	to	the	physician	considering	using	antibiotics,	as	they	tend	to	induce	the	STEC’s	SOS	response,	which	leads	to	activation	of	promoters	that	 lead	 to	 both	 the	 production	 of	 Stx	 and	 another	 generation	 of	 Stx	 phages	(Yang	 et	al.,	 2017;	 Zhang	 et	al.,	 2000).	When	 using	most	 antibiotics,	 there	 is	 a	significant	 correlation	 between	 STEC	 infections	 and	 an	 increased	 rate	 of	 HUS	development	 (Freedman	 et	 al.,	 2016).	 For	 this	 reason,	 the	 currently	 accepted	treatment	 strategy	 by	 physicians	 is	 to	 not	 treat	 probable	 STEC	 infections	with	any	antibiotics	(Freedman	et	al.,	2016;	McGannon	et	al.,	2010;	Szych	et	al.,	2014).	
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Exceptions	 to	 this	 have	 been	 reported;	 for	 example,	 telithromycin,	 a	 ketolide	antibiotic	that	inhibits	protein	production	by	binding	the	50S	ribosomal	subunit,	can	treat	STEC	strains	without	inducing	the	SOS	and	subsequent	Stx	production	(Nakagawa	 et	 al.,	 2003).	 This	 backs	 up	 the	 lack	 of	 progression	 from	 STEC	infection	 to	 HUS	 post-antibiotic	 treatment	 seen	 previously	 (Takeda,	 1998),	however,	 there	 are	 no	 studies	 to	 suggest	 that	 antibiotics	 which	 lead	 to	 DNA	damage	are	capable	of	killing	cells	without	inducing	Stx	production.		Using	 antibiotics	 also	 targets	 other	 gut	 microflora.	 This	 collateral	 damage	reduces	biodiversity	within	the	gut,	which	is	linked	to	an	increased	likelihood	of	STEC	colonisation	(Mir	et	al.,	2016),	so	they	may	make	the	situation	worse	in	the	long	 term.	 Furthermore,	 between	 1988	 and	 2007,	 the	 carriage	 of	 at	 least	 one	antibiotic	 resistance	 gene	 increased	 from	 2.9%	 to	 79.8%	 in	 O157:H7	 strains	isolated	 from	 a	 variety	 of	 sources:	 bovine	 and	 human	 faeces,	 bovine	 milk	products,	 ground	 beef,	 and	 cider	 (Colavecchio	 et	 al.,	 2017).	 This	 limits	 the	options	of	antibiotics	available	to	use	for	a	STEC	infection	but	as	phages	can	be	responsible	 for	 the	 dissemination	 of	 antibiotic	 resistance	 genes	 (Modi	 et	 al.,	2013),	 it	 is	probably	best	not	 to	 treat	STEC	 infections	with	antibiotics,	 thereby	denying	 	 further	 opportunity	 to	 spread	 these	 resistance	 genes	 to	 currently	susceptible	populations.				Alternatives	 to	 small	 molecule	 antibiotics	 have	 started	 to	 arise	 as	 potential	antibiotic	agents.	Peptides	that	bind	essential	factors	on	the	surface	of	E.	coli	cells	are	 now	being	 investigated	 as	 potential	 antimicrobial	 candidates	 (Hagan	et	al.,	2015;	Vimala	et	al.,	2015).	
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1.4.2.2	Inhibitors	Shiga	toxins	can	be	directly	inhibited	by	binding	carbohydrates,	which	recognise	the	StxB	subunits	of	 the	AB5	 toxin	 (Mulvey	et	al.,	 2003;	Nishikawa	et	al.,	 2002;	2005).	For	example,	“SUPER	TWIGs”	act	as	immune-response	aids	that	mimic	the	sugar-rich	glycosylated	extracellular	surface	of	eukaryotic	cells	(Nishikawa	et	al.,	2005).	 They	were	 specifically	 developed	 as	 Stx	 neutralisers,	 which	 also	 utilise	deliberately	oriented	saccharides	to	bind	to	the	StxB	subunit.	This	action	blocks	the	 binding	 of	 StxB	 to	 Gb3	 while	 also	 enabling	 efficient	 phagocytosis	 of	 toxin	molecules	by	macrophage	cells	in	the	circulatory	system.		Inhibitors	of	cell-cell	signalling	have	also	demonstrated	reduction	in	colonisation	efficiency.	 Disruption	 of	 inter-cell	 communication	 impedes	 the	 ability	 of	 the	community	to	form	effective	biofilms,	making	bacterial	cells	more	easily	targeted	by	 the	 immune	 system	 as	 they	 are	 not	 camouflaged	 by	 factors	 secreted	 by	biofilms	(Watters	et	al.,	2016).	This	could	be	a	way	to	limit	the	pathogenicity	(but	may	increase	the	shedding)	of	STEC	(Desin	et	al.,	2015;	Vikram	et	al.,	2012).		
1.4.2.4	Diet	A	high	fibre	diet	was	shown	to	increase	O157:H7	colonisation	in	a	mouse	model	by	up	to	100x	compared	to	a	low	fibre	diet	(Zumbrun	et	al.,	2013).	So	eating	less	fibre	 could	 reduce	 the	 impact	 of	 an	 STEC	 infection	 on	 an	 individual	 human.	Feeding	hay	to	cattle	instead	of	grain	increases	shedding	duration	(Hovde	et	al.,	1999)	meaning	that	the	diet	of	ruminants	may	increase	the	spread	of	STEC	and	therefore	have	an	influence	on	human	health.	
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	The	use	 of	 probiotic	 bacteria	 in	 foodstuffs	 to	maintain	healthy	 competition	 for	gut	 resources	 has	 shown	promise	 as	 a	 preventative	 strategy	 against	O157:H7-induced	death	in	mouse	model	(Takahashi	et	al.,	2004).	Probiotics	produced	by	
Lactobacillus	 acidophilus	 La-5	 can	 even	 down-regulate	 certain	 EHEC	 virulence	factors,	including	Stx2,	when	fed	to	mice	(Zeinhom	et	al.,	2012).		
1.4.2.5	Vaccines:		DNA-	 and	 protein-based	 vaccines	 have	 been	 developed	 in	 mouse	 models	 to	protect	against	STEC	and	Shiga	 toxin,	 respectively	 (Ren	et	al.,	 2013;	Sato	et	al.,	2013).	 Vaccinating	 cows	 with	 type	 III	 secretion	 proteins	 reduced	 both	 the	duration	 of	 shedding	 and	 numbers	 of	 pathogenic	 bacteria	 in	 faeces	 which	reduces	 the	 chance	 of	 contamination	 in	 the	 food	 supply	 chain	 (Potter	 et	 al.,	2004).	 As	 is	 always	 the	 case	 with	 vaccines,	 their	 effectiveness	 would	 be	dependant	on	predictions	of	cases/outbreaks,	which	has	not	been	possible	so	far.		
1.4.2.6	Groundwater	monitoring:	Identical	 phage	 structural	 genes	 have	 been	 recorded	 in	 metavirome	 data	worldwide	 (Short	 &	 Suttle,	 2005)	 demonstrating	 the	 ubiquitous	 nature	 of	phages.	However,	high	levels	of	genetic	heterogeneity	between	Stx	phages	in	the	environment	 mean	 that	 only	 Stx	 genes	 can	 be	 used	 as	 targets	 in	 attempts	 to	monitor	 potential	 STEC	 outbreaks	 (García-Aljaro	 et	al.,	 2004;	Muniesa	&	 Jofre,	2004).	 This	 limitation	 means	 that	 potential	 bacterial	 hosts	 represent	 a	 more	stable	 target.	 One	 concern	 regarding	 the	 efficacy	 of	 this	 strategy	 would	 be	freshwater-dwelling	 amoebae.	 Acanthamoeba	 spp.	 are	 present	 in	 air,	 soil,	 and	
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water	sources	such	as	taps,	reservoirs,	and	swimming	pools	(Rowbotham,	1980;	Thom	et	al.,	1992).	They	are	known	to	feed	on	Gram-negative	bacteria	but	some	pathogenic	 bacteria,	 including	 E.	 coli,	 are	 known	 to	 be	 able	 to	 survive	 and	multiply	post-internalisation,	providing	survival	reservoir	for	STEC	(Chekabab	et	
al.,	 2013;	 Ly	 &	 Müller,	 1990;	 Winiecka-Krusnell	 et	 al.,	 2002).	 Similar	observations	 have	 been	 made	 in	 Tetrahymena	 pyriformis	 where	 prophage	carriage	 increases	 the	 fitness	 of	 both	K-12	 and	O157	E.	coli	 strains,	 promoting	their	 survival	 within	 the	 food	 vacuoles.	 This	 potential	 to	 act	 as	 a	 vector	 for	bacterial	pathogens	is	troubling	from	a	health	perspective,	however,	it	also	raises	the	possibility	that	any	detection	strategy	targetting	on	surface	antigens	of	E.	coli	could	 fail	 to	 detect	 viable	 pathogenic	 E.	 coli	 if	 the	 issue	 is	 not	 accounted	 for.	Production	of	Stx	while	 the	EHEC	are	 internalized	 increases	amoebic	mortality	and	therefore	reduces	the	capacity	of	the	EHEC	reservoir	(Chekabab	et	al.,	2013).		
1.5	The	role	of	bacteriophages	in	disease			Bacteriophages	(phages)	are	known	to	be	the	primary	vectors	for	the	horizontal	gene	 transfer	 of	 Shiga	 toxin-encoding	 genes	 between	 bacteria	 (O'Brien	 et	 al.,	1984).	 Such	 Shiga	 toxin-encoding	 bacteriophages	 (Stx	 phages)	 are	 lambdoid	phages,	 which	 are	 temperate,	 thus	 capable	 of	 entering	 either	 the	 lytic	 or	lysogenic	replication	cycles	(Campbell,	1994).	Stx	expression	 is	associated	with	induction	of	lytic	replication	irrespective	of	which	life	cycle	is	taken	(Tyler	et	al.,	2013).	 The	 pathogenic	 potential	 of	 the	 stx	 genes	 is	 enhanced	 if	 the	 infecting	phage	 enters	 the	 lysogenic	 cycle	 to	 become	 a	 prophage.	 The	 prophage	 is	amplified	 across	 the	 lysogen	 population	 during	 host	 cell	 growth	 and	 division,	
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while	the	host	becomes	a	more	significant	member	of	the	gut	flora.	In	this	event,	when	prophages	are	induced	into	the	lytic	replication	cycle	by	the	activation	of	the	bacterial	host’s	SOS	stress	response,	 there	could	be	many	more	E.	coli	 cells	containing	 the	 Stx	 prophage	 and	 therefore	 there	 is	 a	 greater	 potential	 for	 Stx	expression	(Fogg	et	al.,	2012).			
1.5.1	Stx	phages			Stx	phages	are	highly	mosaic	(Gamage	et	al.,	2004;	Hendrix	et	al.,	2003;	Johansen	
et	 al.,	 2001;	 Smith	 et	 al.,	 2012),	 which	 is	 thought	 to	 be	 due	 to	 in-situ	recombination	events	within	lysogens.	Therefore,	the	presence	of	an	Stx	operon	encoding	at	least	one	of	the	two	variants	(Stx1	or	Stx2)	is	the	only	way	to	classify	a	 bacteriophage	 as	 a	 Stx	 phage	 (Allison,	 2007;	 Muniesa	 et	 al.,	 2004a,	 b).	 Any	“chromosomal”	versions	of	Stx	genes	that	have	been	described	in	the	 literature	have	always	been	ultimately	found	to	be	part	of	a	defective	prophage,	which	has	presumably	undergone	recombination	in	the	host	and	lost	vital	phage	replication	or	assembly	genes	and	is	no	longer	able	to	replicate	(Mizutani	et	al.,	1999).			A	 model	 Stx	 phage,	 ϕ24B	 is	 used	 in	 this	 thesis	 as	 it	 is	 stable	 on	 storage	 and	possesses	 a	 short	 tail	 that	 confers	 a	 large	 host	 range	 (Smith	 et	 al.,	 2007).	Furthermore,	ϕ24B	has	undergone	more	genetic	characterisation	than	other	Stx	phages	(Holt	et	al.,	2017;	Smith	et	al.,	2007;	2012).	ϕ24B	possesses	an	 inverted	integrase	gene,	which	allows	superinfection	events	-	the	presence	of	more	than	one	prophage	in	a	lysogen	genome	(Allison	et	al.,	2003;	Fogg	et	al.,	2007;	2011).	This	 is	 extremely	 rare	 and	 goes	 against	 the	 typical	 immunity	 paradigm	
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developed	 while	 studying	 lambda,	 λ,	 and	 lambdoid	 phages	 in	 general	 which	states	that	only	one	copy	of	a	lambdoid	prophage	can	be	integrated	into	the	host	cell	 genome	 at	 any	 given	 time	 (Fogg	 et	 al.,	 2010).	 Superinfecting	 λ	 phage	 has	been	 studied	 before,	 and	 was	 only	 possible	 using	 mutants	 in	 immunity	 or	excisionase	genes	 (Calef	et	al.,	1965;	Schneider	&	Strack,	1977).	This	 increased	copy	number	of	stx	genes	can	facilitate	a	larger	or	quicker	build-up	of	toxin,	and	the	amount	of	toxin	produced	during	an	infection	is	directly	proportional	to	the	severity	of	disease	phenotype	(Fogg	et	al.,	2012).	Greater	potential	toxin	release	is	 likely	 to	 be	 due	 to	 the	 phage-infected	 cells	 being	 capable	 of	 producing	 and	releasing	 infective	 toxigenic	 phages	 capable	 of	 converting	 gut	 microbiota	residents	into	Shiga	toxin	production	factories	(Gamage	et	al.,	2003).	Uninfected	but	phage-susceptible	 commensal	bacteria	 can	be	powerful	 contributors	 to	 the	overall	production	of	Shiga	toxin	as	they	have	been	shown	to	generate	up	to	40-fold	more	toxin	than	lysogens	alone	(Gamage	et	al.,	2003;	2006).	This	may	also	explain	the	3-log	increase	in	Stx2	levels	compared	to	in	vitro	expectations	during	some	phage	infections	(Tyler	et	al.,	2013).		
1.5.2	Effect	of	prophage	carriage	on	host	fitness		The	effects	of	prophage	carriage	(also	referred	to	as	lysogenic	conversion)	on	the	host	bacterium	are	many-fold	and	detailed	descriptions	of	 them	all	are	beyond	the	scope	of	 this	 thesis.	Examples	 include	but	are	not	 limited	 to	superinfection	exclusion,	 cell	 envelope	 modification	 for	 increased	 pathogenicity,	 and	 defence	systems	to	prevent	the	CRISPR-Cas	from	cleaving	phage	DNA.	These	aspects	are	reviewed	elsewhere	(Bondy-Denomy	&	Davidson,	2014).	
42	
		Specifically	 in	 the	 ϕ24B	 genome,	 there	 are	 several	 examples	 of	 host	 benefits	derived	from	prophage	carriage.	The	most	obvious	change	during	the	infection	is	the	conversion	of	the	E.	coli	host	to	a	pathogen	is	the	introduction	of	stx	into	the	cell,	 allowing	 the	 production	 of	 Shiga	 toxin	 in	 the	 host	 (Schmidt,	 2001).	 The	benefits	to	host	fitness	are	often	ways	to	facilitate	or	increase	the	effectiveness	of	the	toxin	release.			The	upregulation	of	glutamic	acid	carboxylase	(GAD)	operon	confers	additional	acid	resistance	to	the	lysogen	compared	to	a	naïve	MC1061	cell	(Veses-Garcia	et	
al.,	2015),	which	 increases	survival	 rates	of	 the	host	cell	 travelling	 through	 the	stomach	to	get	to	the	lower	GI	tract	where	it	can	colonise.			Other	examples	 in	the	ϕ24B	genome	are	genes	13b,	which	 increases	motility	of	the	host	(Veses-Garcia	et	al.,	unpublished	data),	and	gene	48,	which	is	a	huge	8kb	gene	that	has	domains	homologous	to	antibiotic	resistance	genes.	The	extent	of	any	 increased	 antibiotic	 resistance	 of	 MC1061	 containing	 an	 isolated	 gene	 48	have	yet	to	be	tested.		
1.6	Identification	of	the	receptor	for	ϕ24B		When	the	Stx	phage	ϕ24B	was	first	 identified,	an	effort	was	made	to	determine	its	adsorption	target	on	the	surface	of	E.	coli.	At	this	time,	most	experts	felt	that	Stx	 phages	 could	 only	 infect	 rough	 strains	 as	 the	 smooth	 strains	 prevented	access	 to	 receptors	 on	 the	 cell	 surface	 (van	 der	 Ley	 et	 al.,	 1986).	 It	 was	 later	
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demonstrated	that	Stx	phage	could	infect	a	smooth	serotype	O107	E.	coli	strain	(James	et	al.,	2001).	
	
The	strategy	used	to	 identify	which	antigen	ϕ24B	adsorbed	to	on	the	host	used	an	 adsorption	 resistant	 mutant,	 which	 would	 be	 complemented	 with	 an	expression	 library	generated	 from	 the	genomic	DNA	 (gDNA)	phage	 susceptible	host	(Sergeant,	1998).	The	Stx	phage	ϕ24B	was	originally	identified	on	the	E.	coli	indicator	 strain	MC1061	 (Allison	et	al.,	 2003).	 In	order	 to	 create	 the	necessary	phage-resistant	mutant,	a	culture	of	MC1061	was	infected	with	a	cocktail	of	five	different	Stx	phages	with	different	immunity	profiles	(Sergeant,	1998).	Surviving	cells	 from	 the	 infection	 were	 identified	 by	 spreading	 onto	 non-selective	 agar.	Resultant	 colonies	 were	 screened	 for	 their	 ability	 to	 produce	 phage	 upon	induction.	Four	colonies	were	identified	that	failed	to	produce	infective	phages.	These	four	clones	contained	prophages	of	a	subset	of	the	phages	in	the	cocktail,	and	 lost	 their	 ability	 to	 support	 ϕ24B	 adsorption.	 The	 clones	 were	 named	MC1061-MRL1-4	(MRL	=	Multiple	Resistant	Lysogen).	One	of	 the	MC1061-MRL	strains	 was	 then	 used	 to	 screen	 a	 pUC19-based	 expression	 library	 created	 by	partial	digestion	of	wild	type	MC1061	genomic	DNA	with	Sau3A	I	(Allison	et	al.,	2003;	 Sergeant,	 1998).	 Four	 independent	 clones	 from	 the	 expression	 library	were	 identified.	The	plasmids	 from	 these	 four	 clones	all	 restored	 sensitivity	 to	ϕ24B	upon	the	phage	resistant	mutant,	and	all	four	plasmid	clones	carried	DNA	inserts	 that	 shared	 a	 region	 of	 DNA	 sequence	 identity.	 Subcloning	 of	 one	particular	gene	within	this	shared	region	was	necessary	and	sufficient	to	restore	
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phage	sensitivity	to	MC1061-MRL1.	This	gene	was	named	vpr	for	verocytotoxin	
phage	receptor	(Sergeant,	1998).		
	
The	 ORF,	 vpr,	 shared	 identity	 with	 a	 few	 other	 hypothetical	 proteins	 from	 a	variety	 of	 other	 Gram-negative	 organisms,	 but	 in	 1998,	 bioinformatic	 analysis	had	 a	 more	 limited	 ability	 to	 predict	 potential	 cellular	 function	 from	 DNA	sequence	 data.	 Around	 this	 time	 the	 first	 E.	 coli	 K12	 genome	 sequence	 was	published	 (Blattner	 et	 al.,	 1997).	 Blattner	 and	 colleagues	 had	 annotated	hypothetical	genes	in	the	genome	location	of	vpr	with	the	three	letter	code	yae,	with	vpr	being	assigned	the	designation	yaeT	(Blattner	et	al.,	1997).		
	
Although	 a	 phage	 resistant	 mutant	 (MC1061-MRL)	 was	 isolated	 by	 Sergeant	(Sergeant,	 1998)	 for	 the	 complementation	 library	 for	 phage	 sensitivity,	 this	mutant	 was	 lost	 because	 it	 could	 not	 be	 resuscitated	 from	 -80°C	 stocks.	Unfortunately,	there	are	questions	raised	here	that	will	never	be	answered:	what	and	where	was	the	exact	mutation	that	resulted	in	the	creation	of	MC1061-MRL	strains?;	 how	 did	 MC1061-MRL	 cells	 survive	 if	 the	 receptor	 protein	 was	mutated?;	and	was	the	fragility	and	short-lived	nature	of	MC1061-MRL	due	to	a	mutation	in	the	receptor?		
	
Many	 efforts	 were	 subsequently	 made	 to	 knock	 out	 the	 receptor	 in	 MC1061	using	 a	 number	 of	 strategies.	 These	 utilised	 suicide	 vectors	 and	 attempts	 to	interrupt	 yaeT	 through	 a	 single	 recombination	 event	 through	 to	 the	 complete	replacement	 of	 yaeT	 by	 allelic	 exchange	 through	 double	 homologous	
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recombination	events.	However,	no	knock	out	mutant	was	ever	generated	using	these	methods	(James,	2002;	Sergeant,	1998;	Smith,	2004).	After	these	efforts,	it	was	discovered	that	yaeT	is	considered	to	be	one	of	the	ten	most	essential	genes	in	the	E.	coli	genome	(Gerdes	et	al.,	2003).	It	follows	that	the	essential	nature	of	YaeT	 makes	 its	 disruption	 impossible,	 regardless	 of	 the	 strategy	 employed	 to	attempt	it	and	that	if	natural	point	mutations	arise	those	strains	may	be	less	fit.	
	The	 expression	 of	 YaeT	 is	 regulated	 by	 the	 σE	 regulon	 (Dartigalongue	 et	 al.,	2001b).	In	2007	it	was	demonstrated	that	the	adsorption	potential	of	ϕ24B	was	directly	 proportional	 to	 the	 expression	 of	 YaeT	 following	 perturbations	 to	growth	conditions	 that	up-	or	down-regulated	YaeT	(Smith	et	al.,	2007).	 It	was	also	 demonstrated	 that	 rabbit	 antibodies	 raised	 to	 histidine-tagged,	 denatured	YaeT	blocked	phage	adsorption	in	a	dose	dependent	manner	(Smith	et	al.,	2007).	These	 data	 supported	 the	 idea	 that	 YaeT	 was	 involved	 in	 supporting	 the	adsorption	 of	 ϕ24B,	 but	 failed	 to	 definitely	 prove	 that	 YaeT	 is	 the	 adsorption	target	 for	ϕ24B.	This	study	also	 implied	 that	a	disproportionately	high	number	(70%)	 of	 short-tailed	 Stx	 phages	 from	 a	 collection	 of	 phages	 generated	 over	 5	years	 of	 sampling	 various	 water	 sources	 on	 local	 farmland	 (Robinson	 et	 al.,	2004)	would	utilise	YaeT	as	a	host	recognition	molecule	to	initiate	the	infection	process.			
In	the	10	years	between	1997	and	2007,	397	more	bacterial	genome	sequences	were	 uploaded	 to	 the	 Genbank	 database,	 revealing	 that	 YaeT	 was	 conserved	across	 all	Gram	negative	bacterial	 species	 and	 is	 very	highly	 conserved	 (>90%	
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amino	acid	identity)	across	the	members	of	the	Enterobacteriacea	 family	(Ruhe	
et	al.,	2013b;	Smith	et	al.,	2007).	In	2008,	YaeT	was	renamed	for	what	is	likely	to	be	the	final	time	after	the	Silhavy	group’s	work	that	determined	its	function	to	be	instrumental	in	inserting	β-barrelled	OMPs	into	the	outer	membrane	(Aoki	et	al.,	2008).	 As	 the	 major	 constituent	 of	 the	 β-barrel	 assembly	machinery,	 it	 was	named	BamA.		
	
1.7	Structure	and	Function	of	BamA		
1.7.1	Discovery		BamA	is	now	quite	well	known	and	has	managed	to	overcome	the	identity	crisis	it	had	at	the	turn	of	the	21st	century;	it	was	previously	identified	as	YaeT	in	E.	coli	strain	 MG1655	 (Werner	 &	 Misra,	 2005),	 EcfK	 in	 strains	 MC4100	 and	 ST131	(Dartigalongue	et	al.,	2001a),	YzzN	in	strain	W3110	(Alba	et	al.,	2002),	and	Vpr	in	strain	 MC1061	 (Sergeant,	 1998).	 In	 2003,	 the	 gene	 function	 of	 a	 BamA	homologue,	Omp85,	was	 identified	 in	Neisseria	meningitidis	as	having	 a	 role	 in	outer-membrane	 protein	 assembly	 (Voulhoux	 et	 al.,	 2003).	 This	 was	 possible	only	because	N.	meningitidis	is	an	unusual	Gram-negative	organism	that	is	able	to	survive	without	a	capsule	or	LPS	(Bos	&	Tommassen,	2005).		
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1.7.2	BamA	function		BamA	 is	 a	 member	 of	 the	 Omp85	 superfamily,	 which	 has	 evolved	 to	 have	functions	in	protein	translocation	and	assembly	(Heinz	&	Lithgow,	2014).	BamA	is	the	principle	component	in	the	β-barrel	assembly	machinery	(BAM)	complex.	The	BAM	complex	 is	a	heteropentameric	complex	composed	of	proteins	BamA-BamE,	 which	 is	 responsible	 for	 inserting	 nascent	 β-barrel	 shaped	 outer	membrane	proteins	 (OMPs),	 including	 itself,	 into	 the	outer	membrane	of	Gram	negative	bacteria	(Jain	&	Goldberg,	2007).	β-barrelled	structures	form	a	cylinder	of	antiparallel	beta	sheets	that	usually	create	a	pore	through	the	centre	and	have	a	 hydrophobic	 outer	 surface	 that	 faces	 the	 fatty	 acid	 domains	 of	 the	phospholipids	 in	 the	 bilayer.	 These	 proteins	 facilitate	 selective	 permeability	across	the	outer	membrane	for	a	broad	range	of	metabolites;	therefore	the	BAM	complex,	which	folds	these	β-barrel	shaped	proteins,	is	essential	for	cell	viability	and	 must	 be	 present	 and	 functional	 in	 the	 outer	 membrane	 at	 all	 times.	 The	essentiality	 of	 BamA	 was	 determined	 by	 Gerdes	 et	 al.	 (2003)	 before	 any	functional	data	had	been	collected	(Werner	&	Misra,	2005;	Wu	et	al.,	2005).	This	makes	 the	BamA	and	BAM	complex	difficult	 to	study,	as	both	deletion	mutants	and	loss-of-function	mutants	are	lethal.			
1.7.3	BamA	Structure		BamA	 is	 an	 autotransporter	 protein	 inserted	 into	 the	 outer	 membrane	 that	contains	two	distinct	modules:	one	is	a	membrane-bound	β-barrel	domain	with	16	trans-membrane	regions,	and	the	other	consists	of	 five	soluble	polypeptide-
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transport-associated	 (POTRA)	 domains	 that	 extend	 into	 the	 periplasm	 to	 bind	nascent	 OMPs.	 These	 OMPs	 are	 chaperoned	 across	 the	 periplasm	 to	 the	 BAM	complex	 by	 the	 chaperone	 protein,	 SurA	 (Malinverni	 &	 Silhavy,	 2011)	 where	they	are	transferred	to	the	POTRA	domains.	The	original	model	for	the	structure	of	BamA	published	by	Smith	et	al.	(2007)	was	based	on	FhaC,	a	closely	related	β-barrelled	protein	that	had	already	been	crystallised	(Voulhoux	et	al.,	2003).	This	initial	prediction	misidentified	the	position	where	the	POTRA	domains	end	and	the	β-barrel	begins	in	BamA.	Crystal	structure	evidence	of	BamA	now	shows	us	that	the	first	four	antiparallel	β-sheets	are	much	shorter	than	the	others	and	only	span	~60%	of	the	membrane	(Noinaj	et	al.,	2013).	This	discrepancy	in	expected	length,	which	is	not	present	in	FhaC,	combined	with	the	difficulty	in	predicting	β-barrel	 structures	 (Bigelow	et	al.,	 2004)	probably	 led	 to	 the	 initial	mistake.	The	literature	 was	 corrected	 after	 the	 notation	 used	 in	 this	 study	 was	 employed	(Volokhina	et	al.,	2013)	and	subsequently,	the	notation	for	loop	numbers	in	this	study	were	“mis-numbered”	i.e.	“loop	II”	in	this	study	is	actually	referring	to	loop	4,	 “Loop	IV”	refers	 to	 loop	6,	and	“loop	V”	refers	 to	 loop	7.	References	 to	 these	loops	 in	 this	 thesis	match	 those	 in	 the	 current	 literature	with	 the	 exception	of	primer	names,	which	have	not	been	updated	to	the	new	notation.		Earlier	crystal	and	solution	NMR	structures	were	only	acquired	for	combinations	of	 the	 five	 soluble	 POTRA	 domains	 of	 BamA	 (Gatzeva-Topalova	 et	 al.,	 2008;	2010;	Kim	et	al.,	2007;	Knowles	et	al.,	2008;	Zhang	et	al.,	2011).	As	these	are	all	periplasmic	 domains,	 they	 can	 not	 offer	 insight	 into	 potential	 recognition	sites/surfaces	 for	the	phage	tail	spike	protein	to	recognise	the	surface	of	 the	E.	
coli	 cell.	 A	 series	 of	 crystal	 structures	 have	 been	 obtained	 in	 recent	 years,	
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including	some	of	the	whole	BamA	protein	(Albrecht	et	al.,	2014;	Ni	et	al.,	2014;	Noinaj	et	al.,	2013),	BamA	binding	to	the	BAM	complex	lipoproteins	(Bakelar	et	
al.,	2016;	Bergal	et	al.,	2016;	Chen	et	al.,	2016;	Jansen	et	al.,	2015),	and	even	the	entire	BAM	complex	(Gu	et	al.,	2016;	Han	et	al.,	2016;	Iadanza	et	al.,	2016).			The	 first	 BamA	 barrels	 to	 be	 crystallised	 were	 orthologues	 from	 Neisseria	
gonorrhoeae	 (Fig.	 1.7.3.1)	 and	 Haemophilus	 ducreyi.	 These	 were	 reported	together	 by	 Noinaj	 et	 al.	 (2013)	 where	 the	 presumptive	 open	 and	 closed	conformations	 of	 the	 BamA	 pore	 were	 revealed.	 The	 L6	 loop	 is	 the	 major	difference	between	the	open	and	closed	conformations	on	the	extracellular	side	being	very	accessible	 in	 the	open	conformation	but	 is	 found	within	 the	pore	 in	the	 closed	 state.	 The	 L6	 loop	 provides	 a	 key	 role	 in	 supporting	 the	 protein	folding	and/or	membrane	insertion	function	of	BamA	(Leonard-Rivera	&	Misra,	2012).		
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Figure	1.7.3.1:	Schematic	and	crystal	structure	representations	of	BamA.	(Left)	The	schematic	version	of	BamA	shows	overall	structure	of	the	16-sheet	β-	barrel	 transmembrane	 domain	 with	 POTRA	 domains	 extending	 into	 the	periplasm.	POTRA	domains	are	numbered	1-5	on	both.	 (Right)	3D	 structure	of	BamA	 orthologue	 encoded	 by	 N.	 gonorrheae	 (PDB	 entry:	 4K3B	 (Noinaj	 et	 al.,	2013))	 shows	 the	 secondary	 and	 tertiary	 structures	 present	 in	 BamA.	 Some	secondary	structures	can	be	seen	in	the	extracellular	loops	between	the	linking	the	sheets	in	the	β-	barrel.			
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Although	new	data	is	pointing	to	a	model	whereby	the	BAM	complex	undergoes	a	series	 of	 “spring-loaded”	 conformational	 changes	 when	 binding	 to	 incoming	OMPs,	 the	 exact	 mechanism	 by	 which	 OMPs	 are	 manipulated	 by	 BamA	 is	currently	 unknown,	 and	 the	 control	 mechanism	 between	 the	 open	 and	 closed	states	 of	 the	 protein	 is	 also	 unclear.	 Mechanisms	 have	 been	 predicted	 by	modelling	 structural	 data	 to	 produce	 sensible	 theories	 such	 as	 the	 one	 put	forward	by	Heuck	et	al.	 (Heuck	et	al.,	2011),	which	suggests	that	nascent	OMPs	interact	 with	 the	 lipoproteins	 of	 the	 BAM	 complex,	 BamB-E.	 However,	 these	ideas	can	be	comprehensively	refuted	with	additional	biochemical	data	showing	that	 nascent	 OMPs	 interact	 directly	 with	 the	 POTRA	 domains	 in	 BamA	 while	being	 guided	 by	 the	 lipoproteins	 (Jansen	 et	 al.,	 2012).	 Computer	 models	 of	potential	mechanisms	have	also	been	put	forward	(Noinaj	et	al.,	2013).	With	only	a	small	amount	of	evidence	regarding	the	flexibility	and	range	of	conformational	changes	of	 the	β-barrel	 (Doerner	&	Sousa,	2017),	 a	 comprehensive	mechanism	for	BamA	still	remains	elusive.			It	has	been	suggested	that	the	overall	mechanism	is	cyclical	in	that	β-sheets	that	make	up	the	nascent	OMPs	are	pulled	through	the	BamA	pore	and	inserted	into	the	membrane	two	at	a	time	(Rigel	et	al.,	2013),	but	specific	details	have	not	yet	been	 confirmed.	 These	 data	 models	 open	 up	 the	 possibility	 that	 Stx	 phage	binding	is	probably	conformation-dependant;	however,	it	cannot	be	determined	which	 conformation	 it	 is	 dependant	 on	without	 acquiring	 further	 structural	 or	biochemical	data	regarding	the	 interaction	between	the	BamA	β-barrel	and	the	phage.		
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Crystal	 structures	 show	 evidence	 that	 the	membrane	would	 be	 thinner	 at	 the	lateral	gate	compared	to	the	rest	of	the	bilayer	(Noinaj	et	al.,	2013)	introducing	a	tension	 into	 this	 microenvironment	 (Arrow	 in	 Fig.	 1.7.3.1).	 As	 the	 protein	insertion	 process	 does	 not	 require	 energy	 (Hagan	 &	 Kahne,	 2011)	 and	membrane	proteins	have	a	high	thermodynamic	stability,	the	tension	introduced	to	the	membrane	may	act	as	 the	 initial	 “spring”,	providing	 free	energy	to	allow	the	OMP	to	overcome	the	kinetic	barrier	that	phosphoethanolamine	head	groups	impose	 on	 transmembrane	 moieties	 in	 lipid	 bilayers	 (Gessmann	 et	 al.,	 2014).	This	forced	reduction	of	the	width	of	the	membrane	to	a	defined	level	increases	disruption	proportionally	with	membrane	thickness	(Schiffrin	et	al.,	2017).		
1.8	The	Role	of	BamA	within	the	BAM	complex		It	has	been	demonstrated	that	OMP	“rafts”	are	generated	at	mid-cell	during	outer	membrane	biogenesis	 (Kleanthous	et	al.,	 2015)	 –	 probably	 centred	 around	 the	BamA	protein	(Rassam	et	al.,	2015).	In	vitro	experiments	have	shown	that	BamA	is	able	to	insert	OMPs	into	the	outer	membrane	alone	but	takes	around	2	hours	to	accomplish	what	the	BAM	complex	can	do	in	5	minutes	in	vitro	(Hagan	et	al.,	2013).	 In	 E.	 coli,	 the	 BAM	 complex	 includes	 four	 lipoproteins,	 BamB-E	(previously	 identified	 as	 YfgL,	 NlpB,	 YfiO	 and	 SmpA,	 respectively	 (Sklar	 et	 al.,	2007;	Wu	 et	 al.,	 2005)),	 which	 are	 post-translationally	 palmitoylated	 to	 allow	association	 with	 the	 inner	 leaflet	 of	 the	 outer	 membrane	 (Fig.	 1.8.1).	 BamA	orthologues	have	been	found	in	the	sequenced	genomes	of	all	families	of	Gram-negative	bacteria	so	far,	supporting	evidence	not	only	for	the	essentiality	of	the	complex	but	also	its	crucial	role	in	the	proteination	of	the	LPS	membrane.		
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Figure	1.8.1:	A	schematic	representation	the	BAM	complex.		The	production	of	this	figure	relied	on	consolidating	information	from	all	sources	regarding	BAM	complex	interactions	with	a	few	key	contributors	(Kleanthous	et	
al.,	 2015;	 Noinaj	 et	 al.,	 2011;	 Rassam	 et	 al.,	 2015).	 The	 BAM	 complex	 can	 be	divided	 into	 2	 sub-complexes	 BamAB	 and	 BamACDE.	 BamACDE	 are	 the	facilitators	 of	 OMP	 insertion	 while	 the	 role	 of	 BamAB	 is	 not	 required	 for	 this	process.	BamC	and	BamE	bind	to	BamA	via	BamD,	perhaps	demonstrating	why	BamD	is	essential.	The	supporting	role	of	BamB	is	yet	to	be	determined.	Protein	sizes	 are	 approximately	 to	 scale	 (by	 mass)	 with	 respect	 to	 the	 width	 of	 the	membrane.			
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The	BamA-E	proteins	have	a	stoichiometry	of	1:1:1:1:1	within	the	BAM	complex,	but	there	has	been	speculation	that	the	complex	may	oligomerise	to	a	dimer	or	a	tetramer	 in	vivo	 (Robert	 et	al.,	 2006).	 The	BAM	 complex	 has	 been	 successfully	reconstituted	 in	vitro	 to	show	that	the	OMP	insertion	function	does	not	require	energy	and	that	the	OMP	is	presented	to	the	BAM	complex	by	a	chaperone,	SurA	(Hagan	&	Kahne,	2011).	It	is	unknown	how	many	copies	of	BamA	are	required	by	a	single	phage	to	facilitate	an	adsorption	event.	As	the	structure	of	the	ϕ24B	tail	protein	 has	 been	 predicted	 to	 be	 a	 homotrimer	 (Prof.	 Olga	 Mayans,	 personal	communication),	 it	 is	 logical	 to	 assume	 the	 structure	 of	 the	 tail	 exhibits	 3-fold	rotational	symmetry,	however,	there	is	no	obvious	symmetry	in	the	extracellular	domain	 of	 a	 single	 molecule	 of	 BamA.	 When	 also	 considering	 that	 ϕ24B	 is	 a	lambdoid	phage	and	 that	 the	receptor	 for	λ	phage,	LamB,	 is	also	a	homotrimer	(Vos-Scheperkeuter	&	Witholt,	 1984),	 it	 is	 plausible	 that	 three	 copies	 of	BamA	are	required,	in	close	proximity	to	each	other,	to	allow	adsorption.	The	diameter	of	 the	 BamA	 cylinder	 is	 the	 same	 as	 the	 dimensions	 of	 the	 tail	 (~10nm).	 But	there	are	no	data	of	models	suggesting	a	docking	mechanism.		
1.8.1	Lipoproteins	of	the	BAM	complex			BamB	binds	to	BamA	POTRA	domain	number	3	(Heuck	et	al.,	2011;	Jansen	et	al.,	2015).	BamB	has	been	implicated	in	binding	POTRA	domains	to	guide	the	folding	of	nascent	OMPs	by	the	BAM	complex	and	chaperones	(Jansen	et	al.,	2012;	Noinaj	
et	al.,	 2011).	While	not	essential	 to	 the	protein	 folding	process,	 it	 is	 critical	 for	anti-phagocytosis	of	Klebsiella	pneumoniae	 (Hsieh	et	al.,	2016).	Similar,	but	 less	pronounced	immune-evasion	effects	are	seen	in	Yersinia	enterolitica	(Weirich	et	
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al.,	2017)	and	Pseudomonas	aeruginosa	 (Lee	et	al.,	2017)	 leading	to	speculation	that	BamB	could	become	an	antibiotic	target	in	the	future;	however,	as	BamB	is	not	 surface	 exposed,	 it	would	 require	 a	 treatment	 delivery	 system	 that	 allows	passage	through	the	outer	membrane	(or	the	pore	of	BamA).		Not	 much	 is	 known	 about	 BamC.	 This	 lipoprotein	 spans	 the	 outer	 membrane	with	the	N-terminal	domain	binding	to	BamD	on	the	periplasmic	side	and	the	C-terminal	 domain	 being	 surface	 exposed.	 This	 exposure	 has	 been	 shown	experimentally	 as	 antibodies	 have	 been	 used	 to	 visualise	 BamC	 localisation	 in	live	cells	(Rassam	et	al.,	2015;	Webb	et	al.,	2012).		BamD	 has	 been	 shown	 to	 be	 the	 only	 lipoprotein	 of	 the	 BAM	 complex	 that	 is	essential	 (Kim	 et	 al.,	 2007;	Malinverni	 et	 al.,	 2006).	 BamD	 has	 been	 shown	 to	interact	with	BamA	in	such	a	way	that	an	OMP	binding-induced	conformational	change	 in	BamD	 leads	 to	 a	 further	 conformational	 change	 in	BamA	 to	 insert	 a	new	β-barrelled	protein	into	the	outer	membrane	(Lee	et	al.,	2018).		The	primary	function	of	BamE	appears	to	be	in	detecting	stress	within	the	outer	membrane	 (Konovalova	 et	 al.,	 2016).	 This	 is	 achieved	 by	 threading	 RcsF	(regulator	of	capsule	synthesis)	through	the	pore	of	β-barrelled	proteins	to	allow	“sensing”	of	the	LPS	through	the	detection	of	cationic	antimicrobial	peptides,	or	via	 the	 loss	 of	 negatively	 charged	phosphates	 from	 the	 LPS	 (Konovalova	et	al.,	2014).	This	 threading	 is	performed	whilst	 the	OMP	is	being	 folded	by	the	BAM	complex.	BamE	knockouts	produce	OMP	assembly	phenotypes	that	do	not	vary	
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much	from	WT	cells	despite	a	secondary	role	in	modulating	BamA	activity	(Rigel	
et	al.,	2012;	2013;	Sklar	et	al.,	2007).			While	 the	 BAM	 complex	 can	 still	 function	with	 the	 loss	 of	 BamB	 and	 BamE,	 a	double	knockout	was	found	to	be	lethal	(Sklar	et	al.,	2007).	Interestingly,	single	residue	 mutations	 in	 the	 beta-barrel	 domain	 of	 BamA	 are	 able	 to	 rescue	 this	phenotype	 meaning	 that	 substitution	 mutations	 in	 the	 β-barrel	 are	 able	 to	compensate	for	non-	or	mis-functioning	subunits	and/or	POTRA	domains	(Tellez	&	 Misra,	 2012).	 Furthermore,	 mutations	 in	 residues	 effecting	 electrostatic	interactions	between	BamA	and	BamD	disrupt	the	ability	of	the	BAM	complex	to	begin	the	process	of	folding	nascent	OMPs	into	the	outer	membrane	(McCabe	et	
al.,	 2017).	 The	 impact	 of	 any	 mutations	 on	 the	 resultant	 folding	 and	conformation	 of	 BamA,	 and	 therefore	 tail	 spike	 recognition,	 has	 not	 been	explored.	It	is	reasonable	to	hypothesise	that	these	kind	of	mutations	could	have	allowed	the	MC1061-MRL	strains	to	survive	despite	a	lack	of	phage	adsorption.	The	compromised	BAM	complex	may	also	explain	their	inability	to	survive	long	term	at	-80°C.			Functionally	 significant	mutations	 in	 BamA	 have	 been	 predicted	 (Dwyer	 et	al.,	2013).	But,	like	all	research	into	BamA	function,	this	analysis	neglects	the	phage	receptor	 role	 in	 favour	 of	 interactions	 between	 component	 parts	 of	 the	 BAM	complex	 and	 other	 intracellular	 proteins.	 The	 extracellular	 loops	 that	 are	implicated	 in	 supporting	 phage	 adsorption	 have	 only	 been	 mentioned	 in	reference	to	rescuing	a	BamD	mutant	(Lee	et	al.,	2018).		
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1.9	Aims	of	This	Study		There	are	no	other	phages	have	been	identified	to	exploit	an	essential	protein	as	a	recognition	target	on	their	hosts	as	this	is	a	good	way	to	guarantee	a	supply	of	hosts.	How	many	other	essential	proteins	are	actually	localised	to	the	cell	surface	and	allow	phage	binding	is	unknown.	The	presence	of	this	tail	spike	gene	in	70%	of	Stx	phage	genomes	 (Smith	et	al.,	 2007),	 and	 the	 continued	observation	of	E.	
coli	outbreaks	around	the	world	suggests	that	Stx	phages	remain	an	immediate	risk	 to	human	health	because	of	 the	potential	 host	 range	 shift	 and	 consequent	emergence	 of	 new	pathogens.	Outbreaks	 are	usually	 caused	by	 a	 failure	 of	 the	food	 supply	 chain	 to	 ensure	 food	 is	 safe	 and	 robust	 control	 methods	 exist	 to	monitor	this	supply	worldwide,	however,	as	new	Stx-phage	hosts	are	unable	to	be	predicted,	it	is	more	likely	a	case	of	where	and	when,	rather	than	if,	the	next	outbreak	occurs.			As	Stx	phages	are	the	driving	force	behind	the	dissemination	of	stx	into	new	host	cells	 (Allison,	2007),	 the	 interaction	between	host	and	the	phage	tail	should	be	characterised	 further	 with	 an	 ultimate	 view	 to	 understanding	 the	 molecular	mechanisms	involved.	This	could	potentially	determine	if	ϕ24B	has	the	ability	to	efficiently	 broaden	 its	 host	 range	 for	 a	 wider	 and	 more	 rapid	 dispersal	 of	converting	 phages	 in	 the	 environment,	 and	 may	 also	 inform	 of	 the	 potential	species	or	strains	that	are	likely	to	facilitate	future	STEC	outbreaks.	If	the	tail	of	ϕ24B	 were	 to	 spread	 beyond	 the	 Stx	 phages,	 more	 species	 could	 present	 a	greater	threat	to	human	health	than	they	currently	do.	
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In	order	to	achieve	this,	the	primary	goals	of	the	thesis	were	to:	
• Complete	the	generation	and	validation	of	an	incomplete	library	of	BamA	mutants	(McEwen,	2013).	
• Use	this	library	to	produce	E.	coli	clones	that	present	different	mutations	to	 the	extracellular	surface	and	determine	which	mutants	are	 incapable	of	supporting	phage	adsorption.	
• Produce	a	chimaeric	BamA	mutant	that	would	eliminate	ϕ24B	adsorption	to	E.	coli	MC1061	without	impairing	the	viability	of	the	cell.	
• Develop	 a	 phage	 adsorption	 assay	 that	 is	 less	 prone	 to	 variability	 than	standard	 adsorption	 assays,	 which	 can	 generate	 noisy	 data	 from	 a	significant	amount	of	sample	handling.			
 (McEwen,	2013) 		
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CHAPTER	2.	Materials	and	Methods	
	
2.1	Strains,	Bacteriophages	and	Plasmids		The	 bacterial	 strains,	 bacteriophages	 (Table	 2.1.1)	 and	 plasmids	 (Table	 2.1.2)	used	in	this	study	are	listed	and	described	with	relevant	genotypes.		
	Table	2.1.1:	The	bacterial	and	bacteriophage	strains	used	in	this	study.		
Bacterial	and	
bacteriophage	
strains	
	
Description	(incl.	relevant	genotype	info)	 Source	
E.	coli	strains	MC1061	 str.	 K-12	 F–	 λ–	 Δ(ara-leu)7697	 [araD139]B/r	 Δ(codB-lacI)3	
galK16	galE15	 e14–	mcrA0	 relA1	 rpsL150(StrR)	 spoT1	mcrB1	
hsdR2(r–m+)	 (Casadaban	&	Cohen,	1980)	MC1061	ϕ24B::Kan	 MC1061	containing	an	integrated	ϕ24B::Kan	prophage	 (James	et	al.,	2001)	MC1061	Bam0	 Abbreviated	to	Bam0.	MC1061	with	a	chimaeric	BamA	and	a	KanR	cassette	added	between	bamA	and	skp.	 This	Study	DM1187-Rif	 His4	 leuB	 ,proA/B	 thr1	ara-14	galK		 xyl-5	 str31	 ilv+s	 recA441	
sfiA	 lexA51.	 Bacteriophage	 host	 that	 can	 only	 enter	 lytic	 life	cycle.	RifR	 (James	et	al.,	2001)	JM109	λ	pir	 endA1	 glnV44	 thi-1	 relA1	 gyrA96	 recA1	 mcrB+	 Δ(lac-proAB)	
e14-	[F'	traD36	proAB+	lacIq	lacZΔM15]	hsdR17(rK-mK+)	and	the	Lambda	 phage	 pir	 gene	 that	 allows	 propagation	 of	 Lambda	pir–dependent	plasmid	replicons	like	R6K	in	pKNG101	
(James	et	al.,	2001)	
Top10		 F-	mcrA	Δ(mrr-hsdRMS-mcrBC)	ϕ80lacZΔM15	ΔlacX74	nupG	recA1	 araD139	 Δ(ara-leu)7697	 galE15	 galK16	 rpsL(StrR)	endA1	λ-	-	Transformation	host	 Invitrogen™			
Pectobacterium	strain	
Pectobacterium	
atrosepticum	
The	Sanger	Institute	sequenced	the	genome	of	this	strain.	 ATCC	BAA-672	
Bacteriophages	ϕ24B::Kan	 Mutant	ϕE86654-VT2	phage.	The	 toxin-encoding	Stx	 operon	replaced	with	KanR	cassette.	 (James	et	al.,	2001)	
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Table	2.1.2:	The	plasmids	used	or	created	during	this	study.	
Plasmids	pCR™-Blunt			 pCR-series	cloning	vector	(4600	bp)	with	lac	promoter,	T7,	 M13R	 and	 M13F	 primer	 sites;	 kanamycin	 and	zeocin	 resistance;	 cloning	 for	 blunt-ended	 PCR	products	 containing	 a	 lacZ-alpha	 ccdB	 death	 cassette	(interrupted	by	insert).	
Invitrogen,	UK				
pUC19	 2,686	bp	expression	vector	possessing	a	 lac	promoter.		AmpR,	 high	 copy	 number	 vector	 with	 MCS	 flanked	 by	M13-F20	and	M13R	primer	binding	sites.			 (Yanisch-Perron	et	al.,	1985)	pKNG101	 Marker	 exchange	 suicide	 vector,	 sacBR,	 mobRK2,	oriR6K,	SmR	 (Kaniga	et	al.,	1991)	pKD46	 Red	 recombinase	 expression	 plasmid.	 Contains	 2,154	nt	 (31088–33241)	 of	 phage	 λ	 (GenBank	 accession	no.	J02459).	 (Datsenko	&	Wanner,	2000)	pUC4K	 Used	as	a	PCR	template	for	KanR	 (Roeder	&	Collmer,	1985)	pUC19-GFP-MUT2	 A	mutant	of	GFP	(eGFP)	engineered	 to	use	common	E.	coli	codons	cloned	into	pUC19.		 (Cormack	et	al.,	1996)	pUC19-ϕR1D	 pUC19	 containing	 an	 insert	 of	MC1061	 containing	 the	coding	region	of	BamA.	AmpR	 (Sergeant,	1998)	pBAD/myc-His	C	 Expression	 vector	 under	 araC	 promoter.	 Encodes	 a	myc/His-tag	on	the	CTD	of	the	insert.	AmpR.	 (Guzman	et	al.,	1995)	pCE1a	 KanR.	pCR-Blunt	plasmid	with	the	C-terminal	domain	of	
P.	atrosepticum	bamA	insert	containing	the	following	E.	
coli	epitopes	substituted	into	the	β-barrel	domain:	4a‡	 (McEwen,	2013)	pCE1b	-	fixed	 As	pCE1a	except	with	epitope:	4b	 This	study	pCE1c	 As	pCE1a	except	with	epitope:	6	 (McEwen,	2013)	pCE1d	 As	pCE1a	except	with	epitope:	7a	 (McEwen,	2013)	pCE1e	 As	pCE1a	except	with	epitope:	7b	 (McEwen,	2013)	pCE2a	-	fixed	 As	pCE1a	except	with	epitopes:	4a	4b	 This	study	pCE2b	 As	pCE1a	except	with	epitopes:	4a	6	 (McEwen,	2013)	pCE2c	 As	pCE1a	except	with	epitopes:	4a	7a	 (McEwen,	2013)	pCE2d	 As	pCE1a	except	with	epitopes:	4a	7b	 (McEwen,	2013)	pCE2e	-	fixed	 As	pCE1a	except	with	epitopes:	4b	6	 This	study	pCE2f	-	fixed	 As	pCE1a	except	with	epitopes:	4b	7a	 This	study	pCE2g	-	fixed	 As	pCE1a	except	with	epitopes:	4b	7b	 This	study	pCE2h	 As	pCE1a	except	with	epitopes:	6	7a	 (McEwen,	2013)	pCE2i	 As	pCE1a	except	with	epitopes:	6	7b	 (McEwen,	2013)	pCE2k	 As	pCE1a	except	with	epitopes:	7a	7b	 (McEwen,	2013)	pCE3a	-	fixed	 As	pCE1a	except	with	epitopes:	4a	4b	6	 This	study	pCE3b	-	fixed	 As	pCE1a	except	with	epitopes:	4a	4b	7a	 This	study	pCE3c	-	fixed	 As	pCE1a	except	with	epitopes:	4a	4b	7b	 This	study	pCE3d	 As	pCE1a	except	with	epitopes:	4a	6	7a	 (McEwen,	2013)	pCE3e	 As	pCE1a	except	with	epitopes:	4a	6	7b	 (McEwen,	2013)	pCE3f	 As	pCE1a	except	with	epitopes:	4a	7a	7b	 (McEwen,	2013)	pCE3g	-	fixed	 As	pCE1a	except	with	epitopes:	4b	6	7a	 This	study	pCE3h	-	fixed	 As	pCE1a	except	with	epitopes:	4b	6	7b	 This	study	
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‡	See	figure	3.1.1.1	for	details	of	these	epitopes.	
	
2.2	Growth	Media,	Supplements	and	Buffers			Composition	and	sources	of	media	and	supplements	used	in	this	study	are	listed	in	table	2.2.1.	Lysogeny	Broth	(LB)	and	LB	agar	(LBA)	were	prepared	according	to	 manufacturer’s	 (Merck)	 instructions.	 Phage	 growth	medium	 (PGM)	 was	 LB	containing	 10	mM	CaCl2,	which	 is	 a	 required	 cofactor	 in	 the	 phage	 adsorption	process.	Terrific	Broth,	TB,	was	used	when	higher-density	cultures	of	E.	coli	were	required	 for	 low-yield	 or	 large-scale	 plasmid	 purifications.	 Tryptone	 soy	 (TS)	broth	 and	 TS	 agar	 plates	 were	 used	 to	 grow	 Pectobacterium	 atrosepticum.	Antibiotics	(Table	2.2.1)	were	added	to	media	as	required.	
pCE3i	-	fixed	 As	pCE1a	except	with	epitopes:	4b	7a	7b	 This	study	pCE3k	 As	pCE1a	except	with	epitopes:	6	7a	7b	 (McEwen,	2013)	pCE4a	-	fixed	 As	pCE1a	except	with	epitopes:	4a	4b	6	7a	 This	study	pCE4b	-	fixed	 As	pCE1a	except	with	epitopes:	4a	4b	6	7b	 This	study	pCE4c	-	fixed	 As	pCE1a	except	with	epitopes:	4a	4b	7a	7b	 This	study	pCE4d	 As	pCE1a	except	with	epitopes:	4a	6	7a	7b	 (McEwen,	2013)	pCE4e	-	fixed	 As	pCE1a	except	with	epitopes:	4b	6	7a	7b	 This	study	pCE5	-	fixed	 As	pCE1a	except	with	epitopes:	4a	4b	6	7a	7b	 This	study	pUC19	-	KS	 pUC19	 containing	 a	 concatenation	 of	 KanR	 and	 skp	sublconed	from	a	ligation	into	pCR™-Blunt	 This	study	pUC19	-	EEKS	 pUC19	containing	the	EcEcaKanSkp	fusion	product	 This	study	pUE1a	 pUC19-EEKS	 with	 the	 insert	 from	 the	 pCE	 equivalent	subcloned	into	Eca	using	Xcm	I	and	Sty	I	 This	study	pUE1b	 As	pUE1a	except	with	epitope:	4b	 This	study	pUE1c	 As	pUE1a	except	with	epitope:	6	 This	study	pUE1d	 As	pUE1a	except	with	epitope:	7a	 This	study	pUE1e	 As	pUE1a	except	with	epitope:	7b	 This	study	pUE4a	 As	pUE1a	except	with	epitopes:	4a	4b	6	7a	 This	study	pUE4b	 As	pUE1a	except	with	epitopes:	4a	4b	6	7b	 This	study	pUE4c	 As	pUE1a	except	with	epitopes:	4a	4b	7a	7b	 This	study	pUE4d	 As	pUE1a	except	with	epitopes:	4a	6	7a	7b	 This	study	pUE4e	 As	pUE1a	except	with	epitopes:	4b	6	7a	7b	 This	study	pUE5	 As	pUE1a	except	with	epitopes:	4a	4b	6	7a	7b	 This	study	pUF5	 pUC19	containing	 the	 full	 length	chimaeric	bamA	 gene	with	all	5	E.	coli	extracellular	epitopes	substituted	into	the	β-barrel	domain.	AmpR	 This	study	
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Table	2.2.1:	Media	and	supplements	used	in	this	study	
	 Composition	(final	concentrations)	
Media	Lysogeny	broth	(LB)	 2.5%	LB	broth	(Merck,	Hertfordshire,	UK)	LB	agar	 LB	+	12	g	L-1	agar-agar	(VWR,	UK)	Phage	 Growth	 Medium	(PGM)	 LB	+	10	mM	CaCl2	(BDH	Lab	supplies,	UK)	Salt-free	LB	 10	g	L-1	Tryptone	(Lab	M,	UK);	5	g	L-1,	Yeast	extract	(Merck,	UK)	(NaOH	to	pH	7.0)	Salt	free	LBA	 Salt	free	LB	+	12	g	L-1	agar-agar	(VWR,	UK)	Bottom	agar	 PGM	+	15	g	L-1	Difco,	Agar	granulated	(Difco,	UK)	Top	agar	 PGM	+	4	g	L-1	Difco,	Agar	granulated		(Difco,	UK)	Tryptone	Soy	Broth	(TSB)	 30	g	L-1	Tryptone	Soy	Broth	(Lab	M,	UK)	Tryptone	Soy	Agar	(TSA)	 TSB	+	12	g	L-1	agar-agar	(VWR,	UK)	Terrific	Broth	 12	g	L-1	tryptone,	24g	L-1	yeast	extract,	4	mL	glycerol,	10%	(v/v)	phosphate	buffer	(0.17	M	KH2PO4,	0.72	M	K2HPO4)	SOC	medium	 28	g	L-1		SOB	broth	(Melford,	UK);	20	mM	glucose	(VWR,	UK)	
Media	Supplements	 Working	Concentrations	Ampicillin	 100	µg	mL-1	ampicillin	sodium	salt	(Melford,	UK)	Chloramphenicol	 12.5	µg	mL-1	chlorampenicol	(Sigma,	UK)		Kanamycin	 50	µg	mL-1	kanamycin	monosulfate	(Melford,	UK)	Norfloxacin	 1	µg	mL-1	norfloxacin	(Melford,	UK)	Rifampicin	 300	µg		mL-1		rifampicin	(Melford,	UK)	Spectinomycin	 50	µg	mL-1	spectinomycin	dihydrochloride	pentahydrate	(Sigma,	UK)	Streptomycin	 100	µg	mL-1	streptomycin	sulfate	(Melford,	UK)	Tetracycline	 20	µg	mL-1	tetracycline	(Sigma,	UK)	Sucrose	 5%	(w/v)	sucrose	(Melford,	UK)	CaCl2	 10	mM	CaCl2	(BDH	Lab	supplies,	UK)	ITPG	 100	mM	IPTG	(Melford,	UK)	X-Gal	 40	µg	mL-1	X-gal	(Melford,	UK)	Arabinose	 0.0002%	(w/v)	–	0.2%	(w/v)	L-arabinose	(Sigma,	UK)	
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Table	2.2.2:	Buffers	used	in	this	study	
	 Composition	(final	concentration)	
General	Buffers	TE	 25	mM	Tris-HCl	(pH	7.5);	10	mM	EDTA	TAE	 25	mM	Tris	(to	pH	7.5	with	acetic	acid);	10	mM	EDTA,	TBT	 100	mM	Tris-HCl	(pH	7.5);	100	mM	NaCl;	10	mM	MgSO4	SM	 50	mM	Tris-HCl	(pH	7.5);	100	mM	NaCl;	8	mM	MgSO4	SC	 50	mM	Tris-HCl	(pH	7.5);	100	mM	NaCl;	10	mM	CaCl2	TfBI	 30	mM	KOAc;	50	mM	MnCl2;	100	mM	KCl;	10	mM	CaCl2;	15%	(v/v)	glycerol	TfBII	 10	mM	MOPS	(pH	7.0);	75	mM	CaCl2;	10	mM	KCl,	15%	(v/v)	glycerol	Restriction	 enzyme	dilution	buffer	 10	mM	Tris-HCl	(pH	7.5);	100	mM	KCl;	1	mM	EDTA;	1	mM	DTT;	50%	(v/v)	glycerol;	0.2	mg	mL-1	BSA		
Plasmid	extraction	buffers	P1	 50	mM	Tris.HCl,	pH	8.0;	10	mM	EDTA;	100	µg	mL-1	RNAseA	P2	 200	mM	NaOH;	1%	(w/v)	SDS	N3	 4	M	guanidine	hydrochloride;	0.5	M	potassium	acetate,	(to	pH	4.2	with	acetate)	PE	 80%	(v/v)	ethanol;	10	mM	Tris-HCl	(pH	7.5)	QBT	 50	mM	MOPS	(pH	7.0);	750	mM	NaCl;	0.15%	(v/v)	Triton	X-100;	15%	(v/v)	isopropanol	
Southern	Blot	buffers	20x	SSC	 3	M	NaCl;	0.3	M	sodium	citrate	(pH	7.0)	Depurination	buffer	 0.25	M	HCl	Denaturation	buffer	 0.5	M	NaOH,	1.5	NaCl	Neutralisation	buffer	 0.5	M	Tris-HCl	(pH	7.5),	3	M	NaCl	
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2.3	Procedures		
2.3.1	PCR		PCR	 amplifications	were	 typically	 done	 over	 30	 cycles	 with	 temperatures	 and	duration	 of	 melting	 and	 elongation	 steps	 and	 the	 duration	 of	 all	 steps	 and	reagent	 concentrations	 were	 calculated	 based	 on	 the	 data	 sheets	 for	 the	polymerase	 used:	 myTaq	 Red	 Mix	 (Bioline,	 UK),	 Phusion	 (Thermo	 Fischer	Scientific,	 UK),	 Q5	 (NEB,	 UK),	 or	 Vent	 (NEB,	 UK),	 as	 appropriate.	 Annealing	temperatures	 were	 based	 on	 the	 primers	 listed	 in	 Table	 2.3.1.	 Resultant	 DNA	products	were	analysed	on	1.2%	(w/v)	TAE	agarose	gels	containing	2	µL	Midori	green	(Nippon	Genetics,	Europe)	per	100	mL	agarose.		
Table	2.3.1:	DNA	primers	used	for	PCR	in	this	study.		Restriction	enzyme	recognition	sequences	are	underlined.	
Primer	 Sequence	(5’-	3’)	 Amplification	Template	 Calculated	Tm	(°C)	
Used	for	fusion	of	products	to	create	Bam0	by	homologous	recombination	EcEca	5’	X	site	fwd	 GGTTGATGTCGTCTACAAGG	 MC1061	gDNA	 59.8	EcEca	3’	X	site	rev	 CACGTCTGTACCATAACTCTTG	 MC1061	gDNA	 58.8	EcEca	fusion	fwd	 GTTATGGTACAGACGTGACCTTGGGCTTCCCG	 P.	atrosepticum	gDNA	 78.9	5’	fwd	loop	Eca	 CCAACGTGAGCTATGGCG	 P.	atrosepticum	gDNA/BamA	 65.5	3’	rev	loop	Eca	 CTACCAGGTTTTGCC	 P.	atrosepticum	gDNA/BamA	 51.4	5’	forkaneco	 AAGAATTCAGCCACGTTGTGTCT	 pUC4K	 65.8	3’	revkanskp	 GATCGCCTAAAGTCAAAGGTGTTCCTG	 pUC4K	 70.8	Skp	5’	for	 ATGACTTTAGGCGATC	 MC1061	gDNA	 49.9	3’	rev	SkpEcoRI	 AAGAATTCGTAAGTCAGGTAG	 MC1061	gDNA	 58.0	
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Primer	 Sequence	(5’-	3’)	 Amplification	Template	 Calculated	Tm	(°C)	
Used	to	introduce	E.	coli	sequences	to	P.	atrosepticum	BamA	5’	rev	loop	IIa	 CTGATCAGAGGTGCTCGGATGAACCCCGACAGAGATCC	 P.	atrosepticum	BamA	 84.8	3’	fwd	loop	IIa	 GAGCACCTCTGATCAGGATAACAGCTTCAAAGCGAACGA	 P.	atrosepticum	BamA	 81.5	3’rev	loop	IIb	 CGTGAAATCGTTCGCTTTG	 P.	atrosepticum	BamA	 64.3	5’	fwd	loop	IIb	 TTCAAAGCGAACGATTTCACGTTCAACTATGGATGGTCATAACAACC	 P.	atrosepticum	BamA	 82.5	5’	rev	loop	IV	 GTAATCATAGTCCGGATCGCCAACAAGGTTCGC	 P.	atrosepticum	BamA	 70.7	3’	fwd	loop	IV	 CCGGACTATGATTACGAATGTGCGACTCAGGATTCAACCAATATGG	 P.	atrosepticum	BamA	 83.1	5’	rev	loop	Va	 GCTGGAATCTTCCCAGTTGGTATCCC	 P.	atrosepticum	BamA	 72.4	3’	fwd	loop	Va	 TGGGAAGATTCCAGCCTGAAAGCAGGTGTACC	 P.	atrosepticum	BamA	 78.9	5’	rev	loop	Vb	 GATATTGCTTGGATCGCCGTAATCCGGTACACC	 P.	atrosepticum	BamA	 78.5	3’	fwd	loop	Vb	 GATCCAAGCAATATCCGCGTTTCCAGTGGTATCGC	GTTGC	 P.	atrosepticumBamA	 85.4	5’	fwd	IIb	fix	 GGATGGTCATACAACAACCTG	 P.	atrosepticum	BamA	 57.9	3’	rev	IIb	fix	 CAGGTTGTTGTATGACCATCC	 P.	atrosepticum	BamA	 57.9	
Used	to	sequence	inserts	cloned	into	plasmids	with	M13	primer	sites	M13	fwd	(-20)	 GTAAAACGACGGCCAG	 pCR™-Blunt/pUC19	 58.9	M13	rev	 CAGGAAACAGCTATGAC	 pCR™-Blunt/pUC19	 52.0	
Used	to	detect	the	suicide	vector,	pKNG101.	pKNG101_F	 GATGATACGCACTGAGAAGCC	 pKNG101	 63.8	pKNG101_R	 GACGATGCCAAAGCGCTACACC	 pKNG101	 68.8	
Used	to	clone	ϕ24B	tail	and	tail-associated	genes	FOR	TSP	 TGCGCAGCATTATCAGAG	 ϕ24B	phage/Lysogen	gDNA	 53.6	Rev	tsp	 CATTCTCATCTGACTCC	 ϕ24B	phage/Lysogen	gDNA	 50.4	For	hypotail	 GTCCGAAAGGAGATAAC	 ϕ24B	phage/Lysogen	gDNA	 50.4	Rev	hypotail	 GATTCTTTACTATCCAG	 ϕ24B	phage/Lysogen	gDNA	 45.5	For	Gene	39	 TTCTCGTTGCTACAGCG	 ϕ24B	phage/Lysogen	gDNA	 52.8	Rev	Gene	39	 GTCACAAATGCGTGAC	 ϕ24B	phage/Lysogen	gDNA	 49.2	For	Gene	40	 AAGTGTGGTGAGACTTC	 ϕ24B	phage/Lysogen	gDNA	 50.4	Rev	Gene	40	 GCTGTAAATCTGTCCAGG	 ϕ24B	phage/Lysogen	gDNA	 53.7	
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Used	to	construct	GFP	gene	fusions	NcoI	TSP	for	 GGACCATGGGTGTTGTTGTTTCGGGGAC	 ϕ24B	phage/Lysogen	gDNA	 69.5	SZB	GFP-for	 TGACCATGGGAGAAGAACTTTTCACT	 pUC19-GFP-MUT2	 61.6	SM	GFP-TSP	for	 TGCCGGCGCAGGAAGTGTTGTTGTTTCGG	 ϕ24B	phage/Lysogen	gDNA	 70.9	SM2	GFP-TSP	rev	 TTCCTGCGCCGGCACCAGCTTTGTACAATTCATC	 pUC19-GFP-MUT2	 71.9	SZB	SalI-TSP-	rev	 TCACAGTCGACATGCTTTCCGCAACC	 ϕ24B	phage/Lysogen	gDNA	 66.4	NotI-GFP-TSP	for	 GGTGCGGCCGCCGGCGCAGGAAGTGTTGTTGTTTCGG	 ϕ24B	phage/Lysogen	gDNA	 89.8	NotI-GFP-TSP	rev	 GCCGGCGGCCGCACCTTTGTACAATTCATCC	 pUC19-GFP-MUT2	 73.5	BamB	for	 ATGCAATTGCGTAAATTACTG	 MC1061	gDNA	 52.0	BamBp	for	 GGCTTCTTTGGAACTTGCGCAG	 MC1061	gDNA	 62.1	BamB-GFP	for	 TGCCGGCGCAGGAAGTCCCGGAGAAGAACTTTTCAC	 pUC19-GFP-MUT2	 71.7	BamB-GFP	rev	 TCCTGCGCCGGCACGTGTAATAGAGTACACG	 MC1061	gDNA	 72.1	NotI-GFP-TSP	for	 GGTGCGGCCGCCGGCGCAGGAAGTGTTGTTGTTTCGG	 ϕ24B	phage/Lysogen	gDNA	 89.8	NotI-GFP-TSP	rev	 GCCGGCGGCCGCACCTTTGTACAATTCATCC	 pUC19-GFP-MUT2	 73.5	SM	GFP-rev	 CAGTTATTTGTATAGTTCATCCATGC	 pUC19-GFP-MUT2	 58.5	
BamA	amplification/modification	PhiR1D_BamA_fwd	 GATCAAGGGCGGACCGGTATCC	 pUC19-ϕR1D	 65.8	5’	NcoI	BamA	Fwd	 CGTCCATGGCGATGAAAAAGTTGC	 MC1061/Bam0	gDNA	 62.7	5’	BamAp2	Fwd	 CGAAATAGCAGCCAATTCGATAGCTG	 MC1061/Bam0	gDNA	 63.2	SM_BamA_for	 ATGGCGATGAAAAAGTTGCTC	 MC1061/Bam0	gDNA	 55.9	SM_BamA_rev	 TTACCAGGTTTTACCGATG	 MC1061/Bam0	gDNA	 52.4	3’	SalI	BamA	Rev	 TACGTCGACCCAGGTTTTGCCAATG	 MC1061/Bam0	gDNA	 64.6	FLbam5	rev	 CTACCAGGTTTTGCCAATGTTAAACTGG	 MC1061/Bam0	gDNA	 63.7	NcoI	BamA	over	 GCTAACAGGAGGAATTAACCATGGCGATGAAAAAGTTG	 MC1061/Bam0	gDNA	 69.5	BamAp2	over	 GCTAACAGGAGGAATTAACGAAATAGCAGCCAATTCGATAGCTG	 MC1061/Bam0	gDNA	 72.2	SalI	BamA	over	 GGAGACCGTTTAAACTCAGTCGACCCAGGTTTTGCCAATG	 MC1061/Bam0	gDNA	 73.5		
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2.3.2	Restriction	enzyme	digests		DNA	(500-1000	ng)	was	added	to	appropriate	buffers	and	the	stated	number	of	enzyme	units	in	Table	2.3.2.1	were	added	for	the	respective	restriction	enzymes:			
Table	2.3.2.1:	Restriction	enzymes	used	in	this	study	
Enzyme	 Company	 Units	used	per	reaction	(U)	
EcoR	I	(FastDigest)	 Thermo	Fisher	Scientific,	UK	 0.5	µL	†	
EcoR	I	 Promega,	UK	 6	
EcoR	I	-	HF		 NEB,	UK	 10	
Kpn	I	(FastDigest)	 Thermo	Fisher	Scientific,	UK	 0.5	µL	†	
Nco	I	 Thermo	Fisher	Scientific,	UK	 5	
Pst	I	(FastDigest)	 Thermo	Fisher	Scientific,	UK	 0.5	µL	†	
Sal	I	 Thermo	Fisher	Scientific,	UK	 5	
Sty	I	-	HF	 NEB,	UK	 10	
Xcm	I	 NEB,	UK	 2.5	†	 FastDigest™	enzymes	are	not	assigned	units,	 so	volume	used	per	 reaction	 is	reported	instead.		A	final	volume	of	10	µL	was	used	for	restriction	enzyme	digestion	except	when	this	was	 increased	 to	20	µL	 to	 ensure	 the	 final	 glycerol	 content	was	no	higher	than	 5%	 (v/v).	 Samples	 were	 incubated	 at	 37°C	 for	 45	 min	 (15	 minutes	 for	FastDigest	 enzymes)	 and	 visualized	 on	 a	 1.2%	 (w/v)	 TAE	 agarose	 gel.	 Partial	digests	 used	 1	 µg	 DNA,	 10	 U	 of	 EcoR	 I	 (Promega,	 UK)	 and	 were	 left	 at	 room	temperature	for	1	min	before	running	on	a	1.2%	(w/v)	TAE	agarose	gel	without	heat	 inactivation.	The	desired	 fragment	was	 excised	using	 the	PCR	and	Gel	Kit	(Bioline,	UK)	following	manufacturer’s	instructions	but	eluting	DNA	in	dH2O.	
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2.3.3	Plasmid	Purification		Plasmid	purification	buffers	(Table	2.2.2)	based	on	the	plasmid	purification	kits	manufactured	 by	 QIAGEN	 (UK)	 and	 Bioline	 (UK)	 were	 prepared,	 and	 DNA	binding	columns	 from	Bioline	kits	were	reused	after	washing	 twice	with	dH2O,	once	 with	 QBT	 buffer	 followed	 by	 storage	 at	 4°C	 in	 1	 M	 HCl.	 Columns	 were	replaced	after	either	10	uses,	3	months	or	if	visible	disruption	to	the	membrane	was	 observed.	 Column	 reuse	 and	 homemade	 buffers	 were	 validated	 by	comparing	plasmid	yields	 to	 those	produced	using	brand	new	columns	and	kit	buffers	 where	 no	 difference	 was	 observed	 by	 either	 agarose	 gel	 analyses	 or	spectrophotometric	(Nanodrop	1000)	analysis.	DNA	was	eluted	in	dH2O.		Plasmids	described	as	“high-copy	number”	were	purified	using	the	Plasmid	Mini-Kit	(Bioline)	following	the	manufacturer’s	instructions,	but	using	buffers	detailed	in	 Table	 2.2.2	 (N3	 and	 PE	 buffers	 were	 used	 instead	 of	 P3	 and	 PWB1,	respectively)	and	DNA	was	eluted	in	30	µL	dH2O.			A	 higher	 volume	 protocol	 was	 adapted	 for	 purification	 of	 low	 copy-number	plasmids	(e.g	pKNG101):	Cells	from	an	overnight	culture	(grown	in	100	mL	TB)	were	 resuspended	 in	 P1	 buffer	 (4	 mL).	 P2	 buffer	 (4	 mL)	 was	 added	 and	incubated	 at	 room	 temperature	 (RT)	 for	 5	 minutes.	 N3	 buffer	 (5.5	 mL)	 was	added	to	precipitate	proteins	that	were	pelleted	with	genomic	DNA	at	20,000	g	for	 10	minutes	 (Eppendorf	 5810R,	 rotor	A-4-81).	 The	 supernatant	was	 passed	through	a	mini-kit	spin	column	(Bioline,	UK).	Samples	were	washed	twice	with	PE	buffer,	and	eluted	in	2	x	25	µL	dH2O	for	maximum	yield.	
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2.3.4	Plasmid	transformation		
2.3.4.1	Heat	shock	transformation	Mid-log	phase	cells	(OD600	≈	0.6)	were	made	competent	 following	their	harvest	by	 centrifugation	 at	 5000	g	 for	 5	minutes	 using	TfBI	 then	TfBII	 buffers	 (Table	2.2.2).		Briefly,	the	recovered	cells	were	resuspended	in	ice	cold	TfBI	for	1	hour	with	 regular	 agitation,	 recovered	 by	 centrifugation	 at	 5000	 g	 for	 5	 minutes,	resuspended	in	ice-cold	TfBII	for	a	further	30	minutes	and	then	divided	into	100	µL	 aliquots	 for	use.	 Plasmid	DNA	 (50	ng	 –	500	ng)	was	 added	 to	 an	 aliquot	of	competent	cells	and	kept	on	ice	for	10	minutes.	The	mixture	was	heat	shocked	at	42°C	for	45	seconds	and	returned	immediately	to	 ice.	Pre-warmed	LB	(700	µL)	was	 added,	 and	 cells	were	 allowed	 to	 recover	 at	 37°C	with	 shaking	 for	1	hour	before	spreading	80	µL	onto	selective	LBA	plates.		
2.3.4.2	Transformation	by	electroporation	Mid-log	phase	cells	 (500	mL	of	OD600	≈	0.6)	were	chilled	on	 ice	 for	20	minutes	before	being	centrifuged	at	4000	g	 for	15	minutes	at	4°C.	The	supernatant	was	removed	by	pipette	and	cells	were	 resuspended	 in	500	mL	 ice-cold	10%	(v/v)	glycerol.	Cells	were	centrifuged	at	4000	g	for	15	minutes	at	4°C	and	resuspended	a	further	3	times	in	decreasing	volumes	of	ice-cold	10%	(v/v)	glycerol	(250	mL	then	20	mL	then	2	mL).	The	 final	2	mL	of	concentrated	cells	 (~1-3	x	1010	cells	mL-1)	was	used	immediately	or	frozen	in	50	µL	aliquots	for	storage	at	-80°C.	DNA	(10	ng	–	100	ng)	was	mixed	with	a	50	µL	aliquot	of	competent	cells	on	ice	for	5	minutes	 before	 the	 mixture	 was	 transferred	 to	 an	 ice-cold	 0.2	 mL	electroporation	cuvette.	The	micropulser	(Biorad,	UK)	was	set	to	the	automatic	
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“Ec2”	mode	(for	E.	coli		cells	in	0.2	mL	cuvettes)	and	the	sample	was	pulsed.	1	mL	of	SOC	medium	was	 immediately	added	to	 the	electroporated	mixture	and	was	shaken	 at	 37°C	 for	 60	minutes	 to	 allow	 recovery	 before	 spreading	 500	 µL	 on		selective	LBA	plates.		
2.3.5	Cloning	PCR	products		
2.3.5.1	Cloning	PCR	products	were	cloned	into	either	the	pCR™-Blunt	vector	with	the	Zero	Blunt	PCR	Cloning	Kit	or	the	pCR™	2.1	TA	cloning®	kit	depending	on	the	ends	produced	by	 the	 polymerase	 used,	 following	 the	 manufacturer’s	 (both	 Invitrogen,	 UK)	instructions.			
2.3.5.2	Sub-cloning	Sub-cloning	was	 accomplished	 by	 ligation	 following	 restriction	 digests	 of	 both	the	insert	and	the	plasmid	vector.	Inserts	were	separated	from	cloning	plasmids	using	appropriate	restriction	enzymes.	The	insert	fragment	was	recovered	from	a	 0.6%	 (w/v)	 agarose	 gel	 using	 the	 Gel	 and	 PCR	 Kit	 (Bioline,	 UK);	 the	manufacturer’s	 instructions	were	followed	but	DNA	was	eluted	in	dH2O.	Target	plasmids	 were	 digested	 using	 identical	 restriction	 enzymes	 to	 generate	compatible	 cohesive	 ends.	 The	 plasmid	 backbone	 was	 recovered	 from	 a	 0.6%	(w/v)	agarose	gel	using	the	same	method	as	the	insert.	If	only	one	enzyme	was	used	 to	 cut	 the	 plasmid	 then	 it	was	 treated	with	 Antarctic	 phosphatase	 (NEB,	UK)	to	reduce	the	likelihood	of	vector	re-ligation.	The	purified	insert	was	ligated	into	the	prepared	vector	using	T4	DNA	ligase	(Fermentas	–	now	Thermo	Fisher	
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Scientific,	UK).	Ligated	vector	was	transformed	into	competent	Top10	E.	coli	and	spread	onto	LBA	containing	ampicillin	and	kanamycin.	Colonies	were	screened	for	inserts	using	appropriate	primers	(Table	2.3.1).		
	
2.3.6	Southern	Blot	Analyses		Genomic	 DNA	 (5	 µg),	 extracted	 from	 WT	 MC1061	 cells	 and	 putative	chromosomal	BamA	mutants	of	MC1061	using	a	Genomic	DNA	kit	(Bioline.	UK),	was	digested	with	Kpn	 I	 or	both	Kpn	 I	 and	EcoR	 I	 according	 to	manufacturer’s	(Thermo	Fischer	Scientific,	UK)	instructions	in	a	final	volume	of	20	µL.	Digestions	were	run	through	a	1%	(w/v)	TAE	agarose	gel	at	100	V	for	45	minutes	alongside	Hyperladder	 1kb	 (Bioline,	 UK).	 The	 gel	 was	 imaged	 under	 UV	 light	 next	 to	 a	fluorescent	 ruler	 to	 allow	 determination	 of	 the	 apparent	 molecular	 weight	 of	bands.	The	gel	was	subjected	to	depurination	for	30	minutes,	denaturation	for	2	x	20	minutes,	and	neutralised	for	2	x	20	minutes	–	buffer	compositions	for	these	steps	 are	 in	 table	 2.2.2.	 DNA	was	 transferred	 to	 a	 nylon	membrane	 overnight	using	the	capillary	action	generated	by	20x	SSC	through	a	Whatman	3MM	paper	wick	(Southern,	1975).	DNA	fragments	were	cross-linked	to	the	membrane	with	UV	 light	 (120	mJ)	 in	 a	 Stratalinker	 2400	 (Stratagene	 -	 now	Agilent,	 California,	USA).	DIG-labelled	probes	were	 synthesised	with	 the	PCR	DIG	probe	 synthesis	Kit	(Roche,	UK)	using	Phusion	polymerase	(NEB,	UK).	Lanes	were	probed	for	E.	
coli	 bamA	 and	 the	 kanamycin	 resistance	 gene	 (aphA)	 following	 the	 DIG	 DNA	labeling	and	detection	kit	 instructions	(Roche,	UK).	Hybridisation	of	 the	probes	was	detected	through	the	use	of	a	chromogenic	substrate,	BCIP/NBT	(Sigma,	UK)	
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to	identify	which	bands	the	antibody	bound	to.	Membranes	were	imaged	in	the	ImageQuant4000	(GE	Healthcare,	UK).		
2.3.7	Phage	stock	generation		
2.3.7.1	Small	scale	phage	stock	generation		The	lysogen,	MC1061	ϕ24B::Kan,	was	grown	to	mid-log	phase	(OD600	≈	0.45)	in	phage	growth	medium	(PGM).	Norfloxacin	was	added	to	a	final	concentration	of	1	µg	mL-1	 and	 the	 culture	was	 incubated	 at	 37°C	 for	1	hour	 to	 induce	 the	 SOS	stress	response	in	the	lysogen,	causing	the	autocatalysis	of	the	repressor	protein	and	induction	of	the	prophage	into	the	lytic	replication	cycle	(James	et	al.,	2001).	The	 induced	 culture	 (1	 ml)	 was	 subcultured	 into	 9	 mL	 fresh	 PGM,	 thereby	diluting	norfloxacin	10-fold.	The	cells	were	allowed	to	recover	for	2	hours	before	being	filtered	(0.22	µm,	Millipore)	into	a	plastic	universal	and	stored	at	4°C.	The	phage	titre	of	each	stock	was	determined	by	plaque	assay	(2.3.9).			
2.3.7.2	Large	scale	phage	stock	generation		Larger	phage	stocks	were	generated	using	either	a	scaled	up	version	of	the	small	scale	phage	stock	generation	method	(up	to	3.5	L)	using	the	same	concentrations	and	 ratios	 for	 all	 reagents	or	by	 the	plate-scraping	method.	The	plate	 scraping	method	 used	 10	 mL	 phage	 stock	 generated	 by	 the	 small	 scale	 generation	protocol,	 which	 was	 then	 used	 to	 produce	 50-100	 plates	 containing	 semi-confluent	 plaques	 following	 the	 plaque	 assay	 method	 (2.3.9).	 After	 overnight	
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incubation,	 PGM	 (3	 mL)	 was	 added	 to	 the	 surface	 of	 each	 plate	 with	 semi-confluent	plaques	and	a	sterile	spreader	was	used	to	disrupt	the	top	agar	 layer	and	 facilitate	 the	removal	of	material	 to	a	pooled	sample	of	 top	agar	and	PGM,	both	 containing	ϕ24B	 phages.	 The	 pooled	material	was	 transferred	 to	 250	mL	centrifuge	 tubs	 and	 shaken	 vigorously	 to	 break	 the	 agar	 pieces	 and	 release	 as	many	phages	as	possible	 into	 solution.	The	 resulting	debris	was	 centrifuged	at	1000	g	 for	 10	minutes	 to	 remove	 the	 agar	 and	 the	 supernatant	was	 collected.	NaCl	was	added	the	supernatant	to	a	final	concentration	of	1	M,	into	which	10%	(w/v)	PEG	8000	was	dissolved.	Phages	were	pelleted	by	centrifugation	at	10,000	
g	 at	 4°C	 for	 20	minutes.	 The	pellet	was	 resuspended	 in	 SC	buffer.	 Phage	 stock	was	 cleaned	 up	 by	 harvesting	 the	 aqueous	 phase	 from	 a	 phenol	 chloroform	extraction	 three	 times	 using	 equal	 parts	 phenol:chloroform:isoamyl	 alcohol	(25:24:1)	and	SC	buffer.	If	required,	phages	were	concentrated	further	by	adding	NaCl	to	1	M	and	10%	(w/v)	PEG	8000,	and	centrifugation	at	10000	g	at	4°C	for	20	minutes	before	final	resuspension	in	100	µL	–	500	µL	SC	buffer.	As	before,	a	further	3	rounds	of	phenol	chloroform	extraction	was	performed	to	clean	up	the	sample.	The	concentrated	phage	stock	was	quantified	by	plaque	assay	(2.3.9).		
2.3.8	Plaque	assay	 		Phage	stock	was	serially	diluted	to	10-6	in	phage	growth	medium	(50	µL	into	450	µL).	Mid-log	 phase	 (OD600	 ≈	 0.45)	 DM1187	 cells	 (100	 µL)	were	 added	 to	 each	dilution.	The	total	volume	(550	µL)	of	each	dilution	was	transferred	to	separate	3.5	mL	 aliquots	 of	 top	 agar	 and	mixed	 briefly	 by	 pipette	 before	 being	 poured	onto	pre-set	bottom	agar	plates	 containing	 the	 same	additives	 as	 the	 top	 agar.	
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Plates	were	ventilated	by	using	a	heated	wire	loop	to	introduce	2	x	2mm	slots	on	either	side	of	the	petri	dish	before	incubation	at	37°C	overnight,	and	the	titres	of	plaque	 forming	 units	 (PFU)	 were	 quantified	 by	 counting	 the	 plaques	 on	 agar	plates	possessing	20-200	plaques	(James	et	al.,	2001).			
2.3.9	Transmission	Electron	Microscopy	–	negative	staining		In	a	laminar	flow	hood,	copper	grids	(300	and	400	hexagonal	mesh)	were	coated	with	a	particle-free	0.3%	(w/v)	Pioloform	 (polyvinyl	butyral)	 film.	These	were	desiccated	 overnight.	 Phages	 (5	 µL	 of	 ~1	 x	 109	 stock	 solution)	were	 added	 to	treated	grids	 for	30	seconds,	after	which	 the	excess	was	wicked	off	using	 filter	paper.	Grids	with	 samples	were	 initially	 stained	with	4%	 (w/v)	uranyl	 acetate	(UA)	for	10	seconds	before	washing	once	by	dripping	MilliQ	H2O	across	the	grid.	Subsequent	samples	were	stained	with	2%	(w/v)	UA	as	the	4%	stain	produced	overly	dark	images.	Grids	were	dried	completely	before	being	analysed	on	an	FEI	Tecnai	12	Bio-twin	electron	microscope.		
2.3.10	Fluorescence	microscopy		Phages	 (500	 µL	 of	 1	 x	 109	 stock)	 were	 incubated	 overnight	 at	 4°C	 in	 PGM	containing	 1	 µL	 of	 10,000x	 concentrated	 SYBR-gold	 (Life	 Technologies,	 UK),	which	bound	to	phage	DNA.	Unbound	SYBR-gold	was	removed	from	the	sample	by	dialysis	in	2	x	2	L	PGM	using	100	kDa	MWCO	CE	membrane	to	retain	SYBR-gold	stained	phages	ready	for	imaging.	Four-compartment	glass	bottomed	dishes	(Greiner,	 UK)	 were	 treated	 with	 poly-L-lysine	 for	 30	 minutes	 at	 room	
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temperature	 to	provide	a	 surface	onto	which	E.	coli	could	be	attached.	Mid-log	phase	cells	(OD600	≈	0.40-0.50)	were	concentrated	five-fold	by	centrifugation	for	60	s	at	11,000	g	and	resuspended	in	0.2	volumes	of	PGM.	Concentrated	cells	(50	µL)	were	added	to	the	treated	glass	bottomed	plates	and	allowed	to	rest	at	room	temperature	 for	 20	 minutes	 to	 settle	 onto	 the	 glass	 surface.	 Samples	 were	washed	 twice	 with	 PGM	 to	 remove	 unattached	 cells	 with	 a	 final	 500	 µL	 PGM	added	 to	 the	 glass-bottomed	 dish	 before	 imaging	 on	 the	 fluorescence	microscope.	Once	the	dish	was	loaded	onto	the	microscope	and	the	correct	focus	was	 set	 up,	 images	 were	 taken	 automatically	 every	 10	 s	 across	 all	 required	wavelengths	(Table	5.2.1.1)	for	a	total	of	40	minutes.	Phages	were	added	to	the	medium	after	the	30	s	image	was	taken	at	2	x	105	PFU	mL-1.	Later	preparations	of	cells	were	treated	with	the	DAPI-based	NucBlue®	Live	ReadyProbes®	Reagent	according	to	manufacturer’s	instructions	(Thermo	Fisher	Scientific,	UK)	to	stain	bacterial	DNA	blue.	 A	 propidium	 iodide	 stain	 (Life	 Technologies,	 UK)	was	 also	added	(either	at	the	beginning	or	the	end	of	the	experiment)	to	detect	the	dead	cells.	The	method	progression	is	detailed	in	Chapter	5.			
2.3.11	Rendering	Protein	Images		Co-ordinates	 for	 3D	 protein	 images	 were	 downloaded	 using	 4	 character	alphanumeric	 codes	 from	 the	 Protein	 Data	 Bank	 (PDB)	 within	 molecular	graphics	software,	QtMG	(a	version	of	CCP4MG	released	for	use	with	OSX).	The	model	was	manipulated	to	display	 the	desired	details	and	angle.	An	 image	was	rendered	 using	 the	 “normal”	 method	 and	 the	 following	 settings:	 6.00	 x	 4.35	inches,	250	dpi,	scaled	font	and	image	sizes,	set	transparent	background.		
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Chapter	 3:	 Generating	 a	 Library	 of	 Isogenic	Mutants	 to	
Investigate	the	BamA-Phage	Interaction.	
	
3.1	Restrictions	around	generating	BamA	mutants		Recognition	 targets	 for	 other	 bacteriophages	 are	 known	 to	 undergo	 phase	 or	antigenic	variation	allowing	the	host	 to	 lose	support	 for	phage	adsorption	(van	der	 Woude	 &	 Bäumler,	 2004).	 Phase	 variation	 is	 a	 temporary	 change	 in	 the	volume	of	expression	to	allow	removal	of	the	molecule	from	the	surface	e.g.	the	lambda	phage	receptor,	LamB,	is	only	expressed	when	the	cell	is	in	the	presence	of	 maltose	 (Chapon,	 1982).	 Antigenic	 variation	 is	 a	 mutation	 that	 ultimately	leads	to	a	shape	change	on	the	surface	used	by	the	phage	to	recognise	a	host	cell	(Chaturongakul	&	Ounjai,	2014)	and	therefore	causes	a	loss	of	complementarity.	This	causes	a	biological	arms	race	between	the	phage	and	the	host	cell	known	as	the	Red	Queen	hypothesis	where	the	phage	must	constantly	adapt	to	mutations	of	the	host	cell	(Paterson	et	al.,	2010).		Interestingly,	 BamA	 is	 the	 only	 essential	 phage	 target	 that	 is	 currently	 known.	Consequently,	 the	 possibility	 of	 using	 phase	 variation	 as	 a	 defence	 strategy	 is	unavailable	 and	 any	 antigenic	 variation	 is	 extremely	 limited	 –	 and	 would	 be	restricted	 mostly	 to	 the	 extracellular	 loops	 (Ruhe	 et	 al.,	 2013b;	 Smith	 et	 al.,	2007)	These	restrictions	mean	 that	 instead	of	knocking	out	 the	gene,	a	genetic	chimaera	 would	 need	 to	 be	 made	 in	 order	 to	 maintain	 the	 protein	 folding	
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function	 while	 simultaneously	 removing	 the	 support	 for	 phage	 adsorption	 by	substituting	epitopes	on	the	extracellular	side	of	the	BamA	β-	barrel.		
3.1.1	Differences	between	Enterobacteriaceae	BamA	β-barrels		
Amino	 acid	 level	 sequence	 comparison	 of	 β-barrel	 domains	 identified	 just	 five	specific	 regions	 of	 variation	 in	 the	 primary	 protein	 structure	 of	 BamA	 that	correlated	with	a	loss	of	support	for	phage	adsorption	(Fig	3.1.1.1).	It	should	be	noted	 that	 there	 is	 no	 variation	 elsewhere	 in	 the	 aligned	 sequences.	 This	conclusion	is	supported	by	the	analysis	of	Ruhe	et	al.	(2013),	which	compared	41	
Enterobacteriaceae	 BamA	 sequences	 to	 show	 that	 genetic	 variation	 in	 BamA	sequences	occurs	almost	exclusively	within	these	three	extracellular	 loops	(Fig.	3.1.1.2).	This	shows	that,	in	theory,	the	only	variability	that	could	occur	in	BamA	tertiary	 structure	would	 be	 associated	with	 the	 extracellular	 surface,	 which	 is	exactly	where	that	antigenic	variation	would	need	to	manifest	to	allow	different	phage	 adsorption	 phenotypes	 between	 closely	 related	 species.	 Structural	 data	obtained	for	BamA	of	multiple	species	(Noinaj	et	al.,	2013)	enabled	mapping	of	regions	 expected	 to	 support	 adsorption	 onto	 the	 E.	 coli	 BamA	 structure	 (Fig.	3.1.1.3).	The	model	shows	epitopes	4a,	6,	and	7a	are	exposed	on	the	cell	surface	to	the	extracellular	environment	in	this	conformation.	Conversely,	loops	4b	and	7b	 are	 less	 likely	 to	 affect	 adsorption,	 as	 they	 would	 be	 within	 the	transmembrane	 region,	 which	 is	 inaccessible	 to	 the	 incoming	 phage	 tail	 spike	protein.	However,	it	is	still	possible	these	epitopes	have	a	role	in	a	second	step	of	adsorption,	 as	 lambda	 phage	 has	 (Werts	 et	 al.,	 1994),	 if	 BamA	 undergoes	 a	binding-induced	conformational	change	before	DNA	ejection	occurs.		
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Figure	3.1.1.1:	Sequence	alignments	of	BamA	orthologues	from	seven	
different	species.		From	top	to	bottom	sequences	are	from	S.	flexneri	PT2a	and	PT6,	S.	sonnei	PT36,		
E.	 coli	 MC1061,	 S.	 enterica	 serovar	 Cholesaesuis	 strain	 SC-B67,	 C.	 rodentium	strain	ICC168,	Pectobacterium	atrosepticum	and	P.	luminescens	subsp.	Laumondii	strain	TTO1.	Substitutions	in	type	of	R-group	in	amino	acid	residues	(e.g.	acidic	to	basic)	between	those	sequences	that	support	phage	adsorption	and	those	that	do	not	are	highlighted	in	grey.	Regions	of	interest	from	these	substitutions	have	been	identified	as	loop	4a	(blue),	4b	(green),	6	( ),	7a	(red)	and	7b	(purple).		Adapted	from	Smith	et	al.,	(2007).		
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Figure	3.1.1.2:	Percentage	conservation	of	the	β-barrel	domain	of	BamA	
among	41	species	of	the	Enterobacteriaceae	family.	Level	of	 conservation	of	 each	 residue	of	 the	β-barrel	 is	 colour	 coded	 in	 ranges	from	 0%-10%	 (dark	 blue)	 to	 90%-	 100%	 (red).	 The	 vast	 majority	 of	 the	transmembrane	β-sheets	are	>80%	conserved.	The	only	residues	that	are	<50%	conserved	are	limited	to	Loops	4,	6,	and	7.	Source:	(Ruhe	et	al.,	2013b).	
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Figure	3.1.1.3:	3D	model	of	E.	coli	BamA	with	the	epitopes	to	be	substituted.		Model	of	E.	coli	BamA	presented	as	ribbons	with	the	amino	acids	that	make	up	the	 five	 epitopes	 that	 have	 been	 substituted	 into	 the	 P.	 atrosepticum	 β-barrel	represented	 in	 spheres	 generated	 using	 supplemental	 data	 from	 Noinaj	 et	 al.	(2013).		
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Loop	6	has	a	highly	conserved	641RGF643	motif	that	is	critical	for	maintaining	the	protein	 folding	 function	 (Leonard-Rivera	 &	 Misra,	 2012).	 This	 epitope	 was	crystallised	inside	the	BamA	pore	in	the	closed	structure	(Noinaj	et	al.,	2013)	and	Loop	6	must	be	inside	the	pore	to	begin	the	protein	folding	and	insertion	process	(Wzorek	et	al.,	2017).	Therefore,	it	is	plausible	that	phage	adsorption	itself	is	also	conformation-dependent.			
3.2	Results		
3.2.1	Making	a	chimaeric	BamA	protein		In	 order	 to	 definitively	 prove	 that	 BamA	 supports	 phage	 adsorption	 it	 was	necessary	to	make	a	mutant	strain	that	was	not	susceptible	to	ϕ24B	adsorption.	However,	the	essential	nature	of	BamA	means	that	it	cannot	be	knocked	out,	as	any	loss	of	function	would	lead	to	a	non-viable	cell.	Instead,	to	maintain	function	while	 still	 creating	 a	mutant	phenotype,	 a	 chimaeric	bamA	was	 constructed	by	combining	POTRA	domains	from	the	BamA	orthologue	of	E.	coli	and	the	β-barrel	of	 Pectobacterium	atrosepticum	 (formerly	 known	 as	 Erwinia	 carotovora	 subsp.	
atroseptica	SCRI	1043).		
	
The	 β-barrel	 from	P.	atrosepticum	was	 chosen	because	 it	 has	 been	 shown	 that	this	 exact	 strain	 is	 unable	 to	 support	 phage	 adsorption	 (Smith	et	al.,	 2007).	 In	addition,	 there	 have	 also	 been	 several	 examples	 of	 expressing	 functional	periplasmic	and	outer	membrane	proteins	from	P.	atrosepticum	 in	E.	coli	due	to	
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similarities	 in	 secretion	 systems	 and	 envelope	 physiology	 that	 makes	 P.	
atrosepticum	a	sensible	choice	for	this	experiment	(Barabote	et	al.,	2003;	Hamel	
et	al.,	2001;	Shevchik	et	al.,	1994).	
	
The	chimaeric	version	of	BamA	was	created	by	gene	fusion	and	allelic	exchange.	The	 entire	P.	atrosepticum	bamA	gene	was	 not	 substituted	 into	E.	 coli	 because	another	research	group	had	trouble	with	compatibility	when	expressing	BamA	in	a	range	of	other	species	(Volokhina	et	al.,	2013).	Given	that	the	homologue	from	
P.	atrosepticum	contains	only	four	POTRA	domains	compared	to	the	five	in	E.	coli,	there	were	potential	undesired	side	effects	resulting	from	a	direct	swap.	The	E.	
coli	bamA	was	cloned	into	pKT230	and	transformed	into	P.	atrosepticum	where	it	was	 shown	 to	 fold	 correctly	 and	 localise	 to	 the	 outer	membrane	 (Smith	 et	al.,	2007).	Since	this	strain	still	had	a	functional	native	BamA	no	conclusions	can	be	drawn	on	 any	 functional	 complementation	 of	 the	 POTRA	domains.	 So	 to	 avoid	any	complications	 from	the	 lack	of	POTRA	domains	or	other	potential	different	components	of	the	periplasmic	domains	of	BamA,	the	POTRA	domains	of	E.	coli	were	joined	to	the	β-barrel	domain	of	P.	atrosepticum	by	fusion	PCR	(Fig,	3.2.1).	Thereby	maintaining	all	the	essential	(and	possible	non-essential)	function	of	the	POTRA	domains	and	their	 interactions	with	the	rest	of	the	E.	coli	BAM	complex	and	nascent	OMPs	while	swapping	the	β-barrel	component	for	a	phage	resistant	variant.	Use	of	this	construct	would	be	able	to	show	that	the	β-barrel	domain	of	BamA	is	the	only	factor	playing	a	role	in	providing	an	adsorption	target	for	ϕ24B.			
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Figure	3.2.1:	Fusion	PCR	strategy	to	generate	a	chimaeric	BamA.		(A)	Schematic	showing	the	strategy	of	combining	BamA	homologues	to	create	a	functional	but	phage	resistant	chimaera.	(B)	Blue	–	P.	atrosepticum	DNA,	Green	–	
E.	coli	DNA,	Orange	–	17	bp	overlap	in	PCR	primers	for	fusion.	PCR	amplification	of	 the	POTRA	domains	of	E.	coli	 and	 the	β-barrelled	domain	of	P.	atrosepticum	produced	fragments,	which	have	sequences	that	overlap	at	each	end	so	each	acts	as	the	primer	for	the	other	to	extend	from	the	3’	end	of	the	fragments.	The	fused	product	is	a	genetic	hybrid	of	E.	coli	and	P.	atrosepticum	BamA	with	the	reading	frame	conserved	throughout.		
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3.2.2	Allelic	exchange	with	WT	BamA		In	 order	 to	 create	 a	 strain	 of	 E.	 coli	 that	 is	 resistant	 to	 ϕ24B	 adsorption,	 the	chimaeric	BamA	 construct	was	 introduced	 into	 the	MC1061	 genome	via	 allelic	exchange	 (homologous	 recombination).	 To	 accomplish	 this,	 the	 β-barrel	sequence	of	P.	atrosepticum	was	flanked	by	E.	coli	bamA	sequences	upstream	and	the	 skp	 gene	 downstream.	 A	 kanamycin	 resistance	 cassette	 (KanR)	 was	 also	included	between	the	P.	atrosepticum	bamA	sequence	and	the	E.	coli	skp	gene	to	allow	 for	 positive	 selection	 of	 successful	 exchanges.	 This	 construct	 should	 be	able	 to	 recombine	 with	 the	 wild	 type	 (WT)	 E.	 coli	 genome	 resulting	 in	 the	replacement	 of	 the	 WT	 bamA	 gene	 with	 the	 chimaeric	 bamA	 and	 kanamycin	resistance	gene	(Fig	3.2.2.1).			This	construction	was	done	in	two	steps.	First	the	KanR	cassette	was	fused	to	the	
skp	gene	by	fusion	PCR	to	create	the	“KS	fragment”,	which	was	then	cloned	into	pUC19	via	compatible	EcoR	I	restriction	sites	(Fig.	3.2.2.2A).	Then	the	E.	coli	and	“Erwinia”	bamA	 fusion	sequences	were	also	created	by	fusion	PCR	to	create	the	
E.	coli	and	Erwinia	bamA	gene	fusion	(EE	fragment).	The	EE	fragment	was	then	cloned	 into	 pUC19-KS	 upstream	 of	 the	 KanR	 cassette	 and	 skp	 gene,	 also	 using	
EcoR	I	restriction	sites	to	create	pUC19-EEKS	(Fig	3.2.2.2B).	As	this	had	no	E.	coli	sequences	 substituted	 back	 into	 the	 β-barrel,	 the	 plasmid	 was	 designated	 as	pUC19-EEKS(0)	where	 (0)	 indicates	 no	 sequence	 substitutions.	 The	 order	 and	orientations	of	inserts	were	confirmed	by	PCR.		
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Figure	3.2.2.1:	A	schematic	of	the	EcEcaKanSkp	(EEKS)	construct	used	for	
homologous	recombination.		EEKS	was	created	by	sequentially	subcloning	the	fusions	of	the	chimaeric	BamA	(EE)	 and	kanR	 and	 skp	 (KS)	 into	 pUC19	with	EcoR	 I.	 DNA	matching	WT	E.	coli	chromosomal	 DNA	 is	 coloured	 yellow	 with	 DNA	 to	 be	 introduced	 in	 orange.	Black	crosses	 indicate	 regions	of	homology	between	 the	EEKS	construct	and	E.	
coli	chromosomal	DNA	where	recombination	is	expected	to	occur.	Permutations	of	 the	E.	coli	 epitopes	 (Table	 3.3.1)	 can	 be	 introduced	 into	 the	P.	atrosepticum	section	of	BamA	by	subcloning	using	Sty	I	and	Xcm	I.			
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Figure	3.2.2.2:	Stepwise	process	of	constructing	pUC19-EEKS.	(A)	The	DNA	fusion	of	KanR	and	skp	(KS	fragment)	was	created	by	fusion	PCR	and	cloned	 into	 empty	 pUC19	 vector	 via	 compatible	 cohesive	 ends	 generated	 by	digestion	with	EcoR	I	 to	create	pUC19-KS.	(B)	Gene	fusion	of	 the	E.	coli	 “X	site”	and	 the	 C-terminal	 domain	 of	 P.	 atrosepticum	 cloned	 into	 a	 partially	 digested	pUC19-KS	with	EcoR	I.	Sequence	and	orientation	of	the	ligated	EEKS	constructs	were	 confirmed	 by	 sequencing.	 (C)	 The	 plasmid,	 pUC19-EEKS,	 was	 partially	digested	to	remove	the	EEKS	fragment,	which	was	subcloned	into	the	pKNG101	suicide	vector	for	recombination.		
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Even	with	the	production	of	allelic	exchange	construct,	detecting	recombination	reactions	in	vivo	proved	to	be	very	time-consuming.	The	EEKS(0)	construct	was	subcloned	 using	 EcoR	 I	 into	 a	 suicide	 vector,	 pKNG101	 (Fig	 3.2.2.2C).	 The	pKNG101	 plasmid	 contains	 the	 sacB	 gene	 that	 makes	 Gram-negative	 bacteria	sensitive	 to	 sucrose	 in	 low	 osmolaric	 media	 i.e.	 no	 salt,	 allowing	 for	 positive	selection	 of	 double	 recombination	 events	 (Kaniga	 et	al.,	 1991).	 The	 pKNG101-EEKS(0)	 plasmid	 was	 heat	 shock	 transformed	 into	 competent	 MC1061	 cells.	Colonies	were	obtained	over	multiple	attempt	on	these	plates	showing	that	the	first	 single	 crossover	 event	 was	 successful.	 On	 each	 attempt,	 twenty	 colonies	were	subcultured	both	in	broth	and	on	plates;	however,	these	screenings	for	the	second	recombination	event	returned	no	growth	in	salt-free	LB	broth	with	added	50	µg	mL-1	kanamycin	and	5%	(w/v)	sucrose	or	on	plates	of	the	same.	
	
Another	mutant	generation	strategy	employing	the	Red	recombinase	system	on	the	 pKD46	 plasmid	 (Datsenko	 &	 Wanner,	 2000)	 was	 used	 in	 parallel	 to	 the	pKNG101	 suicide	 vector	 strategy	 to	 enhance	 the	 likelihood	 of	 successfully	generating	 the	desired	 chimaeric	mutant.	 This	 strategy,	 called	 recombineering,	uses	 the	 pKD46	 plasmid,	 which	 encodes	 the	 entire	 recombinase	 system	 from	lambda	phage	 controlled	by	 an	 arabinose-inducible	 promoter	 leading	 to	 vastly	increased	expression	of	recombinases	increased	the	likelihood	of	recombination	occuring	 in	 vivo.	 Indeed,	 using	 pKD46	 resulted	 in	 the	 first	 successful	 allelic	exchange	 (Fig.	3.2.3).	The	strain	was	named	Bam0	as	a	 reference	 to	 this	 strain	harbouring	 a	 BamA	 gene	with	 zero	E.	 coli	 epitopes	 substituted	 into	 the	 BamA	chimaera.	Subsequent	generations	of	this	strain	were	stable	and	could	survive	a	
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freeze	thaw	cycle	to	-80°C,	unlike	the	MC1061-MRL	strains	which	were	unable	to	be	resuscitated.	Confirmation	of	the	recombination	was	screened	first	using	PCR	using	primers	“5’Eca	Loop	Fwd”	and	“3’Rev	skpEcoRI”	(Fig.	3.2.3);	However,	PCR	can	not	be	used	to	confirm	this	because	the	absence	of	the	3	kb	band	(expected	fragment	 size	 without	 KanR	 inserted	 between	 bamA	 and	 skp)	 alongside	 the	presence	of	a	3.8	kb	band	(with	KanR)	is	not	proof	that	such	a	sequence	no	longer	exists	 somewhere	 else	 in	 the	 cell.	 The	 creation	 of	 the	 Bam0	 mutant	 was	confirmed	by	Southern	blot,	which	was	the	only	way	to	rule	out	the	production	of	 a	merodiploid	 cell,	 where	 partial	 chromosome	 duplication	 can	 result	 in	 the	presence	 of	 both	 a	WT	 and	mutant	 copy	 of	 the	bamA	 gene.	 The	 Southern	 blot	shows	that	there	is	only	a	single	band	of	BamA	in	both	of	the	digested	genomic	DNA	preparations	of	Bam0	and	MC1061	(Fig	3.2.4).	The	difference	in	sizes	of	the	fragments	between	the	strains	is	consistent	with	the	expected	recombination	of	the	 EEKS	 construct	 from	 figure	 3.2.2.	 The	 presence	 of	 a	 kanamycin	 resistance	cassette	in	Bam0	also	indicates	that	this	recombination	occurred.	
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Figure	3.2.3:	Screening	colonies	acquired	from	recombineering	protocol.		Transformation	of	pUC19-EEKS(0)	into	MC1061	to	introduce	genetic	constructs	of	the	modified	BamA	gene.	PCR	amplifications	were	performed	using	“EcEca	5’	X	sitefwd”	and	 “3’	 rev	Skp	EcoRI”	 for	 the	 following	 templates:	 (1)	An	MC1061	E.	
coli	 colony	 as	 a	 control	 for	 lack	 of	 recombination.	 (2)	 pUC19-EEKS(0)	 for	 a	positive	control	indicating	recombination	of	the	EEKS(0)	construct	with	genomic	DNA.	 (3)	 A	 colony	 acquired	 using	 the	Red	 recombinase	method.	 PCR	 products	were	sequenced	to	confirm	they	represented	the	expected	BamA	sequence.	M	=	Hyperladder	1kb	(Bioline).		
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Figure	3.2.4:	Southern	blots	to	confirm	single	copy	of	BamA	in	Bam0.		Genomic	DNA	 of	MC1061	 and	Bam0	was	 digested	with	 the	 enzymes	 indicated	and	 probed	 for	 BamA	 gene	 (top)	 and	 the	 kanamycin	 resistance	 gene	 KanR	(bottom)	 using	 DIG-labelled	 DNA	 probes.	 Expected	 sizes	 (indicated	 by	 the	magenta	arrows)	 for	 the	BamA	probe:	 (left-right)	3885,	7351,	3665,	and	3665.	KanR	expected	sizes:	 (left-right)	3466,	7351,	n/a,	and	n/a.	A	single	band	 in	 the	lanes	with	the	BamA	probe	shows	there	is	only	a	single	copy	of	BamA	in	Bam0	and	MC1061.		
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3.3	Creating	a	library	of	isogenic	BamA	mutants		
In	 order	 to	 get	 a	 deeper	 understanding	 into	 a	 potential	mechanism	 for	E.	 coli	BamA	acting	as	the	receptor	 for	ϕ24B,	 the	amino	acid	sequences	of	BamA	from	fully	sequenced	members	of	the	Enterobacteriaceae	were	aligned.	The	analysis	of	the	 alignment	 revealed	 5	 small	 sequences	 within	 the	 species	 that	 supported	ϕ24B	adsorption	and	those	that	were	resistant	to	ϕ24B	adsorption	(Fig	3.1.1.1).	A	 comprehensive	 analysis	 of	 all	 32	 possible	 combinations	 of	 the	 different	epitopes	 (Table	 3.3.1)	 was	 planned	 in	 which	 the	 minimal	 required	 for	 phage	adsorption	support	could	be	discovered.	
	
3.3.1	Previous	construction	of	chimaeric	P.	atrosepticum	BamA	genes			
The	most	recent	completed	work	resulted	in	the	construction	of	chimaeric	genes	possessing	25	out	of	 the	32	possible	combinations	of	E.	coli	epitopes	(McEwen,	2013).	 Table	 3.3.1	 shows	 which	 constructs	 are	 cloned	 into	 pCR-Blunt	 and	sequenced.	Two	constructs	contained	a	nonsense	point	mutation	within	the	gene	and	five	were	yet	to	be	made	as	the	set	of	primers	used	to	introduce	loop	4b	(“5’	fwd	loop	IIb”	and	“3’	rev	loop	IIb”)	required	a	slightly	modified	PCR	protocol	that	required	a	higher	melting	temperature	and	the	addition	of	3%	(v/v)	DMSO	to	the	PCR	reaction	before	the	products	would	consistently	amplify	using	the	same	due	to	 non-specific	 binding	 interactions	 of	 the	 much	 longer	 ‘overlapping	 regions’	incorporated	onto	the	5’	ends	of	the	primers.	
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Table	 3.3.1:	 Pre-isogenic	 BamA	 mutated	 chimaeric	 genes	 created	 by	
McEwen	(2013).	
Number	of	
swapped	
epitopes	
Code	
Epitope	Present	 Cloned	in	
pCR-
Blunt	
Sequence	
confirmed	‡	4a	 4b	 6	 7a	 7b	
0	 0	 		 		 		 		 		 x	 		
1	
1a	 		 		 		 		 		 x	 		
1b	 		 		 	 	 		 x	 		
1c	 		 	 		 	 		 x	 		
1d	 		 	 	 		 		 x	 		
1e	 		 	 	 	 		 x	 		
2	
2a	 		 		 		 		 		 x	 		
2b	 		 	 		 	 		 x	 		
2c	 		 	 	 		 		 x	 		
2d	 		 	 	 	 		 x	 		
2e	 		 		 		 	 		 x	 		
2f	 		 		 	 		 		 	 		
2g	 		 		 	 	 		 	 		
2h	 		 	 		 		 		 x	 		
2i	 		 	 		 	 		 x	 		
2k	 		 		 		 		 		 x	 		
3	
3a	 		 		 		 		 		 x	 		
3b	 		 		 	 		 		 x	 		
3c	 		 		 	 	 		 x	 		
3d	 		 	 		 		 		 x	 		
3e	 		 	 		 	 		 x	 		
3f	 		 	 	 		 		 x	 		
3g	 		 		 		 		 		 	 		
3h	 		 		 		 	 		 	 		
3i	 		 		 	 		 		 	 		
3k	 		 		 		 		 		 x	 		
4	
4a	 		 		 		 		 	 x	 		
4b	 		 		 		 	 		 x	 		
4c	 		 		 	 		 		 x	 		
4d	 		 	 		 		 		 x	 		
4e	 		 		 		 		 		 x	 		
5	 5	 		 		 		 		 		 x	 		
‡		 Green	 indicates	 that	 they	 were	 sequenced	 and	 their	 construction	confirmed.			 Red	represents	clones	with	a	nonsense	mutation.			 White	indicates	that	no	sequence	was	obtained.	
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3.3	Completing	the	library	of	chimaeric	BamA	genes		
The	 work	 from	 the	 previous	 study	 (McEwen,	 2013)	 was	 continued	 and	 the	library	 of	 epitope	 substitutions	 in	 pCR-Blunt	 was	 completed	 to	 include	 the	constructs	not	completed	(Table	3.3.1)	and	sequenced	(Appendix	8.1).	
	
Upon	completion	of	the	library	of	chimaeric	genes,	multiple	attempts	were	made	to	 generate	Bam5	 via	 allelic	 exchange.	 Bam5	would	 be	Bam0	but	 the	 chimeric	BamA	 gene	 would	 have	 substituted	 all	 five	 E.	 coli	 epitopes	 in	 for	 the	 P.	
atrosepticum	epitopes.	Yet	despite	the	immediate	previous	success	with	the	Red	recombinase	 system	 encoded	 on	 pKD46	 to	 create	 Bam0,	 this	 repeatedly	 failed	when	attempting	to	do	the	same	thing	to	create	what	would	be	Bam5.	This	was	the	case	using	either	pKNG101	or	pKD46	with	either	circularised	or	linear	DNA.	It	was	later	discovered	that	the	root	cause	was	an	incorrectly	engineered	primer	ordered	in	2007,	which	was	missing	two	bases	of	the	codon	encoding	Y578.	Not	only	 is	 this	 tyrosine	 residue	 conserved	 in	 BamA	 across	 all	 members	 of	 the	
Enterobactericeae,	 thus	 being	 potentially	 functionally	 important,	 but	 the	 2	missing	bases	introduced	a	2	bp	deletion	in	the	gene	and	therefore	a	-2	reading	frame	shift.	The	shift	immediately	introduces	a	stop	codon	after	S577,	truncating	the	essential	BamA.	This	explains	the	lack	of	positive	recombinants	using	pKD46	and	 the	 total	 lack	 of	 colonies	 for	 the	 second	 recombination	 event	when	 using	pKNG101.	 With	 pKD46,	 the	 cells	 in	 which	 recombination	 occurs	 will	 not	 be	viable	with	a	truncated	BamA	and,	with	pKNG101,	the	cells	are	effectively	being	given	 the	 choice	 between	 either	 a	 suicide	 gene,	 sacB,	 or	 a	 non-functional	
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essential	 gene,	 BamA.	 Either	 of	 these	 results	 in	 a	 non-viable	 cell	 and	 so,	 in	retrospect,	 the	 lack	 of	 recombinants	 indicates	 that	 the	 systems	 were	 working	and	 confirms	 that	 BamA	 cannot	 be	 deleted.	 Unfortunately	 this	 lethal	mutation	was	 found	 in	 all	 the	 constructs	 containing	 the	 4b	 epitope	 (16	 of	 the	 32	combinations).	New	primers	(5’	fwd	IIb	fix	&	3’	rev	IIb	fix)	were	used	to	redo	the	fusion	PCRs	for	the	16	mutants	to	fix	the	reading	frame	shift	and	reinstate	Y578	and	the	rest	of	the	gene.	The	fixed	constructs	were	re-sequenced	so	the	mutant	library	is	still	ready	to	be	used	to	generate	the	isogenic	BamA	mutants	in	E.	coli.	These	 cloned	 constructs	 have	 been	 labelled	 with	 the	 suffix	 “fixed”	 e.g.	 “pCR-Blunt-1b	fixed”.	
	
3.4	Testing	the	infection	phenotype	of	Bam0		
The	 ability	 of	 the	 chimaeric	 protein	 to	 support	 adsorption	 in	 an	 E.	 coli	background	was	tested	using	a	spot	assay:	a	visible	spot	(lack	of	bacterial	growth	on	an	indicator	lawn)	where	10	µL	of	a	phage	suspension	(6	x	107	PFU	mL-1)	was	dropped	 onto	 an	 indicator	 host	 lawn	 would	 indicate	 whether	 a	 successful	infection	has	occurred.		
	
Adsorption	 is	 the	 first	 step	 in	 infection,	 so	 if	 infection	 occurs	 then	 ϕ24B	adsorption	was	supported.	Both	the	lack	of	spot	on	the	P.	atrosepticum	indicator	lawn	 and	 the	 presence	 of	 one	 using	 E.	 coli	 (Fig.	 3.4.1A-B)	 is	 consistent	 with	previous	findings	using	ϕ24B	(Smith	et	al.,	2007).	The	Bam0	strain	was	unable	to	support	phage	 infection	 (Fig.	3.4.1C).	Reintroducing	a	 copy	of	WT	E.	coli	BamA	
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using	the	pUC19-ϕR1D	construct	(Sergeant,	1998;	Smith	et	al.,	2007)	was	able	to	restore	 the	phage	 susceptible	phenotype	 (Fig.	3.4.1D).	This	 showed	 that	 the	β-barrel	domain	of	E.	coli	BamA	can	be	substituted	with	 the	homologous	domain	from	 P.	 atrosepticum	 to	 remove	 adsorption	 support	 while	 complementing	 the	protein	 folding	and	 insertion	 functions	without	 impacting	cell	viability.	Growth	curve	 data	was	 not	 collected	 but	 Bam0	 appeared	 to	 grow	 at	 the	 same	 rate	 as	MC1061	both	in	liquid	(judging	by	time	taken	to	reach	OD600	=	0.45	for	the	spot	assay)	and	colony	appearance	on	agar	plates.		
	
Bam0	 remains	 the	 only	 isogenic	 mutant	 created	 so	 far	 as	 the	 same	recombineering	strategy	was	not	successful	when	attempted	with	EEKS(5)	–	the	mutant	of	the	chimeric	BamA	which	has	all	five	E.	coli	epitopes	substituted	in	for	the	corresponding	residues	of	the	BamA	ortholog	in	P.	atrosepticum	as	shown	in	figure	3.1.1.1.	Ideally,	EEKS(5)	would	have	been	used	to	create	the	Bam5	strain,	which	 was	 expected	 to	 reintroduce	 adsorption.	 However,	 with	 the	 ϕR1D	complementation	(Fig.	3.4.1D),	 the	data	presented	here	show	a	definitive	proof	that	BamA	is	the	adsorption	target	for	ϕ24B	and,	by	extension,	any	other	phage	with	the	same	tail	structure.		
	
			
96	
	
	
	
		
Figure	3.4.1:	Spot	assay	for	phage	infection	of	cells	expressing	variants	of	
BamA.		Schematic	 representations	 of	 the	 BamA	 variant	 encoded	 by	 the	 cell	 is	 shown	above	the	assay	result.	Phage	stock	(10	µL	of	a	6	x	107	titre)	was	spotted	onto	top	agar	containing	 the	strains	 indicated	(A)	P.	atrosepticum,	 a	negative	control	 for	the	spot	assay;	(B)	WT	E.	coli	strain	MC1061,	a	positive	control	with	an	infection	phenotype;	(C)	Allelic	exchange	of	the	WT	BamA	for	the	chimeric	BamA,	loss	of	the	infection	phenotype	from	MC1061;	(D)	Complementing	Bam0	with	WT	E.	coli	BamA	(pUC19-ϕR1D)	from	MC1061	restores	the	positive	infection	phenotype.	
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3.5	Conclusions		
3.5.1	Fusion	PCR	can	create	viable	mutants	in	BamA		The	sequential	addition	of	specific	mutations	into	the	P.	atrosepticum	β-barrel	of	the	 chimaeric	 bamA	 gene	 required	 the	 use	 of	 a	 non-random,	 site	 directed	mutation	methodology.	This	 is	especially	 important	when	making	mutations	 in	essential	genes	where	any	mutation	in	a	highly	conserved	area	is	likely	to	disrupt	an	essential	 function.	Fusion	PCR	using	specially	designed	primers	to	introduce	these	multi-nucleotide	mutations	 is	a	 slow	but	precise	method	 to	make	a	 large	number	(32)	of	specific	mutants.		
	
3.5.2	Creating	a	ϕ24B	resistant	strain,	MC1061-Bam0.		Substituting	E.	coli	 BamA	 for	 a	 chimaeric	BamA	 in	MC1061	by	 introducing	 the	EEKS(0)	 construct	 via	 allelic	 exchange	maintains	 the	 essential	 LPS	membrane	protein	insertion	function.	This	is	evidenced	by	the	viability	of	cells	in	which	this	recombination	has	been	confirmed	through	Southern	blot	analysis.	This	mutant	strain,	Bam0,	was	then	unable	to	support	ϕ24B	infection	in	a	spot	assay.	This	is	a	crucial	step	in	definitive	proof	of	the	function	of	BamA	as	the	phage	receptor.	
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3.5.3	Restoring	ϕ24B	infection	support	to	MC1061-Bam0		Complementing	 the	 Bam0	 strain	 with	 a	 plasmid	 carrying	 and	 expressing	 WT	BamA,	specifically	pUC19-ϕR1D,	was	enough	to	completely	restore	an	infection	susceptible	 phenotype.	 This	 plasmid,	 pUC19-ϕR1D,	 also	 restored	 phage	susceptibility	to	the	original	MRL	mutants	made	by	Sergeant	(1997).	Though	we	will	never	know	what	kind	of	natural	mutation	was	generated	in	the	MRL	strain,	it	seems	very	likely	that	it	lay	somewhere	within	BamA.		
	
3.6	Discussion	of	results			The	creation	of	a	BamA	chimaera	by	fusion	PCR	was	the	first	major	step	towards	performing	 an	 assay	 for	 phage	 adsorption	 via	 an	 essential	 protein	 and	subsequent	infection	of	the	host	cell.	It	has	been	shown	that	the	combination	of	β-barrel	 and	 POTRA	 domains	 is	 important	 as,	 despite	 their	 essentiality,	 BamA	proteins	 seem	 to	 diverge	 quickly	 enough	 in	 evolutionary	 time	 to	 be	 species	specific	 (Volokhina	 et	 al.,	 2013).	 The	 alignment	 of	 the	 POTRA	 domains	 with	respect	 to	 the	β-barrel	 is	 the	most	 important	 factor	when	considering	whether	these	two	regions	will	be	functionally	compatible	(Browning	et	al.,	2015).	When	the	fusion	PCR	experiment	was	designed	there	was	no	data	to	suggest	whether	swapping	 the	 entire	 BamA	 protein	 or	 if	 creating	 a	 chimaera	 of	 E.	 coli	 and	 P.	
atrosepticum	BamA	proteins	would	impact	the	function	of	the	BAM	complex	with	respect	to	lipoprotein	and/or	substrate	binding.		
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	After	 allelic	 exchange	 of	 the	 fused	 chimaeric	 bamA	 with	 the	 genomic	 copy	 of	
bamA	in	E.	coli	MC1061,	it	was	discovered	that	the	POTRA	and	β-barrel	domains	of	 the	 BamA	homologues	 from	E.	 coli	 and	P.	atrosepticum	 are	 able	 to	 combine	into	 functional	 chimaeras	 and	 create	 viable	 cells.	 This	 compatibility	 may	 be	possible	as	 they	have	a	more	conserved	structure	due	 to	minimal	phylogenetic	divergence.	 The	 BAM	 complex	 of	 the	 newly	 created	 Bam0	 strain	 was	 able	 to	function	with	no	observable	difference	to	WT	MC1061,	further	implying	a	strong	inter-species	compatibility	and	no	loss	of	functional	efficiency.		It	was	decided	that	a	library	of	specific	site-directed	mutants	should	be	made	to	investigate	 which	 of	 the	 extracellular	 epitope	 are	 required	 to	 support	 phage	adsorption.	 Non-specific	 mutants	 could	 have	 been	 made	 following	 a	 random	mutagenesis	method,	either	by	chemical	(Bose,	2016)	or	error-prone	PCR-based	(McCullum	et	al.,	 2010)	methods,	which	may	have	allowed	 the	 identification	of	residues	 involved	 in	 the	 adsorption	 process.	 This	 high-throughput	 approach	would	have	yielded	results	more	quickly;	however,	 it	probably	would	not	have	answered	 why	 the	 difference	 between	 the	 extracellular	 surface	 of	 the	 BamA	homologues	in	E.	coli	and	P.	atrosepticum	result	in	different	phenotypes	for	ϕ24B	adsorption.	 Synthetic	 biology	 could	 also	 have	 been	 used	 to	 generate	 these	specific	constructs	in	a	more	time-effective	manner	and	would	have	avoided	the	creation	of	constructs	with	a	reading	frame	shift.			The	heavy	time	commitment	required	to	generate	the	library	of	32	very	specific	isogenic	BamA	mutants	was	a	necessary	step	to	allow	dissection	of	these	critical	
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differences	between	the	BamA	proteins	of	E.	coli	and	P.	atrosepticum,	which	we	already	know	support	or	are	resistant	to	phage	infection	respectively.			An	effort	was	made	to	provide	definitive	evidence	that	the	parent	strain	of	Bam0	is	 MC1061	 using	 pulsed	 field	 gel	 electrophoresis	 (PFGE).	 The	 idea	 was	 that	digesting	both	Bam0	genomic	DNA	(gDNA)	and	MC1061	gDNA	with	EcoR	I	would	produce	identical	restriction	fragment	length	polymorphism	(RFLP)	data,	except	for	1	band	which	would	be	cleaved	in	two	by	the	EcoR	I	sites	introduced	in	the	flanking	the	KanR	and	skp	genes	(this	fragment	would	also	create	a	new	band	on	the	gel).	However,	PFGE	was	abandoned	as	 the	high	and	 low	molecular	weight	ladders	ran	as	smears	 through	the	gels	and	after	exhaustive	 troubleshooting,	 it	was	suspected	that	the	PFGE	equipment	was	not	working	correctly.		The	 successful	 complementation	 of	 the	 Bam0	 strain	 by	 pUC19-ϕR1D	 is	 a	significant	development	and	provides	the	definitive	proof	that	BamA	acts	as	the	receptor	for	ϕ24B.	This	evidence	was	the	final	missing	piece	from	the	analysis	by	Smith	 et	 al.	 (2007),	 which	 was	 only	 went	 as	 far	 as	 introducing	 ϕ24B	susceptibility	 to	 P.	 atrosepticum	 by	 heterologous	 expression	 of	 E.	 coli	 BamA	without	knocking	out	WT	BamA	first.	The	data	collected	now	satisfy	molecular	Koch’s	 postulates	 (Falkow,	 1988).	 This	 allows	 the	 study	 to	move	 forward	 and	plan	 a	 more	 informative	 assay	 for	 expressing	 and	 screening	 the	 library	 of	mutants	for	the	effect	that	they	have	on	ϕ24B	adsorption.	That	assay	is	yet	to	be	established.	 For	 most	 options,	 additional	 DNA	 constructs	 and	 molecular	 tools	would	need	 to	 be	made	before	 performing	 the	 assays.	 Potential	 approaches	 to	answering	this	question	are	discussed	in	Chapter	4.	
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CHAPTER	 4:	 Expressing	 BamA	Mutants	 and	 Generating	
Molecular	Tools	to	Investigate	Adsorption	
	
4.1	Introduction		Having	 created	 a	 library	 of	 32	 isogenic	 bamA	 mutants	 and	 a	 phage	 resistant	strain	 of	 E.	 coli,	 Bam0,	 through	 allelic	 exchange,	 the	 next	 step	 was	 to	 try	 to	express	 the	 mutated	 forms	 of	 BamA	 from	 the	 library	 and	 determine	 how	 the	defined	mutations	 impact	 upon	phage	 adsorption	 to	BamA.	There	 are	multiple	ways	 to	 test	 this	 effect	 and	 each	 method	 has	 its	 own	 advantages	 and	disadvantages.			
4.1.1	Infection	assay		The	 simplest	 method	 was	 to	 ascertain	 whether	 ϕ24B	 was	 able	 to	 infect	 cells	exclusively	 expressing	 one	 of	 the	 engineered	 BamA	 mutants,	 as	 mutations	causing	adsorption	 impairment	should	be	unable	 to	support	phage	 infection	as	the	 virus	will	 have	 no	 or	 limited	 ability	 to	 recognise	 potential	 host	 cells.	 This	method	was	used	in	Chapter	3	to	confirm	that	Bam0	was	unable	to	support	ϕ24B	infection	 (Fig.	 3.4.1).	 A	 limitation	 of	 this	 method	 is	 that,	 rather	 than	 just	measuring	adsorption,	it	examines	the	ability	of	the	mutant	to	support	the	entire	infection	 process.	 Therefore	 further	 experiments	 would	 be	 needed	 to	 confirm	that	 any	 infection	 resistant	 phenotype	 is	 caused	 by	 a	 failure	 at	 the	 adsorption	
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step.	 The	 complementation	 of	 Bam0	 with	 WT	 E.	 coli	 BamA	 provides	 good	evidence	that	the	loss	of	an	infection	phenotype	is	due	to	loss	of	adsorption.			
4.1.2	Adsorption	assay		An	adsorption	assay	uncouples	adsorption	from	the	rest	of	the	infection	process.	The	principle	of	 the	 adsorption	assay	 for	ϕ24B,	 detailed	 in	 Smith	et	al.	 (2007),	involves	 adding	 a	 set	 number	 of	 phages	 to	 a	 known	 number	 of	 host	 cells,	allowing	them	to	interact	for	a	prescribed	period	of	time	and	removing	the	cells	(along	 with	 the	 adsorbed	 phages)	 by	 centrifugation.	 The	 remaining	 phage	particles	 that	 have	 not	 adsorbed	 are	 then	 quantified	 by	 plaque	 assay.	 This	methodology	involves	lots	of	sample	handling,	which	can	lead	to	noisy	data,	and	so	accurate	measurements	can	be	difficult	to	acquire,	but	general	trends	can	be	seen.			
4.1.3	In	vitro	molecular	interaction	assays		Studying	the	protein-protein	interaction	in	vitro	would	be	the	most	quantifiable	method	to	determine	binding	affinities.	As	examples,	surface	plasmon	resonance	(SPR)	 or	 isothermal	 titration	 calorimetry	 (ITC)	 are	 both	 biophysical	 methods	that	 detect	 rates	 of	molecular	 interactions.	 SPR	measures	 small	 changes	 in	 the	angle	 of	 refraction	of	 electromagnetic	waves	 as	 they	 are	 affected	by	molecular	interactions	in	the	sample,	and	ITC	measures	interaction	rates	by	comparing	the	heat	generated	when	molecules	 interact	when	mixing	known	concentrations	of	each	 interaction	 partner	 (Pierce	 et	al.,	 1999).	 These	methods	 could	 be	 used	 to	
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determine	 binding	 affinities	 of	 the	 phage	 tail	 and	 BamA.	 The	 presence	 of	hydrophobic	 transmembrane	 regions	would	present	 a	 practical	 issue	 for	 these	methods	 as	 introducing	 detergents	 make	 data	 more	 complicated	 to	 interpret	(Rajarathnam	&	Rösgen,	2014).	The	use	of	peptides	that	mimic	the	extracellular	epitopes	 of	E.	 coli	would	 circumvent	 the	 need	 to	 solubilise	 the	whole	 β-barrel	structure	including	the	hydrophobic	transmembrane	domains.	However	it	would	be	impossible	to	ensure	that	the	peptides	would	be	presented	to	the	phage	in	a	conformationally	 appropriate	 manner.	 Additionally,	 if	 the	 phage	 binding	 to	BamA	results	 in	a	conformational	change	 in	BamA	the	use	of	peptides	may	not	provide	 the	phage	with	 the	 structures	necessary	 to	 induce	BamA	 to	open	up	a	surface	 for	 a	 secondary	 binding	 event,	 should	 this	 be	 part	 of	 the	 adsorption	process.	 The	 failure	 of	 these	 assays	 to	work,	 though,	would	 not	 be	meaningful	and	very	difficult	to	troubleshoot	as	protein	conformation	and	protein	sequence	importance	in	the	support	of	phage	binding	are	likely	to	be	impossible	to	unpick.		
4.1.4	Fluorescent	microscopy	assay		The	 final	 option	 considered	 here	 was	 a	 fluorescence	 microscopy-based	 assay.	SYBR	gold	is	a	fluorescent	stain	that	has	been	used	to	label	phage	DNA	in	order	to	monitor	phage	 infection	of	host	cells	 (Mosier-Boss	et	al.,	2003).	This	 type	of	assay	allows	the	visualisation	of	the	cells	that	are	susceptible	to	adsorption,	and	the	 release	 of	 fluorescent	 phage	 DNA	 into	 the	 bacterial	 host’s	 cytoplasm	resulting	 in	 the	 bacterial	 cell	 fluorescing.	 Cells	 that	 are	 resistant	 to	 phage	adsorption	will	not	lead	to	fluorescent	cells.			
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4.1.5	Method	evaluation		The	infection	assay	has	been	performed	for	Bam0	and	will	continue	to	serve	as	a	valuable	 first	 test	 to	determine	 infectivity	of	ϕ24B	on	 the	 isogenic	 strains	of	E.	
coli.	 To	 gain	 further	 understanding	 of	 the	 adsorption	 process	 another	method	will	 need	 to	 be	 used.	 The	molecular	 interaction	 characterisation	 assays	would	provide	 quantifiable	 data	 but	 are	 further	 removed	 from	a	 biologically	 relevant	scenario	 than	 either	 the	 fluorescence	microscopy	 or	 the	 adsorption	 assay.	 The	removal	of	the	phage	and	BamA	(or	peptides)	from	the	in	vivo	environment	may	necessitate	 more	 assumptions	 about	 exactly	 what	 is	 going	 on	 during	 the	interaction.	 This	 is	 not	 true	 of	 the	 fluorescence	 microscopy	 assay,	 which	 can	visualise	 phage	 adsorption	 and	 DNA	 ejection	 facilitating	 the	 troubleshooting	process	should	the	assay	fail.	Microscopy	data	can	be	analysed	in	a	quantifiable	way	 on	 a	 single-cell	 level,	 this	 will	 eliminate	 the	 noise	 generated	 during	 the	adsorption	 assay.	 For	 these	 reasons,	 the	 fluorescence	 microscopy	 assay	 was	developed	specifically	for	ϕ24B	in	Chapter	5.		All	 of	 these	 assays	 have	 different	 requirements	 in	 terms	 of	 DNA	 constructs,	protein	purification,	and	molecular	tools.	The	most	useful	construct	to	extend	the	complementation	of	Bam0	would	be	the	creation	of	the	“Bam5”	strain	of	E.	coli,	which	 would	 express	 the	 chimaeric	 BamA	 with	 all	 five	 E.	 coli	 epitopes	substituted	into	the	β-barrel	structure	of	the	P.	atrosepticum	BamA	as	this	would	provide	 a	 cleaner	 proof	 of	 adsorption	 restoration.	 As	 EEKS(5)	 is	 the	 construct	that	differs	the	most	from	EEKS(0).	It	would	also	suggest	that	there	would	be	no	
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problems	 when	 introducing	 any	 of	 the	 32	 constructs	 to	 MC1061	 via	 allelic	exchange,	as	they	are	effectively	a	continuum	between	the	two.			
4.2	Re-attempting	creation	of	Bam5	strain	with	“fixed”	EEKS(5)		As	 mentioned	 in	 section	 3.4.1,	 the	 plasmid	 pUC19-EEKS(5)	 (pUE5)	 did	 not	undergo	 allelic	 exchange	 when	 introduced	 into	 MC1061	 containing	 pKD46,	 a	plasmid	 encoding	 the	 Red	 recombinase	 system.	 As	 stated	 in	 Chpater	 3,	 this	failure	can	be	explained	by	the	frame	shift	mutation	within	the	coding	region	that	would	 have	 immediately	 introduced	 a	 stop	 codon	 in	 the	 essential	 BamA	 gene.	“Fixing”	 this	 frame	 shift	 mutation	 (as	 described	 in	 Chapter	 3.3)	 should	 allow	allelic	exchange	to	occur	and	produce	the	Bam5	strain.		
4.2.1	Fixing	the	EEKS(5)	construct		In	 order	 to	 reattempt	 this	 allelic	 exchange,	 the	mutation	 in	 the	EEKS(5)	 insert	was	 fixed	 by	 fusion	 PCR	 using	 two	 pairs	 of	 primers	 to	 generate	 separate	overlapping	fragments	(Fig	4.2.1A-B).	These	fragments	were	then	fused	by	PCR	to	produce	the	~3200	bp	band	of	the	EEKS	insert.	The	gel	extraction	of	this	band	only	yielded	26	ng	µL-1.	In	order	to	generate	a	higher	concentration	of	linear	DNA	for	 transformation,	 this	 PCR	 fragment	 was	 cloned	 into	 pUC19	 using	EcoR	 I	 to	make	pUE5,	and	this	plasmid	was	used	as	a	template	to	re-amplify	the	EEKS(5)	construct	using	“5’	EcEca	X	site”	and	“3’	rev	SkpEcoRI”	primers	(Fig.	4.2.1C).		
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4.2.2	Allelic	exchange	using	EEKS(5)		Separately,	both	the	linear	amplification	product	of	EEKS(5)	and	the	circularised	pUE5	plasmid	were	transformed	by	electroporation	into	mid-log	phase	MC1061	harbouring	 the	 pKD46	 plasmid	 using	 a	 micropulser	 (BioRad,	 UK).	 Cells	 were	recovered	 at	 30°C	 and	 spread	 on	 selective	 plates	 and	 incubated	 at	 30°C	overnight	 to	 maintain	 the	 pKD46	 plasmid,	 which	 possesses	 a	 temperature	sensitive	 origin	 of	 replication.	 If	 no	 colonies	 were	 observed,	 plates	 were	incubated	for	a	further	overnight	step	in	case	allelic	exchange	did	occur	and	the	cells	exhibited	slower	growth	as	a	 result.	Colonies	were	 replica	plated	onto	LB	plates	 containing	 kanamycin	 and	kanamycin	&	 ampicillin.	 These	 colonies	were	also	 used	 to	 directly	 inoculate	 aliquots	 of	 liquid	 LB-kan.	 These	 broth	 cultures	were	 incubated	at	43°C	overnight	 to	 cure	 the	cells	of	pKD46,	as	 the	plasmid	 is	unable	to	replicate	at	this	temperature.	Daughter	cells	 lose	the	plasmid	and	the	only	way	the	cell	can	survive	is	if	a	recombination	reaction	occurred	to	insert	the	KanR	cassette	into	the	genomic	DNA.			Using	“5’	EcEca	X	site”	and	“3’	rev	SkpEcoRI”	primers,	colonies	were	screened	for	the	 presence	 of	 a	 successful	 exchange	 event	 resulting	 from	 the	 insertion	 of	 a	kanamycin	resistance	gene,	aphA,	between	bamA	and	skp	in	the	MC1061	genome.	Despite	 being	 picked	 from	 kanamycin	 plates,	 no	 colonies	 displayed	 further	growth	on	 the	kanamycin	 replica	plate	nor	was	 there	any	growth	 in	 the	 liquid	cultures	 at	 43°C.	 The	PCRs	 resulted	 in	 2.4	 kb	 bands	 (Fig.	 4.2.1D),	which	 is	 the	expected	size	of	bands	in	the	absence	of	recombination	and	the	size	of	the	bands	in	 all	 samples	 were	 identical	 to	 the	 negative	 control	 (naïve	 MC1061	 cells).	
107	
	
Figure	4.2.1:	Fixing	4b	loop	in	EEKS	and	attempted	allelic	exchange	in	
MC1061	pKD46.	(A)	Fixing	the	EEKS(5)	construct	containing	the	reading	frame	error	was	done	by	fusion	PCR.	Primers	1-4	are	“EcEca	5’	X	site	fwd”,	“3’	rev	IIb	fix”,	“5’	fwd	IIb	fix”,	and	“3’	rev	SkpEcoRI”,	respectively.	(B)	Amplification	using	primer	sets	1	&	2	and	3	&	4	of	overlapping	fragments	from	the	E.	coli	recombination	site	(X	site)	to	the	
skp	gene.	Overlapping	sequences	covering	the	4b	epitope	facilitated	gene	fusion	while	also	 repairing	 the	 frame	shift	mutation.	 (C)	Amplification	of	 the	EEKS(5)	created	by	fusion	PCR	over	a	range	of	annealing	temperatures.	(D)	Screening	for	successful	 recombinations	 with	 templates:	 (-),	 MC1061	 cells;	 (+),	 pUC19-EEKS(5);	24,	41,	42,	and	48	are	selected	clones	that	were	screened	with	all	being	negative	for	recombination.	M	=	Hyperladder	1kb	(Bioline,UK)	
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Altogether,	this	demonstrates	that	the	kanamycin	resistance	gene,	and	therefore	the	 β-barrel	 from	 P.	 atrosepticum,	 did	 not	 transfer	 to	 bacterial	 genomic	 DNA	during	any	of	the	attempts.			
4.3	Subcloning	full	length	BamA	in	pUC19		Up	 to	 this	point,	most	of	 the	genetic	manipulation	work	on	BamA	has	 focussed	exclusively	on	 the	β-barrel	domain	and	has	 ignored	 the	amino	 terminus	of	 the	protein	including	the	POTRA	domains	located	within	the	periplasmic	space.	Any	complementation	assay	or	in	vitro	work	would	require	the	full	length	chimaeric	BamA	 (FLbamA)	 to	 be	 expressed.	 The	 EEKS	 constructs	 used	 so	 far	 did	 not	include	the	first	1232	bases	of	the	BamA	gene,	so	the	full-length	chimaeric	gene	needed	to	be	cloned.	Figure	4.3.1	shows	the	strategy	used	to	achieve	this,	Bam0	gDNA	was	extracted	using	the	ISOLATE	II	Genomic	DNA	Kit	(Bioline,	UK)	and	the	POTRA	domains	of	 the	chimaeric	BamA	gene	was	amplified	 from	this	 template	using	 primers	 “SM_BamA_for”	 and	 ”EcEca	 5’	 X	 site	 rev”.	 The	 β-barrel	 of	 BamA	was	amplified	from	the	“fixed”	pUE5	plasmid	using	primers	“EcEca	5’	X	site	fwd”	and	“3’	rev	loop	Eca”.	These	two	fragments	were	then	fused	together	by	PCR	with	the	recombination	site	(X	site)	on	each	fragment	acting	as	primer	for	the	other	fragment	(Fig.	4.3.1A).			This	 FLbam5	 construct	 was	 cloned	 into	 pCR-Blunt	 (Invitrogen,	 UK)	 following	manufacturer’s	 instructions	and	 the	construction	confirmed	by	PCR	and	EcoR	I	restriction	 endonuclease	 digestion	 mapping	 (Fig.	 4.3.1B).	 The	 plasmid,	 pCR-Blunt,	 encodes	EcoR	 I	 restriction	 sites	 flanking	both	 sides	of	 the	PCR	 fragment	
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insertion	site	within	its	MCS.	The	EcoR	I	released	fragment	was	gel	purified	and	subcloned	 into	 an	 empty	 pUC19	 vector,	 which	 had	 been	 digested	 and	 treated	with	 Antarctic	 phosphatase	 (NEB,	 UK).	 The	 ligation	 reaction	 had	 an	 insert	 to	vector	ratio	of	2:1	and	the	ligation	reaction	was	left	at	4°C	overnight.	The	ligation	reaction,	 2.5	 µL,	 was	 transformed	 into	 Top10	 cells	 using	 heat	 shock	 and	 the	mixture	was	plated	onto	LB	ampicillin	plates	spread	with	IPTG	and	X-gal.	All	63	colonies	from	the	first	attempt	did	not	contain	inserts	and	were	most	likely	just	vector	 re-ligations	 (Fig	 4.3.2).	 From	 the	 76	 picked	 colonies	 on	 the	 second	attempt,	 48	 of	 these	 were	 screened	 using	 M13	 primers.	 A	 prominent	 band	 at	around	1	kb	appeared	in	all	lanes,	including	the	negative	template	control	(data	not	 shown).	 A	 subset	 of	 6	 samples	 showed	 bands	 elsewhere	 so	 these	 were	screened	 again	 with	 fresh	 PCR	 grade	 water	 and	 freshly	 diluted	 M13	 primers.	Only	 one	 sample	 showed	 a	 band	 at	~2400	 bp	 using	 both	 sets	 of	 primers	 (Fig.	4.3.1C).	 This	 sample	was	 sequenced	 (GATC,	 UK)	 and	 it	was	 shown	 to	 have	 no	mutations	 and	 was	 cloned	 in	 matching	 orientation	 to	 the	 lacZα	 and	 vector	promoter.	The	pUC19-FLbam5	plasmid	was	heat	shock	transformed	into	Bam0,	which	was	subjected	to	the	same	infection	assay	as	described	in	section	3.4.	The	plasmid	did	not	restore	an	infection	phenotype	onto	Bam0.			
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Figure	4.3.1:	Creation	of	pUC19-FLbam5.		(A)	A	combination	of	polymerase	and	PCR	conditions	was	found	which	allowed	the	gene	fusion	of	the	NTD	and	CTD	to	produce	a	full	length	Bam5	(FLbam5).	(B)	FLbam5	 was	 cloned	 into	 pCR-Blunt	 following	 the	 manufacturer’s	 instructions	(Invitrogen,	UK).	(C)	Screening	of	colonies	transformed	with	FLbam5	subcloned	into	pUC19	revealed	only	1	successful	ligation.	M	=	Hyperladder	1kb	(Bioline,UK)		
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Figure	4.3.2:	Screening	of	the	first	attempt	at	subcloning	FLbam5	into	EcoR	
I-	digested	pUC19.		All	63	colonies	picked	and	screened	using	M13	primers	for	the	first	screening.	No	bands	at	~2.5	kb	(marked	by	arrows:	2.4	kb	gene	+	100	bp	in	flanking	regions	up	to	the	M13	primer	binding	sites)	demonstrates	there	was	not	a	successful	clone	of	on	 this	 first	 attempt.	 (+)	=	FLbam5	cloned	 into	pCR-Blunt.	M	=	Hyperladder	1kb	(Bioline,UK).	
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It	 was	 assumed	 that	 FLbam5	 being	 cloned	 in	 the	 same	 direction	 would	 aid	expression	 and	 therefore	 facilitate	 the	 restoration	 of	 ϕ24B	 adsorption	 in	 an	infection	 assay.	 However,	 in	 both	 the	 presence	 and	 absence	 of	 IPTG	 in	 the	medium,	 there	was	no	 restoration	of	 the	phage	 adsorption.	This	 is	 contrary	 to	the	 pUC19-ϕR1D	 plasmid,	 which	 contains	 the	 E.	 coli	 BamA	 homologue,	 which	does	 restore	 adsorption	 (Fig.	 3.4.1).	 The	 vector	 promoter	 for	 pUC19-ϕR1D	 is	oriented	 in	 the	 opposite	 direction	 to	 the	 BamA	 insert,	 which	 expresses	 BamA	without	 IPTG	 induction	 (Sergeant,	 1998;	 Smith	 et	 al.,	 2007).	 It	 was	 not	determined	 whether	 any	 mRNA	 of	 the	 Bam5	 gene	 was	 transcribed	 from	 this	construct	 so	 a	 definitive	 conclusion	 on	 transcription	 and/or	 expression	 levels	cannot	be	made	at	this	time.		
4.4	Cloning	FLbam5	into	an	expression	vector		While	it	is	concerning	that	pUC19-FLbam5	(pUF5)	did	not	restore	infection,	the	plasmid	 pUC19-ϕR1D	 created	 by	 Sergeant	 (1998)	 did	 restore	 infection	 (Fig	3.4.1).	Given	 that	 the	primary	protein	 structures	of	 the	 intended	products	of	2	constructs	are	functionally	identical,	the	more	likely	conclusion	is	that	there	is	an	issue	with	expression	of	the	Bam5	construct	from	the	lac	promoter	of	the	pUF5	plasmid,	as	opposed	to	the	FLbam5	being	incapable	of	reintroducing	adsorption	support.			
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4.4.1	Altering	the	expression	system		In	order	to	determine	whether	the	expression	system	was	the	cause	of	the	lack	of	adsorption	 support	 by	 Bam5,	 there	were	 two	modifications	 to	 the	 vector	 that	could	be	made.	One	option	included	the	use	of	an	alternative	expression	system.	Previously,	BamA	was	expressed	 in	pUC19	 (Sergeant,	1998;	Smith	et	al.,	 2007)	and	overexpressed	 in	pQE-32	 (Smith	et	al.,	 2007).	Over	expression	of	BamA	 in	pQE-32	 required	 the	 presence	 of	 the	 pRep4	 plasmid,	 which	 constitutively	expresses	 the	 lacI	 repressor	 to	 prevent	 leaky	 expression	 from	 IPTG-inducible	promoters,	 as	 even	 low-level	 expression	 of	 BamA	 beyond	 that	 normally	produced	 by	 the	 endogenous	 bamA	 gene	 was	 lethal	 and	 prevented	 successful	cloning	(Smith	et	al.,	2007).	The	pBAD	myc-His	C	plasmid	was	chosen	as	a	vector	for	potential	isogenic	BamA	expression	because	inserts	are	controlled	under	the	araC	 promoter,	 which	 is	 completely	 silent	 until	 expression	 is	 induced	 by	 L-arabinose	(Miyada	et	al.,	1984).	This	will	ensure	that	BamA	expression	is	turned	off	and	will	not	hinder	the	cloning	process.	When	cloning	into	pBAD	myc	His	C,	inserts	are	routinely	designed	to	be	cloned	in	using	restriction	digests	of	Nco	I	at	the	5’	end	(using	the	start	codon	in	the	recognition	sequence:	CCATGG)	to	Sal	I	at	the	3’	end,	which	lines	up	the	reading	frame	to	omit	the	myc	tag	and	only	adds	the	His-tag	to	the	C-terminal	domain	(CTD)	of	the	protein.	This	strategy	was	used	here.		The	other	option	would	be	to	include	the	native	promoter	region	of	BamA	in	the	insert	 so	 that	 Bam5	 would	 be	 under	 the	 influence	 of	 “normal”	 expression	patterns	as	it	was	in	pUC19-ϕR1D.	There	is	experimental	evidence	(transcription	
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initiation	 mapping)	 for	 two	 separate	 BamA	 promoters	 (Salgado	 et	 al.,	 2013),	which	are	both	under	the	control	of	the	σE	regulon:	the	BamAp	promoter	begins	107	bp	upstream	of	the	start	codon	and	controls	the	expression	of	BamA	alone	(Dartigalongue	et	al.,	2001b),	while	BamAp2	is	902	bp	from	the	start	codon	and	promotes	 the	 operon	 containing	 the	 following	 genes:	 BamA-skp-lpxD-fabZ-lpxAB-rnhB-dnaE	(Rhodius	et	al.,	2006)	(Fig.	4.4.1.1A).			Constructs	 for	 cloning	 BamA	 into	 pBAD	were	 designed	 to	 use	 either	 the	 araC	promoter	 in	 the	vector	or	 the	BamAp2	(which	would	also	 include	BamAp)	that	would	 mimic	 native	 expression	 of	 BamA	 (Fig.	 4.4.1B).	 It	 was	 assumed	 that	expression	of	BamA	under	native	conditions	would	be	non-lethal	to	any	host	cell	as	 it	would	be	 regulated	by	 the	 standard	 trans	acting	 soluble	 regulators.	Up	 to	this	 point,	 the	 chimaeric	 BamA	 clones	 have	 not	 included	 any	 native	 promoter	regions.	 The	 Bam0	 strain	 was	 created	 by	 allelic	 exchange	 of	 EEKS(0)	 and	MC1061	 genomic	DNA	 (gDNA).	 Therefore,	 gDNA	 from	 this	 strain	was	 the	 only	source	 of	 a	 chimaeric	 BamA	with	 the	 BamAp2	 promoter	 located	 upstream,	 so	this	strain	was	used	as	the	template	for	the	insert.	The	E.	coli	epitopes	could	be	introduced	afterwards	by	 substituting	 the	Xcm	 I	 to	Sty	 I	 fragment	 (sites	 in	Fig.	3.2.2)	by	restriction	digestion	for	the	Bam5	fragment	in	a	single	extra	step	once	the	full	sequence	of	promoter	and	Bam0	gene	had	been	cloned	into	a	plasmid.			Attempts	 to	 clone	 the	 amplified	 insert	 were	 made	 using	 five	 different	polymerases.	Screening	colonies	repeatedly	failed	to	identify	plasmid-containing	colonies	when	using	the	Zero	Blunt™	PCR	cloning	kit	(Invitrogen,	UK)	with	blunt-ended	 PCR	 products	 generated	 using	 Q5,	 Vent	 (both	 NEB,	 UK)	 or	 Phusion	
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Figure	4.4.1.1:	Promoters	of	the	σE	regulon,	which	promotes	BamA,	in	E.	
coli.		(A)	 Gene	 sequence	 in	 the	 Bam0	 strain.	 The	 numbered	 promoters	 control	 the	following	 genes/operons:	 (1)	 BamAp2:	 BamA-skp-lpxD-fabZ-lpxAB-rnhB-dnaE.	(2)	 BamAp:	 BamA	 only.	 (3)	 hlpAp:	 skp-lpxD-fabZ-lpxA.	 (4)	 lpxDp:	 lpxD.	Promoters	were	found	using	RegulonDB	(Gama-Castro	et	al.,	2016).	(B)	The	plan	involved	amplifying	and	cloning	two	version	of	Bam0	into	pBAD	myc	His	C.	One	insert	would	be	under	control	of	 the	araC	promoter	 (left)	and	 the	other	would	include	the	native	BamAp2	promoter	(right).	
or	
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(Thermo	 fisher,	UK)	polymerases.	The	same	 lack	of	colonies	resulted	when	 the	TA	Cloning™	Kit	(Invitrogen,	UK)	using	BIO-X-ACT	(long)	and	Taq	(both	Bioline,	UK)	polymerases	were	used,	which	led	to	trying	an	alternative	cloning	strategy.		
4.4.2	Cloning	directly	by	PCR		This	final	strategy	used	to	clone	FLbam5	into	the	pBAD	expression	system	was	to	use	 PCR	 primers	 designed	 to	 amplify	 the	 insert	 directly	 into	 pBAD	 through	 a	further	PCR	amplification.	This	was	achieved	by	using	primers	for	the	insert	that	have	 extensions	 on	 their	 5’	 ends	 that	 complement	 the	 vector.	 Thereby,	 after	amplification,	the	insert	contains	vector	sequence	(green	and	red	in	Fig.	4.4.2.1A)	that	act	as	primers	when	the	insert	and	vector	are	mixed	for	a	second	PCR	(Fig.	4.4.2.1B).	 The	 extension	 step	 will	 amplify	 the	 entire	 backbone	 to	 generate	 a	nicked	plasmid	 that	 is	 stable	 enough	 to	 be	 transformed	without	 needing	 to	 be	ligated.	 The	 empty	 vectors	 used	 as	 templates	 in	 the	 second	 PCR	 must	 be	destroyed	by	Dpn	I	digestion	(destroys	methylated	sequences,	i.e.	DNA	that	was	synthesised	 in	 situ	 is	 methylated	 while	 DNA	 synthesised	 in	 vitro	 is	 not	methylated)	before	transformation	to	ensure	that	any	colonies	contain	the	insert	(Fig	4.4.2.1C-D).		There	was	still	an	effort	to	clone	BamA	with	both	the	native	and	araC	promoters.	This	 required	 two	different	 forward	primers,	 (“NcoI	BamA	over”	and	 “BamAp2	over”)	with	 the	same	reverse	primer,	 “SalI	BamA	over”,	again,	using	Bam0	as	a	template	 for	 the	 initial	 amplification	 of	 BamA	 with	 pBAD	 vector	 extensions.	These	 reactions	 were	 transformed	 by	 heat	 shock	 into	 Top10	 cells,	 and	 the
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Figure	4.4.2.1:	Cloning	inserts	via	overlap	extension	PCR.		(A)	 Primers	 with	 vector-specific	 extensions	 are	 used	 to	 amplify	 the	 insert	resulting	 products	 are	 Bam0	 at	 2.4	 kb	 and	 Bam0p2	 at	 3.4	 kb	 (B)	 in	 a	 second	reaction,	 the	 insert	 and	vector	are	mixed	 so	 that	 the	 insert	 acts	 as	 a	primer	 to	extend	 around	 the	 vector	 backbone	 to	 produce	 a	 nicked	 plasmid	 (C)	 empty	vector	is	destroyed	by	Dpn	I	so	that	only	clones	get	transformed.	(D)	Plating	the	transformation	 on	 selective	 medium	 allows	 successful	 clones	 to	 produce	colonies.	M	 =	 HyperLadder	 1kb	 (Bioline,	 UK).	 Image	 adapted	 from	 (Bryksin	 &	Matsumura,	2010)		
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desired	 constructs	 were	 selected	 by	 spreading	 the	 transformation	 mix	 onto	selective	 plates.	 After	 overnight	 incubation	 at	 37°C,	 the	 results	 continued	with	the	 theme	 of	 no	 colonies.	 There	 were	 still	 no	 colonies	 even	 after	 36	 hours	 at	37°C.	Due	to	time	constraints	this	was	only	attempted	once.			
4.5	Molecular	tools	using	the	ϕ24B	tail	spike	protein		Work	so	far	has	described	attempts	to	gather	more	information	about	BamA	and	how	 altering	 the	 host	 side	 of	 the	 interaction	 leads	 to	 changes	 in	 support	 for	adsorption	and	infection.	On	the	phage	side	of	the	interaction	we	also	need	more	information	on	the	tail	as	this	is	the	structure	that	recognises	the	bacterial	host	and	mediates	adsorption.	Currently	all	 information	on	 the	phage	 tail	and	other	structural	genes	are	very	limited.			The	 ϕ24B	 particle	 is	 categorised	 as	 a	 member	 of	 the	 podoviridae,	 phages	characterised	 by	 a	 very	 short	 tail	 (~10	 nm	 in	 this	 case),	 and	 so	 is	 a	 relatively	small	phage.	Smaller	phages	generally	form	larger	plaques,	as	the	particle	is	able	to	diffuse	through	the	agar	more	readily.	However,	plaque	size	for	ϕ24B	is	very	small,	which	is	at	odds	with	this	conventional	wisdom	regarding	smaller	phages.	A	potential	explanation	for	this	is	that	the	interaction	between	the	phage	tail	and	BamA	is	stronger	than	typical	phage-receptor	interactions.	In	combination	with	the	presence	of	BamA	(often	upregulated	in	conditions	that	induce	the	lytic	cycle	(Veses-Garcia	et	al.,	2015)),	newly	formed	phages	bursting	from	a	host	cell	may	associate	with	BamA	molecules	in	the	debris	from	that	host	cell	and	therefore	be	
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unable	to	infect	a	new	cell	and	increase	the	area	of	infection	thereby	not	allowing	the	plaque	size	to	increase	at	the	faster	rate.			It	 is	established	 that	 the	presence	of	 tail	 associated	 fibres	 increases	 the	rate	of	adsorption	 (Hendrix	 &	 Duda,	 1992)	 as	 they	 allow	 an	 extra	 step	 in	 host	recognition	by	the	phage	particle,	which	tethers	the	phage	to	the	cell,	while	the	tail/base	plate	finds	the	specific	adsorption	target	(Rakhuba	et	al.,	2010).	Despite	not	 possessing	 any	 such	 tail	 fibres,	 ϕ24B	 adsorption	 appears	 to	 occur	 more	quickly	 than	 expected	with	 just	 a	 tail	 spike	 protein.	Once	 again,	ϕ24B	 displays	evidence	of	a	strong	association	between	the	tail	and	BamA.			As	there	are	very	few	structural	genes	in	the	ϕ24B	genome	(Fig.	4.5.1)	and	none	of	 these	 genes	 seem	 large	 enough	 to	 provide	 enough	 of	 a	 surface	 to	 facilitate	interaction,	 it	 is	 predicted	 that	 only	 the	 tail	 spike	 protein	 is	 involved	 in	 host	recognition.	There	 are	no	published	data	 regarding	 the	 structure	of	 this	 phage	tail,	 despite	 its	 prevalence	 in	 Stx	 phages	 and	 so	 information	 is	 limited	 to	 an	inspection	 under	 the	 transmission	 electron	 microscope	 which	 revealed	 a	 tail	structure	 of	 ~10	 nm	 x	 10	 nm	 and	 a	 bioinformatic	 approach	 to	 estimating	 3D	structure	by	Prof.	Olga	Mayans	(personal	communication,	2014),	which	revealed	a	collagen-like	triple	helix	with	a	globular	domain	on	each	end.			
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Figure	4.5.1:	representation	of	the	ϕ24B	genome	(57677	bp).	Genes	encoded	on	 the	 forward	 strand	are	on	 the	outer	 track	and	genes	on	 the	reverse	 strand	 are	 on	 the	 inner	 track.	 Genes	 typical	 of	 lambdoid	 phages	 are	coloured	and	labelled	in	green,	the	chloramphenicol	resistance	gene	(CAT)	is	in	red,	and	those	structural	genes	suspected	to	form	the	tail	structure	are	dark	blue.		All	other	genes	are	 in	 light	blue.	Diagram	created	using	Artemis	(Rutherford	et	
al.,	 2000)	 and	 DNAplotter	 (Carver	 et	 al.,	 2009)	 with	 the	 genome	 sequence	published	by	Smith	et	al..	(2012).	
ϕ24B	
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Attempts	to	 improve	on	this	 information	with	the	use	of	negative	staining	with	uranyl	acetate	under	a	Transmission	Electron	Microscope	(TEM)	were	of	a	 low	resolution	 and	 were	 therefore	 unable	 to	 clearly	 see	 any	 tail	 structures	 (Fig.	4.5.2A-C).	These	images	were	not	an	improvement	on	those	previously	collected	(Allison	et	al.,	2003).	The	tail	has	been	visualised	more	clearly	recently	in	the	lab	of	 Andrey	 Letarov	 using	 cryo-EM	 (Fig.	 4.5.2D-E),	 but	 images	 have	 not	 been	collated	and	analysed	yet.	Given	the	small	size	and	limited	decoration	of	the	tail,	no	further	insight	on	adsorption	can	been	drawn	before	these	data	are	analysed.		
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Figure	4.5.2:	Negatively	stained	EM	images	of	ϕ24B		(A)	TEM	image	of	a	cluster	of	ϕ24B	stained	with	4%	(w/v)	uranyl	acetate	(B-C)	identical	images	with	measurements	overlaid	on	(C)	to	show	key	dimensions	of	the	 phage	 capsid	 and	 tail.	 (D-E)	 Cryo-electron	micrograph	 images	 donated	 by	Andrey	 Letarov	 (Winogradsky	 Institute	 of	 Microbiology)	 of	 negatively	 stained	frozen	ϕ24B	preparations	ready	for	cryo	EM	analysis.	Scale	bars	are	(A)	200	nm	and	(B-E)	50	nm.		
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4.5.1	Creation	of	a	GFP-TSP	fusion	gene		A	 useful	 molecular	 tool	 to	 investigate	 adsorption	 would	 be	 a	 GFP-tagged	 tail	spike	 protein	 (TSP).	 This	 would	 allow	 visualisation	 of	 interactions	 between	BamA	and	TSP	under	the	fluorescent	microscope.	As	such,	it	would	also	provide	evidence	as	to	whether	the	tail	spike	is	able	to	bind	to	the	host	cell	unassisted	by	any	 as	 yet	 unidentified	 accessory	 proteins.	 The	 fusion	 of	 two	 soluble	 proteins	usually	requires	a	linker	region	to	allow	space	between	the	proteins	for	efficient	folding	 (Klein	 et	 al.,	 2014)	 and	 to	 prevent	 the	 inadvertent	 blockage	 of	 any	functions	 {Chen:2013fd}.	 As	 such,	 a	 short	 flexible	 alanine-glycine	 bridge	(AGAGAG)	 was	 designed	 into	 this	 gene	 fusion	 to	 be	 introduced	 via	 primer	extensions	between	GFP	and	TSP.		TSP	 proved	 to	 be	 a	 troublesome	 amplification	 target.	 There	 are	 sequence	repeats,	 which	 is	 common	 for	 tail	 spike	 genes	 that	 produce	 a	 collagen-like	tertiary	structure.	These	repeats	are	likely	to	be	the	reason	for	every	attempted	PCR	 amplification	 resulting	 in	 at	 least	 a	 partial	 smear	 (see	 Fig.	 4.5.1.1A	 for	 an	example).	 There	 is	 evidence	 to	 suggest	 that	 amplification	 of	 TSP	 could	 be	stabilised	by	magnesium	concentration	(Fig	4.5.1.1B).	However,	this	stabilisation	effect	disappears	when	attempting	to	fuse	eGFP	upstream	of	TSP	(Fig.	4.5.1.1C).	Altering	annealing	temperatures	(35°C	to	50	°C),	DMSO	concentration	(0%	(v/v)	to	5%(v/v)),	and	 	added	Mg2+	volume	(0	µL	to	5	µL)	yielded	the	same	smeared	products.	Ultimately,	the	ratios	of	the	GFP	and	TSP	fragments	and	only	running	25	cycles	instead	of	30	were	the	only	factors	which	helped	to	generate	a	putative	fusion	product	with	minimal	smearing	(Fig.	4.5.1.1D).	A	GFP	to	TSP	ratio	of	2:7	
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was	the	highest	that	could	be	achieved	with	the	yield	of	TSP	PCR	product	on	that	occasion	 (only	7	ng	µL-1).	 This	 reaction	produced	 a	band	 at	 around	2.7	 kb,	 the	expected	size	of	a	GFP-TSP	gene	fusion.	The	remainder	of	this	PCR	reaction	was	separated	 on	 another	 agarose	 gel	 but	 the	~2.7	 kb	 band	was	 not	 visible	 under	blue	 light.	 The	 presence	 of	 the	 band	 was	 confirmed	 using	 UV	 light	 but	 the	potential	 damage	 to	 the	 DNA	 caused	 by	 this	 imaging	 led	 to	 abandoning	 this	sample	and	cloning	was	not	attempted.	Instead,	the	~2.7	kb	band	was	generated	again	 using	 the	 same	 GFP	 and	 TSP	 PCR	 products	 as	 templates	 and	 extracted	using	the	PCR	and	Gel	kit	(Bioline,	UK).	The	DNA	from	this	extraction	produced	a	low	yield	(3.3	ng	µL-1),	which	did	not	successfully	clone	using	the	pCR-blunt	kit	(Invitrogen,	UK).	The	putative	gene	fusion	PCR	product	was	not	observed	again	despite	 multiple	 attempts	 using	 the	 same	 conditions.	 The	 only	 difference	between	 this	 and	 the	 reactions	 that	 did	 produce	 the	 2.7	 kb	 band	 was	 that	 a	different	TSP	PCR	fragment	was	used	as	a	template.	Further	re-amplifications	of	the	 TSP	 fragment	 did	 not	 facilitate	 the	 appearance	 of	 a	 band	 for	 the	 TSP-GFP	fusion.		
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Figure	4.5.1.1:	Amplifying	tail	spike	protein	(TSP)	by	PCR.	(A)	Initial	attempts	at	amplifying	TSP	by	PCR	led	to	smeared	products	(reaction	was	set	up	in	triplicate)	(B)	Increasing	the	Mg2+	concentration	in	the	reaction	by	adding	0	µL,	2	µL	or	5	µL	MgSO4	to	the	reaction	mixture	produced	a	band	at	2	kb.	(C)	Temperature	gradient	of	the	fusion	reaction	in	the	presence	and	absence	of	DMSO	using	the	same	additional	2	µL	of	MgSO4	concentration	as	used	in	(B).	(D)	Increasing	the	ratios	of	TSP	to	GFP	molecules	in	a	reaction	by	using	75	ng	of	GFP	loaded	 with	 17.5	 ng,	 35	 ng,	 35	 ng,	 and	 52.5	 ng	 of	 TSP	 respectively.	 M	 =	HyperLadder	1	kb	(Bioline,	UK).		
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The	 smearing	 problem	 with	 TSP	 has	 been	 observed	 in	 the	 lab	 previously,	although	a	cause	for	it	had	not	been	explored	experimentally.	Upon	checking	the	TSP	 gene	 for	 regions	 of	 similarity/identity,	 there	 is	 a	 45	 bp	 tandem	 repeat	starting	at	1570	bp	and	1615	bp	in	the	TSP	gene	(found	using	a	tandem	repeats	finder	(Benson,	1999)),	which		could	contribute	to	the	appearance	of	the	smears.	These	 sequences	 of	 DNA	 could	 re-anneal	 to	 each	 other	 incorrectly	 and	incrementally	increase	or	decrease	the	size	of	PCR	products	by	~45	bp	at	a	time.			A	further	explanation	was	raised	when	a	sample	was	taken	immediately	after	the	primers	 were	 added	 at	 the	 mid-point	 of	 the	 fusion	 reaction	 and	 run	 on	 an	agarose	gel	alongside	the	final	PCR	product.	Comparison	of	the	two	stages	of	the	same	 reaction	 revealed	 that	 the	 smearing	 only	 seemed	 to	 occur	 during	 the	second	 stage	of	 the	 fusion	 reaction	 (Fig.	 4.5.1.2),	 indicating	 the	 addition	of	 the	primers	as	a	potential	cause	as	 they	are	 the	only	component	absent	during	 the	first	stage	of	15	cycles.				
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Figure	4.5.1.2:	Comparison	of	DNA	product	mid-	and	post-primer	addition	
in	a	fusion	PCR	amplification.	Samples	(5	µL)	of	a	50	µL	PCR	amplification	were	taken	after	the	primers	were	added	 at	 15	 cycles	 (left)	 and	 from	 the	 final	 PCR	product	 (right).	 DNA	 after	 15	cycles	still	shows	as	bands	(bands	at	sizes	that	are	not	labelled	are	unidentified	products),	yet	the	band	for	a	fused	GFP-TSP	was	unable	to	be	reproduced.	All	of	the	DNA	appears	as	a	large	smear	after	the	second	stage	and	a	total	of	35	cycles.	M	=	HyperLadder	1	kb	(Bioline,	UK)		
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4.5.2	Fusing	GFP	and	TSP	by	introducing	a	Not	I	site		As	 attempts	 to	 reform	 the	 GFP-TSP	 band	 by	 PCR	 only	 yielded	 smears,	 it	 was	decided	that	the	second	PCR	step	of	the	fusion	strategy	was	too	problematic	to	efficiently	 create	 a	GFP-TSP	gene	 fusion.	As	 the	 initial	TSP	PCR	was	 capable	of	producing	 a	 band,	 an	 alternative	 strategy	 was	 developed	 that	 added	 a	 Not	 I	recognition	site	to	the	alanine-glycine	bridge	between	GFP	and	TSP	during	that	initial	 fragment	 creation.	 This	was	 done	 using	 primers	 that	 substituted	 2	 base	pairs	 of	 the	 bridge	 linker	 changing	 one	 of	 the	 glycine	 residues	 to	 alanine	 (Fig.	4.5.2.1A).	After	the	PCR	products	have	been	digested	using	Not	I	the	GFP	and	TSP	genes	can	be	joined	together	by	a	DNA	ligase-mediated	reaction.			The	resulting	gene	 fusion	would	encode	 the	GFP-tagged	TSP	protein.	However,	the	Not	 I-TSP	 fragment	 could	 not	 be	 generated	 as	 the	 reaction	 only	 produced	smears	 under	 a	 range	 of	 temperatures	 and	 concentrations	 of	 DMSO	 (Fig.	4.5.2.1B-C).	GFP	also	appears	to	run	at	1.3	kb	which	is	too	high.	The	reason	for	this	was	not	pursued.	Producing	the	GFP-Not	I	and	Not	I-TSP	fragments	was	only	attempted	 twice	 at	 this	 range	 of	 temperatures	 (41°C	 to	 55°C)	 and	 DMSO	concentrations	(0%	(v/v)	-	10%	(v/v))	before	focus	was	shifted	to	other	avenues	of	research.			
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Figure	4.5.2.1:	Attempting	to	create	fragments	for	fusion	using	Not	I.	(A)	The	DNA	and	encoded	residues	of	 the	bridge	 linker	and	flanking	regions	of	the	planned	GFP-TSP	construct	with	the	bases	and	residue	(lower	case	and	bold)	to	be	changed	to	generate	a	Not	I	restriction	site	(underlined).	(B)	Temperature	gradients	 for	 both	 overlapping	 fragments	 with	 TSP	 amplifications	 producing	smears.	 (C)	 Increasing	 DMSO	 concentration	 does	 not	 facilitate	 the	 creation	 of	stable	 TSP	 bands	 rather	 than	 smears	 in	 the	 amplification	 reaction.	 M	 =	Hyperladder	1	kb	(Bioline,UK)	.
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4.6	Discussion	of	results		While	the	decision	to	go	ahead	with	the	fluorescence	microscopy	assay	had	been	made,	 the	 creation	 of	 molecular	 tools	 for	 the	 other	 assays	 considered	 in	 this	thesis	are	still	important	for	future	work.			The	 creation	 of	 the	 MC1061-bam5	 strain	 was	 attempted	 using	 the	 same	recombineering	method	used	to	create	Bam0,	yet	 it	was	unsuccessful.	Also,	 the	complementation	of	the	Bam0	using	the	pUC19-FLbam5	plasmid	(pUF5)	did	not	restore	 phage	 adsorption.	 Both	 of	 these	 results	 do	 not	 support	 the	 hypothesis	that	substituting	E.	coli	extracellular	epitopes	into	the	β-barrel	of	P.	atrosepticum	BamA	would	restore	phage	adsorption.	The	hypothesis	is	based	on	the	fact	that	the	amino	acid	sequence	of	the	P.	atrosepticum	β-barrel	would	then	be	identical	to	 the	E.	coli	β-barrel	domain.	Together,	 the	 failed	production	of	bam5	and	 the	lack	 of	 complementation	 with	 FLbam5	 suggest	 that	 there	 is	 a	 potentially	unforeseen	 issue	 with	 regards	 to,	 for	 example,	 protein	 expression	 or	 correct	folding.	 It	 is	 likely	 that	 the	 issue	 lies	 in	an	area	 that	prevents	 the	protein	 from	being	 expressed	 appropriately	 from	 these	 constructs	 because	 there	 is	 no	theoretical	 reason	 for	all	E.	coli	 extracellular	epitope	substitutions	 to	 cause	 the	BamA	protein	to	fail	to	function,	especially	considering	that	MC1061	underwent	the	allelic	exchange	of	EEKS(0)	to	create	Bam0	with	no	observable	detrimental	effects.	 It	may	be	 that	 the	protein	 is	being	expressed	and	 folding	correctly	and	another	residue	of	BamA	is	required	to	maintain	the	essential	protein	insertion	function,	as	there	will	be	some	minor	differences	in	primary	structure	between	the	homologues	(Fig.	4.6.1).	
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Figure	4.6.1:	Sequence	alignment	of	BamA	proteins		Sequence	 alignment	 of	 BamA	 homologues	 from	 E.	 coli	 and	 P.	 atrosepticum	compared	to	the	Chimaeric	BamA.	Identical	residues	are	shaded	in	dark	blue	and	residues	that	differ	are	not	shaded.	Loops	are	coloured	as	follows:	4a	(blue),	4b	(green),	 6	 ( ),	 7a	 (red)	 and	 7b	 (purple).	 Alignment	was	 performed	 using	MUSCLE	and	visualised	in	Jalview.		
	 		
	 	
132	
When	deciding	where	to	go	next	with	the	native	promoters	(section	4.4),	an	RNA	extraction	should	have	been	done	to	determine	if	any	FLbam5	transcripts	were	present.	 However,	 with	 other	 tasks	 on	 the	 go,	 I	 tried	 to	 go	 ahead	 with	 a	workaround	without	dissecting	the	problem	properly	first.	The	thinking	behind	this	at	the	time	was	that	 lack	of	functional	rescue	in	the	infection	assays	meant	that	seeing	no	(or	very	low)	expression	of	Bam5	was	the	most	likely	outcome.	If	that	 were	 the	 case	 then	 FLbam5	 could	 be	 subcloned	 into	 pBAD	 to	 determine	expression	from	the	arabinose-inducible	araC	promoters	instead.	Alternatively,	if	expression	was	occurring,	but	at	 lower	levels	than	native	expression	(assuming	that	 native	 levels	 of	 expression	 would	 rescue	 the	 infection	 phenotype),	 then	there	was	no	way	to	increase	induced	expression	from	lac	promoters	beyond	the	levels	 already	 attempted.	 FLbam5	 could	 be	 subcloned	 into	 a	 dose-response	system	 i.e.	 the	 araC	 promoters	 of	 the	 pBAD	 system,	 so	 checking	 mRNA	production	levels	was	omitted	due	to	time	restrictions.	Ultimately,	FLbam5	was	not	cloned	into	the	pBAD	myc	His	C	plasmid	so	whether	this	system	would	have	circumvented	 the	 issue	 or	 not	 cannot	 be	 concluded	 at	 this	 time.	 The	 pKT230	plasmid	may	be	a	better	expression	vector	to	try	to	being	a	low	copy	number	and	having	been	successfully	used	in	the	past	(Smith	et	al.,	2007).			Further	 characterisation	 of	 the	 genes	 associated	with	 the	 tail	 structure	 is	 still	required.	 Ammonium	molybdate	 has	 been	 used	 as	 a	 gentler	 contrast	 stain	 for	electron	microscopy	to	highlight	fine	strucutral	details	in	some	phages	(Pickard	
et	al.,	2010).	This	may	have	allowed	a	higher	resolution	 image	 to	be	generated	when	 using	 the	 TEM	 on	 our	 non-frozen	 samples.	 Whichever	 stain	 Andrey	Letarov	is	using	(unknown	at	time	of	writing)	is	clearly	working	very	well	to	give	
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superior	detail	on	single	images.	The	result	of	averaging	all	the	images	from	this	cryo	EM	work	will	be	very	interesting	to	see.			Due	 to	 the	difficulties	 in	amplifying	clean	PCR	products	 containing	TSP	 further	information	 regarding	 the	ϕ24B	 tail	 remains	 elusive.	 The	 cloning	 failures	with	TSP	 derived	 constructs	 could	 be	 rooted	 in	 the	 smearing	 effect.	 If	 there	 is	mismatched	annealing	of	the	DNA	strands	there	would	be	3’	overhangs	for	which	the	complement	strand	could	not	be	synthesised.	Consequently,	 the	compatible	ends	required	 for	either	of	 the	pCR	Blunt	and	TA	cloning	kits	(both	 Invitrogen,	UK)	 would	 not	 be	 present	 and	 the	 cloning	 would	 always	 fail,	 resulting	 in	 the	characteristic	lack	of	colonies	for	this	chapter.		While	the	difficulty	in	developing	molecular	tools	for	other	lines	of	experimental	investigation	 were	 ultimately	 disappointing,	 a	 fluorescence	 microscopy	 assay	was	developed	in	an	effort	to	examine	ϕ24B	adsorption	and	DNA	ejection.	As	the	components	 required	 for	 beginning	 the	 development	 of	 the	 assay	 had	 already	been	made,	the	work	could	continue	without	needing	to	accommodate	any	plans	for	future	work	e.g.	other	BamA	mutants,	during	the	process.			
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Chapter	5:	Developing	a	fluorescence	assay	for	detecting	
adsorption	and	DNA	ejection	stages	of	ϕ24B	infection.		
5.1	Introduction		This	 chapter	 follows	 the	 development	 of	 a	 fluorescence	 microscopy-based	adsorption	assay	for	the	purpose	of	determining	which	E.	coli	BamA	epitopes	are	required	to	support	ϕ24B	adsorption.	All	data	acquired	during	this	study	can	be	found	 in	 Appendix	 8.2	 via	 this	 link	 to	 a	 space	 on	 the	 university	 website:	https://pcwww.liv.ac.uk/~hallison/Stuart_Thesis/index.html		
5.1.1	Assays	for	investigating	adsorption		Previous	chapters	have	explored	the	avenues	of	discovering	the	key	differences	between	 BamA	 produced	 by	 E.	 coli,	 which	 is	 capable	 of	 supporting	 phage	adsorption,	and	the	P.	atrosepticum	homologue,	which	is	resistant	to	adsorption.	This	chapter	details	the	initial	development	of	a	fluorescence-based	assay	that	is	designed	 to	 detect	 positive	 adsorption	 and/or	 infection	 phenotypes	 at	 the	resolution	 of	 a	 single	 cell,	 eliminating	 the	 need	 for	 adsorption	 assays,	 which	generate	 noisy	 data.	 The	 noisy	 data	 could	 be	 caused	 by	 a	 number	 of	 factors	including	 that	 the	 adsorption	 assay	 only	 measures	 the	 phages	 that	 failed	 to	adsorb	 and	 so	 there	 is	 a	 possibility	 that	 free	 phage	 particles	 get	 trapped	 and	pelleted	during	 the	 centrifugation	process,	decreasing	 the	phages	detected	and	increasing	 the	 perceived	 adsorption	 efficiency.	 Also,	 the	 15	minute	 incubation	
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time	to	allow	for	adsorption	to	occur	could	allow	enough	time	for	the	first	phages	to	 bind	 to	 initiate	 replication,	 increasing	 the	 number	 of	 phage	 particles	 and	thereby	decreasing	the	perceived	adsorption	efficiency.		The	 aim	of	 the	work	 detailed	 here	was	 to	 detect	 differences	 in	 the	 adsorption	and	 genome	 ejection	 phenotypes	 displayed	 by	 the	 library	 of	 mutants	 from	Chapter	 3.	 This	 assay	 should	 be	 able	 to	 corroborate	 conclusions	 from	 simple	plaque-based	 experiments	 while	 also	 providing	 a	 greater	 resolution	 of	 what	happens	 at	 the	 single	 cell	 level	 of	 binding,	 phage	 genome	 ejection	 and	 then	infection	for	various	BamA	mutants	from	the	library.				
5.2	Pilot	Study		Initially,	 a	 pilot	 study	was	 performed	 in	 order	 to	 determine	whether	 the	 cells	infected	by	ϕ24B	labelled	with	SYBR	gold	could	be	visualised	and,	if	they	could,	which	 of	 the	 available	 fluorescence	 microscopes	 (the	 Zeiss	 Axio	 Examiner	 Z1	(upright)	or	the	Zeiss	Axio	Observer	Z1	(inverted))	was	the	most	appropriate	to	use	for	answering	the	following:		
• Can	SYBR	gold	stained	phages	be	visualised	under	the	microscope?	
• Can	individual	adsorption	events	be	seen	and	how	quickly	do	they	occur	after	adding	phages?	
• Can	genome	ejection	be	visualised	and	how	long	does	that	take?		
136	
5.2.1	Materials	and	methods	used	for	data	collection	and	analysis		The	 microscopes	 used	 for	 the	 pilot	 study	 were	 the	 Zeiss	 Axio	 Observer	 Z1	(inverted)	epifluorescent	microscope	and	the	Zeiss	Axio	Examiner	Z1	(upright)	LSM	800	multiphoton	microscope.	 Images	were	captured	by	an	 iXon	Ultra	897	high	 sensitivity	 camera.	 Data	 collection	 was	 performed	 using	 the	 multi-D	acquisition	 tool	 in	 Micro-Manager	 version	 1.4.14	 with	 the	 settings	 in	 Table	5.2.1.1	and	all	data	 for	analysis	were	extracted	 from	stacked	 .tif	 files	using	FIJI	(Schindelin	et	al.,	2012)		
Table	5.2.1.1:	The	relevant	fluorescent	channels	available	during	the	pilot	
study		
Channel	 Channel	
“ID”	
Wavelengths	of	
excitation	(nm)	
Wavelengths	of	
emission	(nm)	
Exposure	
time	(ms)	Light	 DIC	 n/a	 n/a	 50	DAPI	 DAPI	 355-375	 420-470	 200	SYBR	gold	 GFP	 450-490	 500-550	 400	PI	 dsRED	 538-562	 570-640	 200			
5.2.2	Results	of	the	pilot	study		To	label	ϕ24B	particles,	10	µL	of	SYBR	gold	stain	(Thermo	Fisher	Scientific)	was	added	to	a	1	mL	sample	of	phages	(2.8	x	109	PFU	mL-1).	This	sample	was	dialysed	against	2	L	phage	growth	medium	(PGM)	using	dialysis	tubing	with	a	12	kDa	–	14	kDa	 cut	 off	 (Medicell	 International,	 UK)	 for	 2	 hours	 at	 room	 temperature	 to	remove	the	free	SYBR	gold	stain.	DM1187	cells	were	pre-infected	with	SYBR	gold	
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stained	phages	at	an	MOI	=	1.	These	cells	were	observed	using	both	the	Examiner	Z1	 (upright)	 and	 the	 Observer	 Z1	 (inverted)	 epifluorescence	 microscope	 to	compare	 the	 sample	 handling,	 data	 collection	 procedures,	 and	 image	 quality	associated	with	each	(Fig.	5.3.1).			Live	motile	cells	were	observed	tumbling	in	solution	(Fig.	5.3.1A).	A	fluorescent	cell	was	tracked	on	the	upright	microscope	(Axio	Examiner	Z1)	for	at	least	60	s	(5.3.1C)	 and	 although	 the	 sample	 had	 dried	 out	 by	 the	 time	 the	 sample	 was	observed	 on	 the	 inverted	 (Axio	 Observer	 Z1),	 fluorescent	 cells	 could	 be	 seen	trapped	within	crystal	 structures,	presumably	salt	 crystals,	 that	had	 formed	on	the	 surface	 of	 the	 slide	 (Fig.	 5.3.1B).	 All	 raw	 data	 for	 all	 imaging	 runs	 can	 be	found	in	Appendix	8.2.		
5.2.3	Conclusions	of	the	pilot	study		As	observed	(Fig.	5.3.1E)	highly	fluorescent	E.	coli	cells	were	detected,	the	pilot	was	 deemed	 to	 be	 successful.	 Additionally,	 the	 inverted	 epifluorescent	 Axio	Observer	Z1	was	determined	to	be	the	best	instrument	to	use	because	there	was	a	high	sensitivity	camera	already	attached.	There	was	no	difference	in	the	image	quality	 or	 usability	 of	 the	 software	 packages.	 In	 order	 to	 get	 enough	magnification	(2500x),	the	100x	oil-immersion	objective	was	used	in	conjunction	with	 the	 2.5x	 optovar,	 an	 optional	 additional	 lens	 that	 further	 increases	 the	magnification.		
138	
	
Figure	5.3.1:	Images	from	the	pilot	study	for	the	fluorescence-based	assay.		(A	&	C)	E.	coli	cells	tumbling	in	variable	orientations/focal	planes	and	trapped	in	crystal	formations	in	dried	out	samples,	respectively.	(B	&	D)	Duplicate	image	of	(A	&	C),	respectively,	with	cells	indicated	with	red	arrows.	(E)	Image	taken	whilst	tracking	 a	 single	 fluorescent	 cell	 under	 the	 upright	 fluorescence	 microscope.	Scale	bars	=	5	µm.		
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However,	some	issues	were	raised	during	the	imaging	process	that	needed	to	be	addressed	before	running	 further	experiments.	An	observation	during	 the	pilot	study	was	that	tumbling	bacterium	in	solution	(Fig.	5.2.1A)	could	not	be	tracked	easily	 for	 the	 intended	 40-minute	 duration	 of	 the	 experiment.	 Moreover,	successfully	tracking	a	single	motile	bacterium	in	3	dimensions	for	the	extended	timeframe	adds	the	disadvantage	of	ensuring	only	one	cell	will	be	in	focus	for	the	duration	and,	therefore,	severely	limits	potential	analysis.	To	limit	the	impact	of	tumbling	and	motility,	the	decision	was	made	to	fix	the	cells	to	the	surface	of	the	microscope	 slide	 to	 enable	 the	 viewing	 and	 analysis	 of	 multiple	 cells	simultaneously	for	the	entire	40	minutes.	Two	methods	were	explored	to	attach	the	cells	to	the	surface:	using	agar	or	poly-L-lysine.			For	 the	 agar	method,	 50	 µL	 of	 0.4%	 (w/v)	 LB	 agar	was	 dropped	 into	 concave	wells	 (volume	 =	 15	 µL)	 within	 a	 microscope	 slide	 (Cat	 No:	 N/A144,	 Academy	Science,	UK)	resting	on	a	heat	block	at	45°C.	The	heat	ensured	the	agar	did	not	set	prematurely	or	unevenly	across	the	slide.	The	application	and	setting	of	the	agar	 was	 not	 easy	 to	 replicate	 as	 some	 agar	 drops	 were	 so	 thin	 that	 they	ruptured	after	setting	and	some	even	slid	out	of	the	concave	wells.	Furthermore,	the	domed	nature	of	the	drops	meant	that	only	a	few	cells	remained	on	the	agar	and	 flattening	 the	 drop	 with	 a	 cover	 slip	 prior	 to	 setting	 led	 to	 an	 increased	likelihood	 of	 the	 agar	 rupturing.	 The	 next	 treatment,	 the	 use	 of	 poly-L	 lysine	avoided	the	use	of	agar.		Poly-L-lysine	(PLL)	treatment	of	the	glass	slides	was	based	on	a	strategy	used	for	atomic	 force	 microscopy	 (Lonergan	 et	 al.,	 2014).	 The	 treatment	 consisted	 of	
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dropping	150	µL	of	0.01%	(w/v)	PLL,	pH	7.0	 (Sigma,	UK)	onto	glass-bottomed	dishes	(Cat	No:	89125-438,	VWR,	UK)	or	microscope	slides	that	were	incubated	at	room	temperature	for	30	minutes	before	removing	the	remaining	liquid	with	a	pipette.	As	the	cells	were	successfully	attached	to	the	surface	of	the	PLL	treated	surfaces	 when	 viewed	 under	 the	 light	 microscope,	 and	 the	 treatment	 is	 more	consistent	and	easier	to	apply	than	agar,	the	PLL	treatment	was	used	for	further	experiments.			Having	 found	 a	 good	 method	 to	 immobilise	 the	 cells,	 further	 parameter	optimisation	was	undertaken.	 In	 the	 initial	pilot	 study,	 the	PGM	containing	 the	pre-infected	 cells	 was	 associated	 with	 high	 levels	 of	 what	 was	 thought	 to	 be	background	 autofluorescence,	 which	 was	 thought	 to	 be	 caused	 by	 the	 high	concentration	of	the	unbound	(or	dissociating)	SYBR	gold	stain	that	had	not	been	removed	 from	 the	 medium	 before	 imaging.	 Improving	 the	 dialysis	 step	 could	solve	both	of	these	possibilities	simultaneously.	The	removal	of	PEG	8000	would	have	been	heavily	restricted	using	the	12	kDa	-14	kDa	MWCO	membrane	as	the	pore	 size	 was	 not	 4x	 larger	 (the	 minimum	 recommendation)	 than	 the	 PEG	polymer	that	needed	to	be	removed,	which	had	an	average	molecular	weight	of	8	kDa.	 The	 pore	 size	 of	 the	 membrane	 used	 was	 increased	 to	 100	 kDa	 MWCO	(SpectraPor®	 CE	 tubing	 from	 Spectrum	 Labs,	 UK),	 which	 would	 easily	accommodate	release	of	the	both	the	PEG	8000	(average	mass	of	8	kDa)	and	the	free	SYBR	gold	while	retaining	ϕ24B	phages.	The	estimated	radius	of	a	globular	protein	 of	 100	 kDa	 (the	 MWCO	 for	 the	 dialysis	 tubing)	 is	 3.05	 nm	 (Erickson,	2009).	Since	the	ϕ24B	particle	has	a	radius	of	~25	nm,	it	would	easily	be	retained	in	this	setup.	
141	
A	practical	limitation	to	using	a	microscope	slide	and	cover	slip	was	that	phages	and	cell	 stains	 could	not	be	added	 in	a	 reliable	and	 reproducible	manner	part-way	through	an	experiment.	Glass-bottomed	dishes	(Greiner,	UK)	eliminated	this	problem	as	any	liquid	could	be	added	directly	to	the	medium	with	the	freedom	to	diffuse	 rapidly	 across	 the	 entire	 sample.	This	 allowed	phages	 to	be	 added	 into	solution	after	beginning	 to	record	 the	video	without	 losing	position	or	 focus	of	the	sample.	Propidium	 iodide	 (PI)	crosses	compromised	membranes	and	could	be	used	to	assay	for	dead	cells	after	the	assay	had	been	performed.	It	can	also	be	added	before	in	order	to	monitor	the	timing	of	cell	death.		The	issue	of	the	constant	slow	shift	in	focal	plane	away	from	the	cells	was	caused	by	 the	 slow	drying	out	 of	 the	 sample	during	 the	40-minute	 imaging	 time.	This	drying	out	was	countered	by	increasing	the	volume	of	PGM	covering	the	surface	of	 the	 glass-bottomed	 dish	 from	 100	 µL	 to	 500	 µL	 during	 the	 fluorescence	infection	assay.	This	resulted	 in	a	stable	 focal	plane	 for	much	 longer	(up	 to	2.5	hours).		
5.3	Visualising	ϕ24B	phages	under	the	microscope		
5.3.1	ϕ24B	phages	in	solution			Staining	ϕ24B	phages	with	SYBR	gold	allows	 them	to	be	seen	 in	solution.	They	move	in	and	out	of	the	focal	plane	very	quickly	so	they	appear	as	“flashes”,	which	the	software	 is	unable	 to	 track.	Figure	5.3.1.1(A-C)	shows	phages	(indicated	by	red	 arrows)	 that	 happen	 to	 be	 in	 the	 focal	 plane	 when	 snapshots	 are	 taken.	
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Figure	5.3.1.1:		The	presence	of	phages	in	solution	during	the	experiments		(A-C)	Snapshots	of	SYBR	gold	stained	phages	(indicated	by	red	arrows)	tumbling	in	solution	at	140	s,	260	s,	and	330	s,	respectively.	(D)	The	signal	produced	using	Channel	ID	“GFP”	2	hours	after	the	addition	of	phages.	The	larger	white	areas	are	bacteria	and	the	pinpricks	of	white	are	stained	phages.	Scale	bars	=	5	µm.			
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It	is	not	only	cells	that	adhere	to	PLL	treated	surfaces;	phages	also	stick.	This	can	be	seen	 in	 figure	5.3.1.1D	 taken	120	minutes	after	 the	addition	of	phages.	This	decreases	 the	 number	 of	 potential	 infective	 particles	 in	 the	 solution	 by	 an	indeterminate	proportion.	It	is	not	clear	how	comparable	this	is	to	the	reduction	in	the	number	of	phages	that	would	have	diffused	into	an	agar	preparation,	as	a	similar	 image	 was	 not	 taken	 on	 agar.	 After	 seeing	 the	 effect	 of	 the	 adhesive	surface,	 and	 after	 increasing	 the	 volume	 in	 the	 dish	 to	 500µL,	 the	 number	 of	phages	added	per	experiment	was	 increased	to	a	 final	concentration	of	2	x	105	PFU	 mL-1.	 The	 final	 MOI	 cannot	 be	 calculated	 accurately	 as	 the	 number	 of	bacteria	that	were	successfully	immobilised	cannot	be	determined.			
5.3.2	Phages	adsorbing	to	cells		Phages	 (added	 at	 30s),	 seen	 as	 fluorescent	 dots,	 were	 observed	 associating,	presumably	adsorbing,	to	DM1187	cells	by	60	seconds	into	the	imaging	run	(Fig.	5.3.2.1).	These	dots	remained	associated	with	the	outside	of	the	cell	until	450	s	and	550	s	where	 the	 fluorescent	dots	become	 indistinguishable	 from	 the	SYBR	gold	signal	accumulating	inside	the	cell.	This	accumulation	continues	to	increase	further	until	900	s	when	the	imaging	stopped.		
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Figure	5.3.2.1:	Visualising	adsorption	of	SYBR	Gold	stained	phages	to	
DM1187.		105	Phages	were	added	after	30	s.	Fluorescent	dots	can	be	observed	associating	with	 the	 cells	 by	 60	 s.	 At	 70	 s	 one	 cell	 alters	 orientation	 but	 still	 shows	 an	associated	phage.	By	200s	the	cell	begins	to	accumulate	fluorescence	indicating	a	transfer	of	SYBR	gold	 labelled	DNA	 from	the	phage	particles	 into	 the	cell.	Over	the	 course	 of	 900	 s	 (15	 minutes),	 the	 fluorescence	 accumulates	 into	 a	 strong	fluorescent	signal	from	the	cell.	Scale	bars	=	1	µm.		
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5.3.3	Phages	ejecting	DNA		Breaking	 down	 the	 intervals	 in	 figure	 5.3.2.1	 further	 shows	 a	 probable	 DNA	ejection	event.	In	figure	5.3.3.1,	the	fluorescence	from	the	phage	adsorbed	at	the	pole	 of	 the	 DM1187	 cell	 appears	 to	 be	 transferred	 into	 the	 intracellular	environment,	 which	 becomes	 increasingly	 bright	 over	 the	 course	 of	 the	experiment	(Fig.	5.3.2.1).	This	method	combined	with	phage	host	specificity	has	been	exploited	to	detect	specific	species	 in	a	mixture	(Mosier-Boss	et	al.,	2003)	so	 this	 transfer	 of	 SYBR	 gold	 fluorescence	was	 the	 expectation	 of	what	would	indicate	a	DNA	ejection	event.		The	diffuse	nature	of	the	fluorescent	signal	after	ejection	could	be	the	SYBR	gold	stain	 dissociating	 from	 the	 phage	 DNA	 and	 associating	 with	 cellular	 DNA	 (or	RNA),	which	 is	present	 in	greater	abundance	and	so	has	 the	potential	 to	dilute	the	signal.	There	are	data	 to	suggest	 that	 the	SYBR	gold	 label	 is	predominantly	retained	by	the	phage	DNA	post-ejection	(Kunisaki	&	Tanji,	2010),	which	would	imply	that	there	were	other	infection	events	by	a	greater	number	of	phages	not	visualised	during	the	assay.			When	quantifying	the	fluorescence	of	a	labelled	phage	it	was	important	to	avoid	fluorescence	 signals	 located	within	 the	 cell	 as	much	as	possible.	Therefore,	 the	area	analysed	was	 limited	to	only	 include	a	phage-sized	area	at	 the	edge	of	 the	cell,	 which	 then	 needed	 to	 be	 adjusted	 for	 any	 slight	 movement	 under	 the	microscope.	The	circular	area	analysing	 the	 fluorescent	profile	of	 the	phage	on	the	 top	 cell	needed	 to	 re-centred	at	 frames	6,	7,	8,	 9,	 12,	14,	21,	28,	 and	37	 to
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Figure	5.3.3.1.	Visualisation	of	phage	DNA	labelling	with	SYBR	gold	
transferring	from	ϕ24B	particles	to	a	DM1187	cell.		Fluorescence	 signal	 from	 the	 SYBR	 gold	 label	 can	 be	 seen	 accumulating	 inside	this	cell	between	100	s	and	240	s	of	the	imaging	collection.	The	red	arrow	shows	another	 phage	 adsorption	 event	 that	 is	 not	 analysed	 here.	 For	 illustration	purposes,	the	approximate	area	of	SYBR	gold	penetration	from	“phage	1”	into	the	cell	is	circled	in	yellow	in	the	final	column.	Scale	bars	=	1	µm.		
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ensure	 the	 phage	 signal	 was	 within	 the	 area	 being	 analysed.	 The	 same	 area	covering	 the	 phage	 on	 the	 bottom	 cell	 was	 more	 stable	 and	 only	 needed	 re-centring	at	frames	13,	14,	15,	19,	and	25.	The	fluorescence	of	either	phage	1	or	2	(Fig.	5.3.3.2A)	could	not	be	distinguished	from	cellular	fluorescence	after	frame	55	and	 frame	45,	 respectively.	Phage-associated	 fluorescence	 remains	constant	relative	 to	 cellular	 fluorescence	 for	 the	 first	 200	 s	 (approximately	 3	 minutes)	before	decreasing	at	a	steady	rate	until	the	phage	fluorescence	can	no	longer	be	distinguished	 from	 the	 constantly	 increasing	 cell-associated	 fluorescence	 (Fig.	5.3.3.2B).	The	phage	fluorescence	represents	the	contribution	of	a	single	stained	particle	yet	the	increase	in	cellular	fluorescence	is	most	likely	to	be	an	ensemble	effect	 of	 multiple	 infection	 events.	 This	 complicates	 any	 analysis	 as	 the	 total	fluorescence	amounts	to	a	much	greater	signal	than	an	individual	phage,	yet	the	presence	 of	 additional	 phages	 cannot	 be	 determined	 from	 the	 data	 collected.	There	is	an	additional	phage	visible	in	the	same	focal	plane	as	“phage	1”	in	Figure	5.3.3.1	 (red	 arrow	 -	 visible	 at	 100s	 and	 130s).	 Therefore	 it	 is	 likely	 that	 other	phages	have	also	absorbed	to	this	cell	 in	other	focal	planes,	where	they	are	not	visible	 but	 do	 contribute	 to	 the	 overall	 cellular	 fluorescence	 over	 time.	 In	 this	sample	it	would	seem	that	ϕ24B	phage	are	more	likely	to	bind	at	the	poles	of	the	cell	or	diffusion	into	midcell	is	hindered	in	some	way.	This	could	be	by	a	partially	formed	septum	or	the	SYBR	gold	stain	associating	with	peripheral	genomic	DNA,	thereby	 slowing	 the	 progress	 of	 the	 label	 into	 the	 centre	 of	 the	 cell.	 BamA	 is	present	across	the	whole	outer	membrane	with	new	BAM	complexes	assembling	at	 mid-cell	 (Rassam	 et	 al.,	 2015).	 More	 data	 collection	 is	 required	 before	 any	conclusions	can	be	made	as	to	whether	this	is	generally	true	of	a	ϕ24B	infection	or	whether	it	was	just	these	cells.		
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Figure	5.3.3.2	Quantification	of	figure	5.3.2.1	showing	fluorescence	
associated	with	two	individual	phages	adsorbed	to	DM1187	cells.	(A)	 An	 excerpt	 from	 figure	 5.3.2.1	 showing	 data	 sources	 for	 (B).	 (B)	 Graph	showing	 the	phage-associated	 fluorescence	minus	cellular	 fluorescence.	Phages	were	added	after	30s	causes	a	signal	spike,	which	is	maintained	until	180	s	when	fluorescence	 begins	 to	 transfer	 from	 the	 phage	 into	 the	 cell.	 Trend	 lines	 are	plotted	using	data	at	180	s	and	beyond	only.			
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5.4	Examining	the	Bam0	strain			Initial	 attempts	 at	 measuring	 phage	 infection	 in	 DM1187	 were	 normalised	against	background	fluorescence	to	eliminate	the	contribution	that	any	build	up	of	 background	 fluorescence	 (as	 seen	 in	 figure	 5.3.1.1)	would	 have	 to	 the	 total	signal.	A	dilemma	was	encountered	during	the	analysis	when	a	decrease	in	SYBR	gold	fluorescence	was	detected;	the	decrease	could	not	be	definitively	attributed	to	either	the	loss	of	fluorescence	from	the	cell/phage	or	whether	the	focal	plane	had	 shifted	 towards	 the	 outside	 of	 the	 cell	 or	 the	 signal	 had	 dropped	 for	 any	reason.	To	control	 for	this,	 the	stain	“NucBlue”	(Thermo	Fisher,	UK),	which	is	a	DAPI-based	DNA	stain,	was	used	to	 identify	bacterial	DNA	as	a	control	 for	cell-associated	fluorescence	before	imaging	started.	On	the	first	attempt	the	NucBlue	stain	was	present	but	the	sample	could	not	be	processed	as	the	microscope	had	the	 incorrect	 filter	 box	 installed	 so	 the	 light	was	 filtered	 out	 before	 detection.	The	correct	filter	box	was	installed	for	all	subsequent	sessions.		
5.4.1	Bam0	cells			Bam0	cells	were	shown	to	be	resistant	to	ϕ24B	phage	infection	(Fig.	3.4.1).	For	this	reason,	Bam0	should	serve	as	a	negative	control	for	phage	infection	against	the	DM1187	strain	used	 for	 the	experiments.	During	 these	experiments	 “phage	infection”	 was	 observed	 (Fig	 5.4.1.1A).	 Phage	 infection	 would	 present	 as	 an	increased	 cellular	 fluorescence	 from	 the	 SYBR	 gold	 stain.	 However,	 this	fluorescence	appeared	suspiciously	synchronised	to	all	cells	at	once	and,	notably,		also	 appears	 without	 the	 addition	 of	 any	 phage	 particles	 (data	 not	 shown),
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Figure	5.4.1.1:	Tracking	fluorescence	during	adsorption	assay	with	Bam0.	(A)	Quantification	of	SYBR	gold	fluorescence	profiles	within	10	individual	Bam0	cells	 which	 demonstrates	 a	 synchronised,	 yet	 unexplained,	 “event”	 at	 ~1090	seconds.	 (B)	All	 three	 labels	are	present	at	 the	end	of	 the	experiment.	NucBlue	shows	bacterial	DNA	stained	prior	to	the	imaging	collection,	and	while	the	SYBR	gold	would	imply	phage	infection	according	to	the	assay	design,	the	build-up	of	PI	shows	that	the	cells	are	dead	and	free	SYBR	gold	could	have	diffused	into	the	dead	cell.	Scale	bars	=	1	µm	
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thereby	showing	that	the	fluorescence	build	up	is	not	caused	by	phage	infection	activity	 in	 this	 case.	Other	 instances	of	 the	 same	observation	were	made	using	Bam0	 cells	 both	 with	 and	 without	 the	 addition	 of	 SYBR	 gold	 labelled	 ϕ24B	particles.	The	build	up	of	SYBR	gold	fluorescence	correlates	with	the	build	up	of	PI	fluorescence	(Fig	5.4.1.1B)	and	suggests	that	the	”event”	causes	cell	death.			
5.4.2	Bam0	complemented	with	pUC19-ϕR1D		Bam0	 cells	 containing	 the	 pUC19-ϕR1D	 plasmid	 were	 also	 subjected	 to	 the	assay,	 though	 limited	 conclusions	 should	 be	 drawn	 from	 this	 as	 this	was	 only	performed	 with	 a	 single	 replicate.	 The	 complemented	 cells	 appeared	 very	elongated	 under	 the	 microscope	 and	 seemed	 compartmentalised,	 where	 it	looked	 as	 though	 the	 septum	 formed	 but	 cell	 division	 had	 not	 occured	 (Fig	5.4.2.1A-B)	 as	 the	 pUC19	 plasmid	 causes	 a	 delay	 in	 cell	 division	 in	 order	 to	ensure	 plasmid	 maintenance	 in	 both	 daughter	 cells	 (Ingmer	 et	 al.,	 2001).	Staining	samples	with	PI	after	data	collection	showed	an	identical	pattern	i.e.	all	cells	that	are	positive	for	SYBR	gold	after	20+	minutes	are	also	positive	for	PI	–	including	 individual	 sections	 of	 the	 compartmentalised	 cell	 (Fig.	 5.4.2.1C).	 The	same	event	that	affected	the	Bam0	strain	may	or	may	not	have	occurred	during	the	assay	of	this	sample	too;	however,	it	is	not	possible	to	confirm	this	as	labelled	ϕ24B	 particles	 were	 added	 to	 this	 single	 replicate,	 giving	 two	 competing	explanations	for	the	observations	made.	The	premature	cell	death	observed	was	either	caused	by	an	unknown	event	similar	to	that	shown	in	 figure	5.4.1.1.	The	compromise	 of	 Bam0	 cells	 would	 limit	 any	 phage	 biology	 analysis,	 had	 there	been	any,	to	the	first	19	minutes,	where	Bam0	cells	are	still	alive.	
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Figure	5.4.2.1:	Observing	Bam0	strain	complemented	with	pUC19-ϕR1D.	(A)	 Bam0	 pUC19-ϕR1D	 under	 a	 light	 microscope	 showing	 the	 extent	 of	 cell	elongation.	A	cell	with	proportions	matching	previous	experiments	is	highlighted	by	the	red	arrow.	(B)	Visualisation	of	 the	compartmentalisation	of	DNA	in	a	an	elongated	Bam0	pUC19-ϕR1D	cell.	The	red	arrows	show	areas	of	NucBlue	stain	that	are	separated	from	each	other	despite	being	in	the	same	cell.	(C)	Images	of	dead	Bam0	cells	 taken	at	1170	 s	on	all	 channels.	Not	 all	 cells	 “infected”	 (SYBR	gold	channel)	but	those	that	are	have	died	(PI	channel).	Scale	bars	=	10	µm.	
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5.5	Conclusions		
5.5.1	Visualisation	of	phages	during	the	assay			The	model	phage	used	 for	 the	assay,	ϕ24B,	 can	be	visualised	by	an	established	and	simple	SYBR	gold	labelling	method	(Mosier-Boss	et	al.,	2003).	Phages,	in	the	form	 of	 fluorescent	 dots,	 were	 seen	 both	 in	 solution	 and	 adhered	 to	 the	 PLL-coated	surface	of	the	glass	bottomed	dish	after	the	experiment	had	concluded		
5.5.2	Visualisation	of	phage	DNA	ejection			There	 were	 examples	 of	 what	 appeared	 to	 be	 an	 infection	 in	 progress	 when	tracking	 fluorescence	 transfer	 from	 the	 phage	 to	 the	 cell.	 One	 such	 event	 is	presented	in	figure	5.3.3.1,	where	the	build-up	of	cellular	fluorescence	is	visible	over	time.	Quantitative	analysis	of	this	event	showed	that	fluorescence	transfer	into	 the	 cell	 has	 a	 lag	 phase	 of	 3	 minutes	 before	 beginning.	 This	 lag	 phase	assumes	 instant	 adsorption,	 which	 is	 reasonable	 to	 make	 with	 the	 number	 of	phages	 added	 to	 the	 experiment.	 An	 exact	 MOI	 is	 not	 calculable	 due	 to	 an	unknown	number	of	cells	adhered	to	the	dish.			
5.5.3	Unexplained	cell	death		The	 synchronised	 accumulation	 of	 SYBR	 gold	 fluorescence	 in	 Bam0	 cells	suggests	 that	 the	 membranes	 lose	 integrity	 due	 to	 conditions	 in	 the	 assay	causing	 cell	 death.	 While	 the	 reason	 for	 this	 compromised	 state	 is	 not	
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immediately	apparent;	although,	as	the	no-phage	control	(PGM	containing	SYBR	gold	only)	also	showed	cell	death	 it	 is	 likely	caused	by	 the	experimental	 setup,	the	 death	 of	 Bam0	 cells	 limits	 any	 potential	 conclusions	 to	 only	 the	 first	 20	minutes	 after	 addition	 of	 phages	 in	 all	 experiments.	 Once	 the	 assay	 does	 not	display	 any	 cell	 death,	 the	 adsorption	 phenotype	 of	 Bam0	 can	 be	 determined	with	greater	confidence	and	 then,	 if	negative,	 this	can	act	as	a	negative	control	for	testing	other	isogenic	mutants.		
5.6	Discussion	of	results			The	simple	 infection	assay	 from	figure	3.4.1	has	also	been	visualised	under	the	fluorescent	microscope	in	figure	5.3.1E.	This	successful	infection	by	at	least	one	labelled	ϕ24B	particle	results	in	the	production	of	a	fluorescent	E.	coli	cell,	which	was	motile	in	the	pilot	study	and	immobilised	on	the	surface	of	a	glass	bottomed	dish	 in	 subsequent	 experiments.	 The	 ability	 to	 quantify	 areas	 of	 fluorescence	allowed	 the	 analysis	 to	 hone	 in	 on	 the	 infections	 of	 single	 cells	 by	 multiple	phages	 over	 a	 period	 of	 about	 20	 minutes.	 Visualisation	 of	 host	 cells	 is	 only	possibly	after	infection	by	multiple	individual	phages	as	the	signal	to	noise	ratio	is	not	high	enough	for	a	standard	 fluorescence	microscope	 from	a	single	phage	(Mosier-Boss	et	al.,	2003)			The	 assay	 development	 is	 not	 finished,	 especially	 in	 light	 of	 the	 unknown	conditions	 that	 cause	 bacterial	 cells	 to	 die	 more	 quickly	 than	 expected.	 A	potential	 avenue	 that	 could	 be	 worth	 exploring	 include	 potentially	 revisiting	agar	as	 it	 is	probably	more	effective	at	 immobilising	cells	without	killing	 them.	
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The	main	drawback	of	agar	was	the	need	to	invert	the	slide	and	so	adding	phages	during	 the	 imaging	 was	 not	 possible.	 The	 mid-assay	 addition	 of	 phages	 was	important	 be	 able	 to	measure	 the	 time	 taken	 between	 inoculation	with	 phage	and	the	start	of	DNA	translocation,	which	appears	to	only	take	around	3	minutes.	The	 upright	 microscope	 (Examiner	 Z1)	 could	 be	 used	 instead	 and	 would	circumvent	this	 issue.	Even	with	this,	 the	slide	setup	would	need	deeper	divots	or	 some	 way	 of	 making	 a	 more	 solid	 agar	 base	 to	 ensure	 the	 agar	 does	 not	rupture	or	dry	out	in	the	timeframe	of	the	assay.			Removing	 all	 of	 the	 PGM	 during	 the	 washing	 procedure	 caused	many	 cells	 to	group	 together,	 making	 contacting	 with	 each	 other,	 in	 the	 remaining	microdroplets	 of	 medium.	 BamA	 is	 implicated	 in	 a	 primary	 role	 in	 contact-dependent	 growth	 inhibition	 (CDI)	 in	 Enterobactericeae	 (Ruhe	 et	 al.,	 2013a).	Currently,	there	are	no	data	to	suggest	what	impact	CDI	may	have	on	either	the	protein	insertion	function	or	the	ϕ24B	adsorption	process.	So	it	was	considered	prudent	 at	 this	 stage	 to	 avoid	 cell-cell	 contact	 during	 experiments	 as	much	 as	possible.	 Therefore,	 the	 attached	 cells	 were	 washed	 by	 tilting	 the	 plate	 and	running	PGM	from	top	to	bottom	to	remove	unattached	cells	while	avoiding	cells	congregating	in	microdroplets.	If	it	turns	out	that	CDI	does	not	significantly	alter	BamA	 activity,	 conformation,	 or	 interaction	with	ϕ24B	 then	 pipetting	 away	 all	PGM	would	be	a	good	way	to	group	cells	 for	 imaging	to	get	a	higher	density	of	cells	and,	therefore,	more	data	per	experiment.		
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5.6.1	DNA	ejection	from	ϕ24B			There	 are	 no	 data	 regarding	 the	 specific	 DNA	 ejection	 of	 ϕ24B;	 however,	 as	 a	lambdoid	phage,	an	approximate	comparison	can	be	made	to	phage	lambda,	λ.	It	has	been	shown	that	λ	has	a	constant	DNA	ejection	time	even	in	genome	length	mutants	 of	 37.7	 kb	 to	 48.5	 kb	 as	 the	 initial	 ejection	 rate	 increases	 for	 longer	genomes	(Löf	et	al.,	2007).	The	 increase	 in	 initial	ejection	rate	 is	caused	by	the	increase	in	forces	associated	with	DNA	bending	and	inter-strand	repulsion	(Löf	
et	al.,	 2007)	and	 so	we	might	expect	ϕ24B	 to	have	a	 similar	ejection	 time	 to	λ,	even	with	a	larger	genome	size	of	57.7	(Smith	et	al.,	2012).	Other	factors	such	as	temperature	 and	 presence	 of	 ions	 are	 also	 known	 to	 impact	 ejection	 rates.	 An	increased	 concentration	 of	 Mg2+	 ions	 reduces	 the	 repulsion	 and	 consequently	increases	 the	 DNA	 ejection	 time	 (Wu	 et	 al.,	 2010),	 whereas	 an	 increase	 in	temperature	 means	 there	 is	 more	 energy	 to	 both	 trigger	 and	 maintain	 DNA	ejection	(Raspaud	et	al.,	2007)	and	will	decrease	the	overall	ejection	time.		The	 total	 genome	 ejection	 time	 cannot	 be	 inferred	 from	 figures	 5.3.2.1	 and	5.3.3.1	because	the	end	point	of	ejection	cannot	be	established	beyond	the	phage	and	 cellular	 fluorescence	 signals	 becoming	 indistinguishable.	 It	 is	 possible	 for	ejection	 rates	 of	 fluorescently	 stained	 phages	 genomes	 to	 be	 measured	 but	 it	requires	 a	 more	 sophisticated	 experimental	 setup	 e.g.	 microfluidics	 in	hydrodynamic	flow	(Mangenot	et	al.,	2005).	A	conclusion	that	can	be	made	from	these	 figures	 is	 that	 there	 is	 a	 3	 minute	 delay	 between	 the	 beginning	 of	adsorption	 and	 the	 beginning	 of	 DNA	 ejection.	 As	 the	 phage	 being	 analysed	bound	within	10	s	of	being	added	to	the	solution,	 it	 is	assumed	that	initial	host	
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recognition	 occurred	 immediately.	 Linear	 trend	 lines	 assume	 constant	 DNA	translocation	 speed	 –	but	 these	data	 imply	 that	 the	 rate	 is	 comparable	 to	 λ,	 in	which	total	ejection	time	is	around	2	mins	at	30°C	(García	&	Molineux,	1999).		All	 of	 the	 experiments	 were	 done	 at	 20°C.	 As	 adsorption	 and	 phage	 genome	ejection	 rates	 are	 known	 to	 be	 temperature-dependent	 (Raspaud	 et	al.,	 2007),	cooling	 the	 microscope	 stage	 could	 slow	 down	 these	 processes	 and	 allow	 a	higher	 temporal	 resolution	of	 the	 events	described	here.	This	may	also	 reduce	the	 impact	of	some	 issues	experienced	such	as	evaporation	of	 the	medium	and	overgrowth	of	 bacterial	 cells	 during	 the	 assay.	However,	 stage	 cooling	 is	 not	 a	feature	of	the	Z1	Observer	so	different	equipment	would	need	to	be	used.			
5.6.2	Premature	cell	death		The	major	drawback	of	the	experimental	set	up	was	that,	generally,	immobilised	bacterial	 cells	 died	 after	 approximately	20	minutes	 in	 this	 environment.	 There	was	 no	 immediate	 answer	 to	 this	 and	 further	 experiments	 to	 answer	 any	questions	 could	 not	 be	 conducted	 due	 to	 time	 constraints.	 Cells	 tumbling	 in	solution	appear	to	replicate	as	normal	and	often	build	up	enough	to	obscure	the	view	after	50	minutes	to	60	minutes	of	the	assay.	Conversely,	the	replication	of	immobilised	cells	does	not	appear	to	proceed	across	the	same	timeframe	and	so	a	gentler	 immobilisation	strategy	may	be	required.	Poly-L-lysine	has	been	used	to	 successfully	 attach	E.	coli	 cells	 to	 surface	 to	 allow	 imaging	 over	 longer	 time	periods	 (Vadillo-Rodríguez	 et	 al.,	 2004)	 despite	 having	 a	 bactericidal	 effect	(Colville	et	al.,	2010).	Immobilisation	strategies	that	were	not	considered	include	
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attachment	 using	 antibodies	where	 cells	 remain	 viable	 for	 6h	 (when	 stored	 in	PBS	 at	 4°C)	 (Suo	 et	 al.,	 2009)	 and	 phages	 (Hosseinidoust	 et	 al.,	 2011),	 since	adding	another	phage	aspect	to	the	experiment	may	complicate	conclusions.			The	standard	LIVE/DEAD®	BacLight™	Bacterial	Viability	Kit	(Life	Technologies,	UK)	could	not	be	used	to	determine	cell	viability	during	the	assay	as	the	SYTO®	9	green-fluorescent	nucleic	acid	stain	excites	and	emits	at	the	same	wavelengths	as	 SYBR	 gold.	 The	 live/dead	 stain	 was	 initially	 used	 in	 the	 absence	 of	 a	propidium	 iodide	 (PI)	 product	 to	 get	 an	 impression	 of	 the	 timelines	 for	 cells	dying	during	the	experiment	but	PI	alone	was	used	for	images	acquired	after	25	May	2016.			Figure	 5.4.1.1	 shows	 that	 PI	 is	 able	 to	 leak	 into	 cells	 with	 compromised	membranes	of	Bam0	 in	 the	absence	of	phages	 in	 solution.	This	means	 that	 the	cell	death	observed	 is	phage-independent.	PLL	has	known	antibiotic	properties	but	 not	 over	 the	 timescale	 of	 the	 experiment	 –	 and	 probably	 not	 such	 a	synchronised	 effect	 on	 all	 cells.	 E.	 coli	 K-12	 cells	 immobilised	 on	 PLL	 have	survived	 for	 at	 least	 4	 hours	 in	 other	 experiments	 (Rozhok	et	al.,	 2005;	 2006)	including	 in	the	experiments	by	Lonergan	et	al.	 (2014),	which	this	method	was	based	on.	Conversely,	PLL	failed	to	immobilise	E.	coli	O157	cells,	which	is	thought	to	 be	 due	 to	 the	 pili,	 flagella,	 and	 other	 appendages	 preventing	 the	 cell	 from	making	a	full	enough	contact	with	the	immobilisation	surface	(Suo	et	al.,	2008).				
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No	 conclusions	were	made	 the	 reason	 for	 the	 cell	 death	 seen	 in	 the	 assay.	 So	questions	remain:		
• What	conditions	cause	the	“event”	to	occur,	and	can	it	be	prevented?	
• Is	the	cell	death	caused	by	something	that	is	already	known?	For	example,	the	 cell	 death	 could	 be	 due	 to	 photo-sensitivity	 of	 bacterial	 cells	(Nakahigashi	 et	 al.,	 1991).	 This	 could	 be	 in	 isolation	 from	 or	 in	combination	with	the	effects	of	PLL	(Colville	et	al.,	2010).			
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Chapter	6:	General	Discussion		
	
6.1	Aims	of	this	study		The	general	aim	of	this	thesis	was	to	continue	the	work	stemming	from	evidence	collected	 by	 Smith	 et	al.	 (2007)	 that	 the	 BamA	 protein	 is	 the	 host	 recognition	target	for	>70%	short	tailed	Stx	phages	possessing	a	highly	conserved	tail	spike	protein.	 BamA	 is	 also	 highly	 conserved	 due	 to	 its	 essential	 function	 of	 folding	nascent	 β-barrel	 membrane	 proteins	 in	 the	 outer	 membrane	 of	 all	 Gram-negative	 bacteria.	 The	 phage	 ϕ24B	 infects	 E.	 coli;	 however,	 it	 is	 capable	 of	adsorbing	 to	 the	 BamA	 protein	 of	 other	 members	 of	 the	 Enterobacteriaceae	(Smith	et	al.,	2007).	Due	to	the	high	proportion	of	Shiga	toxin	phages	that	encode	this	particular	tail,	there	is	a	greater	chance	of	a	mutation	that	could	potentially	facilitate	a	host	range	shift.			This	thesis	can	be	summarised	briefly	by	the	following	accomplishments:			 1. The	adaptation	of	an	existing	method	(Datsenko	&	Wanner,	2000)	to	create	a	novel	strain	of	E.	coli,	Bam0,	that	contains	a	chimaeric	BamA	gene,	which	becomes	resistant	to	ϕ24B	adsorption.		2. Adsorption	support	was	then	complemented	in	Bam0	with	WT	E.	coli	BamA	 in	 an	 infection	 assay.	 Thus,	 the	 heretofore-missing	 proof	 that	
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BamA	is	the	receptor	molecule	for	ϕ24B	has	been	presented	in	order	to	satisfy	molecular	Koch’s	postulates.			 3. 	The	 complementation	 assay	 shown	 here	 can	 also	 be	 used	 to	determine	 the	 ability	 of	 which	 BamA	 mutants	 support	 ϕ24B	adsorption	from	the	newly	made	library	of	32	BamA	mutants.			4. The	 development	 of	 a	 fluorescence	microscopy	 assay	 that	 is	 able	 to	monitor	 adsorption	 of	 a	 single	 ϕ24B	 particle	 to	 an	 adsorption	susceptible	 cell	 and	 acquire	 temporally	 resolved	 data	 of	 a	 DNA	ejection	event.		Overall,	 the	accomplishments	 largely	match	 the	aims	of	 the	 study	expressed	 in	section	 1.9	 but	 they	 are	 currently	 limited	 by	 the	 trouble	 with	 complementing	Bam0	with	 a	 chimaeric	BamA	mutant.	 So	 far	only	 a	WT	E.	coli	 BamA	has	been	shown	to	restore	support	for	phage	adsorption.			For	the	fluorescence	microscopy	assay,	the	proof	of	principle	has	been	shown	to	work	 but	 it	 still	 requires	 some	 adaptation	 or	 optimisation	 before	 it	 is	 able	 to	reliably	collect	data	for	all	32	BamA	mutants.	Taking	all	of	the	data	together,	this	thesis	 presents	 crucial	 groundwork	 for	 developing	 a	 greater	 understanding	 of	ϕ24B	adsorption	to	susceptible	hosts.	
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6.2	Future	work		The	 results	of	 the	 infection	assays	 and	 the	 fluorescence	microscopy	assays	 are	able	 to	 corroborate	 each	 other,	 with	 the	 microscopy	 providing	 the	 ability	 to	acquire	 further	 information	regarding	the	timings	of	ϕ24B	adsorption	and	DNA	ejection.	 Solving	 the	 issues	 discussed	 in	 section	 4.6	 regarding	 the	 ability	 of	chimaeric	BamA	mutants	to	be	expressed	and	fold	correctly	in	vivo	would	allow	both	 of	 these	 assays	 to	 generate	 the	 data	 required	 to	 assess	 which	 E.	 coli	epitopes	are	important	for	supporting	ϕ24B	adsorption.			Any	constructs	required	for	future	work,	especially	if	that	construct	contains	TSP	sequence,	may	be	more	time-	and	cost-effective	to	buy	custom	genes	instead	of	relying	on	PCR	products	for	cloning.			High-	 speed	 atomic	 force	 microscopy	 (AFM)	 could	 be	 employed	 using	 a	functionalised	cantilever	 tip	with	either	whole	ϕ24B	particles	or	 just	a	purified	his-tagged	 TSP	 preparation.	 This	 would	 mean	 that	 tip	 would	 encounter	resistance	when	 the	 tail	 interacts	with	 BamA.	 The	 technique	 could	 be	 used	 to	map	both	the	number	and	distribution	of	bioavailable	BamA	molecules	that	are	present	on	 the	surface	of	a	cell,	 and	quantify	 the	strength	of	 the	 interaction	by	how	much	 extra	 force	 is	 required	 to	 separate	 the	 cantilever	 tip	 from	 the	 cell	surface	again.		Alternatively,	 the	 use	 of	 a	 quartz	microbalance	 would	 be	 capable	 of	 detecting	small	changes	in	mass	of	a	sample	attached	to	its	resonator	arm.	The	resonator	
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arm	will	vibrate	at	a	given	 frequency	until	 the	mass	of	 the	sample	changes.	By	immobilising	ϕ24B	particles	to	the	resonator	arm	and	adding	E.	coli	cells	to	the	solution,	data	could	be	collected	to	determine	if	the	a	BamA	mutant	expressed	by	those	cell	that	is	capable	of	supporting	ϕ24B	adsorption	as	the	cells	would	bind	to	 the	 cantilever	 via	 the	 phages	 and	 change	 the	 vibration	 pattern.	 This	 assay	could	 be	 semi-quantitative	 with	 regard	 to	 the	 strength	 of	 the	 BamA-ϕ24B	 tail	interaction.	 If	 the	 interaction	 is	 weak	 then	 the	 vibrations	 may	 be	 enough	 to	“undo”	the	reaction	before	the	adsorption	process	is	complete.			The	 ultimate	 proof	 would	 be	 to	 infect	 a	 mouse	 model	 previously	 used	 in	 Stx	studies	 (Mohawk	 &	 O'Brien,	 2011)	 with	 those	 strains	 determined	 to	 resist	 or	support	ϕ24B	adsorption	and	challenge	those	mice	with	a	dose	of	ϕ24B	in	vivo.	Monitoring	these	mice	for	the	presence	or	lack	of	symptoms	of	a	STEC	infection	would	corroborate	 in	vitro	experiments;	however,	this	may	not	be	considered	a	necessary	step	by	an	ethical	review	panel.			The	 information	collected	 from	 the	assays	mentioned	 (or	 similar	assays)	 could	be	 used	 to	 form	 a	 better	 picture	 of	 the	 dissemination	 of	 Stx	 genes	 in	 the	environment.	 In	order	 to	protect	 the	 food	supply	chain	against	potential	 future	contamination	by	new	Stx	phage	host	cells	 that	we	currently	do	not	suspect.	 It	may	also	improve	responses	to	future	outbreaks	and	even	grant	the	potential	to	monitor	water	and	food	supply	for	potential	sources	of	contamination.		
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Chapter	8	Appendices	
	
8.1	Sequencing	confirmation	of	constructs	made	in	this	study		Initally,	 sequencing	data	was	 saved,	 then	alignment	 files	 created	by	 comparing	the	sequencing	data	to	reference			sequences	were	saved.	Files	can	be	found	on	at	https://pcwww.liv.ac.uk/~hallison/Stuart_Thesis/index.html	 in	 the	 section:	“Appendix	8.1	Sequencing	data”.		
8.2	Fluorescence	microscopy	data	generating	for	this	study		Videos	 and	 images	 used	 for	 making	 figures	 in	 Chapter	 5	 can	 be	 found	 at	https://pcwww.liv.ac.uk/~hallison/Stuart_Thesis/index.html	 in	 the	section	“8.2	Thesis	data”.	Files	have	been	named	after	and	sorted	by	the	 figure(s),	 in	which	they	 appear.	 The	 instructions	 followed	 for	 generating	 and	 analysing	 data	 from	image	analysis	are	also	included.			All	 data	 collected	 for	 this	 study,	 usable	 or	 otherwise,	 has	 been	 included	 at	https://pcwww.liv.ac.uk/~hallison/Stuart_Thesis/index.html	 in	 the	section	“8.2	All	data”.			
